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1. Introduction
Angiogenesis takes place during development, and vascular remodeling is a controlled ser‐
ies of events leading to neovascularization, which supports changing tissue requirements.
Blood vessels and stromal components are responsive to pro- and anti-angiogenic factors
that allow vascular remodeling during development, wound healing and pregnancy. In
pathological situations such as cancer, however, the same angiogenic signaling pathways
are induced and exploited. Cancer angiogenesis is a requirement for the development and
growth of solid tumors beyond 2–3 mm3 (Cao et al., 2011). Several angiogenic activators in‐
cluding members of the vascular endothelial growth factor (VEGF) and fibroblast growth
factor (FGF) gene families and various inhibitors of angiogenesis have been described. In
steady-state conditions, the balance between angiogenic activators and inhibitors results in
very limited new blood vessel growth in the majority of tissues. The balance tilts in favor of
the angiogenic stimulators, however, in a variety of proliferative processes. It is now gener‐
ally accepted that angiogenesis is a rate-limiting process in tumor growth. Without new
blood vessels to supply nutrients and dispose of catabolic products, tumor cells cannot sus‐
tain proliferation and thus are likely to remain dormant (Ferrara, 2010; Daniele et al., 2012).
Survival and proliferation of cancer depends on angiogenesis, which could be a target of can‐
cer therapy. Angiogenesis is a complex physiological process. One example of this is found in
the signaling pathways associated with the stimulus of various pro-angiogenic factors, VEGF
and its receptors (VEGFR) which represents one of the best-validated signaling pathways in
angiogenesis. A number of drugs approved by the FDA on market have been shown to inhibit
anti-angiogenic pathway of VEGF. These agents include bevacizumab, a humanized anti-
VEGF-A monoclonal antibody (Ferrara 2010), and two small molecule inhibitors targeting
VEGFR2, sorafenib and sunitinib (Bergers and Hanahan 2008; Ellis and Hicklin 2008; Escudier
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et al., 2007; Motzer et al., 2007). Not all cancer patients, however, benefit from such anti-angio‐
genic therapies, and some that do benefit initially have been shown to become less responsive
during the treatment as well as show some adverse effects over time (Bergers and Hanahan
2008; Chen and Cleck, 2009; Ellis and Hicklin 2008). Over the last few decades, numerous anti-
angiogenic agents have been developed, and some of them have been tested in clinical settings.
Angiogenesis includes a complex and multistep process, however, that has not been sufficient‐
ly elucidated. Hence, there is an urgent need to investigate the mechanisms that mediate resist‐
ance to anti-angiogenic agents. Recent advances have been made in identifying a number of
novel alternate processes involved in angiogenesis. If these new findings of alternate mecha‐
nisms are confirmed, cancer therapy strategies may also be affected.
Artemisinin (ART) is a natural product of the plant Artemisia annua L. Reduction of ART yields
the more active dihydroartemisinin (DHA), a compound which can be further converted to dif‐
ferent derivatives, including, artesunate (AS) and artemether (AM), which are generally refer‐
red to as artemisinins (ARTs). ARTs are widely known for their potent antimalarial activity,
but also been potential anti-cancer activity both in vitro and in vivo over the past few years.
ARTs have inhibitory effects on cancer cell growth and also inhibit angiogenesis. Several stud‐
ies have revealed that ART inhibits the growth of many transformed cell lines and has a selec‐
tive cytotoxic effect. In one study, ART was shown to be more toxic to cancer than normal cells.
In most of the systems, preloading of cancer cells with iron or iron-saturated holotransferrin
triggers ART cytotoxicity with an increase in the activity of ARTs by 100-fold in some cell lines.
It has been hypothesized that iron-activated ARTs induce damage by release of highly alkylat‐
ing carbon-centered radicals and radical oxygen species (ROS). Radicals may play a role in the
cell alterations reported in ARTs-treated cancer cells such as enhanced apoptosis, arrest of
growth, inhibition of angiogenesis, and DNA damage. More studies have demonstrated that
ART and its derivatives possess an anti-angiogenic activity (Li and Hickman, 2011).
ARTs inhibit angiogenesis which is a vital process in metastasis. AS and DHA inhibit cho‐
rioallantoic membrane angiogenesis at low concentrations and decrease the levels of two
major VEGF receptors on human umbilical vein endothelial cells (ECs). AS inhibits prolifer‐
ation and differentiation of human microvascular dermal ECs in a dose-dependent manner
and reduces Flt-1 and KDR/flk-1 expression. Conditioned media from K562 cells pretreated
with AS and DHA inhibits VEGF expression and secretion in chronic myeloid leukemia
K562 cells, leading to a decrease in genetic activity associated with angiogenesis. ARTs in‐
hibit cell migration and concomitantly decrease the expression of matrix metalloproteinase
proteins such as MMP2 and the avß3 integrins in human melanoma cells. ARTs also regu‐
late the levels of urokinase plasminogen activator (u-PA), and the matrix metalloproteinases
MMP2, MMP7 and MMP9 all of which are related to metastasis. Also, ARTs have been
shown to increase production of reactive oxygen species and also inhibits the hypoxia in‐
duced production of a transcription factor, hypoxia inducible factor-1α (HIF1α). The HIF1α
transcription factor increases tumor angiogenesis to support the survival of poorly nourish‐
ed cancer cells. ARTs have shown pleiotropic effects through different experimental studies.
Definitely,  ART  compounds  exhibit  a  wide  spectrum  of  biological  activities,  including,
for example, anti-angiogenic, anti-tumorigenic and even anti-viral, all of which are medi‐
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cally relevant. In particular, cancer angiogenesis plays a key role in the growth, invasion,
and metastasis of cancers. After more than 30 years of intensive study, many agents, in‐
cluding novel candidate of ARTs, that target angiogenesis as cancer therapy and preven‐
tion  of  metastasis  of  existing  tumors  have  been  translated  from  the  laboratory  to  the
bedside. Therefore, ARTs-induced inhibition of angiogenesis could be a promising thera‐
peutic strategy for treatment of cancer and prevention of metastasis.  Various clinical tri‐
als  using  ARTs  for  anti-cancer  therapy  have  been  guided  by  the  anti-angiogenesis
research of ARTs that has been conducted anti-cancer.  Since new and alternative angio‐
genesis  mechanisms have been found,  further research on the mechanism of  anti-angio‐
genesis  could  lead  us  to  understand  more  deeply  the  possibilities  inherent  in  the
development of ARTs for cancer therapy (Li and Hickman, 2011).
The new strategies for the development of ARTs for cancer therapy and metastasis preven‐
tion should include a plan for increasing their anti-angiogenic activity through a variety of
approaches ranging from medicinal chemistry approaches to develop more potent ART-ana‐
logues to changes in formulation and/or dosing. The real potential and benefits of the ART
drug class for cancer treatment and metastasis prevention remain yet to be discovered. Giv‐
en the interest in using ARTs for cancer therapy, the door has been opened for challenging
research in this area, which is likely to yield new cancer therapies that now do not exist. The
aim of this chapter is to provide an overview of the recent advances and new development
of this class of drugs as potential anti-angiogenic agents.
2. Activities of artemisinins (ARTs) as anti-cancer agents
Significant  antitumor  activity  of  ART  and  licensed  semisynthetic  its  derivatives  has
been  documented  in  vitro,  in  vivo  and  through  clinical  trials  considerable  research  has
been focused on the  most  active  compounds,  namely,  artesunate  (AS)  and dihydroarte‐
misinin (DHA).
2.1. ART and its derivatives
ART and its derivatives are lactonic sesquiterpenoid compounds first discovered in China.
A crude extract of the wormwood plant Artemisia annua (qinghao) was first used as an anti‐
pyretic 2000 years ago. The antipyretic therapy dates back to the third century B.C. in the
“Handbook of Prescriptions for Emergency Treatment” edited by Ge Hong (281-340 B.C.)
where he recommended tea-brewed leaves of the wormwood plant to treat fever and chills.
The specific effect of ART on the fever of malaria was reported in the 16th century in the
“Compendium of Materia Medica” published by Li Shizen in 1596 cited Ge Hong’s prescrip‐
tion (Li and Weina, 2011). The active constituent of the extract was identified and purified in
the 1970s, and named qinghaosu, or artemisinin (ART). Although ART proved effective in
clinical trials in the 1980s, a number of semi-synthetic derivatives were developed to im‐
prove the drug’s pharmacological properties and antimalarial potency (Li et al., 2007). The
structure of ART, which includes an endoperoxide bridge (C-O-O-C), is unique among anti‐
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malarial drugs. Semisynthetic ARTs are obtained from dihydroartemisinin (DHA), which is
the reduced lactol derivative of ART, the main active metabolite of ARTs (Li et al., 1998).
The first generation of semisynthetic ARTs includes the lipophilic arts, arteether (AE) and
artemether (AM), while artesunate (AS) is the water soluble derivative (Li and Weina, 2011).
AS and its bioactive metabolite, DHA, have been the topic of considerable research attention
in recent years for both anti-cancer and antimalarial indications. The key structural feature
in all of the ART-related molecules that mediates their antimalarial activity, and some of
their anti-cancer activities, is an endoperoxide bridge. The endoperoxides are a promising
class of antimalarial drugs which may meet the dual challenges posed by drug-resistant par‐
asites and the rapid progression of malarial illness. Of the available derivatives, AS has the
most favorable pharmacological profile for use in ART-based combination therapy treat‐
ment of uncomplicated malaria and intravenous therapy of severe malaria (Li and Weina,
2010a). The effectiveness of AS has been mostly attributed to its rapid and extensive hydrol‐
ysis to DHA (Batty et al., 1998b; Davis et al., 2001; Li et al., 2009; Navaratnam et al., 2000).
Artemisone, a second-generation ART which is not metabolized to DHA, has shown im‐
proved pharmacokinetic properties including a longer half-life and lower toxicity (D'Ales‐
sandro et al., 2007; Schmuck et al., 2009) (Figure 1). Fully synthetic ART derivatives have
also been designed by preserving the peroxide moiety which confers potent drug activity.
These compounds are easily synthesized from simple starting materials; accordingly, these
compounds are currently under intense development (Creek et al., 2008; Jefford 2007; Ram‐
irez et al., 2009; Taylor et al., 2004). Hundreds of these compounds have been made; many
resemble ART, but only one of these compounds, arteflene, has been taken beyond preclini‐
cal development (Radloff et al., 1996).
ART and its active derivatives have been widely used as antimalarial drugs for more than 30
years, and they have also been shown recently to be effective in killing cancer cells (Li et al.,
2011). A number of studies demonstrated that ART and its bioactive derivatives exhibit po‐
tent anti-cancer effects in a variety of human cancer cell model systems. Recently, the anti-
angiogenic activity of ARTs has been demonstrated, and these compounds have been shown
to be potential anti-cancer agents (Crespo-Ortiz and Wei, 2012).
2.2. ARTs as first-line therapies for treatments of malaria
Global malaria control is being threatened on an unprecedented scale by rapidly growing
resistance of P. falciparum to conventional monotherapies such as chloroquine, sulfadoxine-
pyrimethamine  (SP)  and amodiaquine.  Multi-drug resistant  falciparum  malaria  is  widely
prevalent in South-East Asia and South America. Now Africa, the continent with highest
burden of malaria is also being seriously affected by drug resistance. A significant advant‐
age of ART and its derivatives in malaria treatment shows early evidence of cross-resist‐
ance  to  other  antimalarial  drugs.  As  a  response  to  the  rising  tide  of  antimalarial  drug
resistance, WHO issued new Guideline for the Treatment of Malaria (WHO 2006; 2008) and
recommends that treatment policies for falciparum malaria in all countries experiencing re‐
sistance to monotherapies should be combination therapies, preferably those containing an
ART derivative.
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Figure 1. Chemical structures of artemisinin (ART) and its five derivatives, dihydroartemisinin (DHA), artemether (AM),
arteether (AE), artesunate (AS) and artemisone
2.2.1. WHO policies in malaria treatments
The pharmacological and clinical evaluations of ART group of drugs have been taken place
for 30 years and four advantages have been evaluated.
1. Rapid action and high efficacy against multi-drug resistant P. falciparum
2. Evidence of ART drug resistance confirmed on the Cambodia-Thailand border
3. Low toxicity (excellent safety profile)
4. Gametocidal effect (prevents the transmission of malaria from person to person)
To treat uncomplicated malaria, the objective is to cure the infection. This is important as it
will help prevent progression to severe disease and prevent additional morbidity associated
with treatment failure. Cure of the infection translates to eradication of the parasite from the
body. In treatment evaluations in all settings, emerging evidence indicates that it is necessa‐
ry to follow patients for enough time to document a clinical cure. In assessing drug efficacy
in high-transmission settings, temporary suppression of infection for 14 days has not been
considered sufficient. The public health goal of treatment is to reduce transmission of the in‐
fection to others, i.e. to reduce the infectious reservoir. A secondary but equally important
objective of treatment is to prevent the emergence and spread of resistance to antimalarials.
Tolerability, the adverse effect profile and the speed of therapeutic response are also impor‐
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tant considerations. A brief summary of the WHO policies (WHO, 2010) for treatment of un‐
complicated falciparum malaria is listed below:
Artemisinin-based combination therapies (ACTs) are the treatment recommended by WHO
in 2010 for all cases of uncomplicated falciparum malaria as first-line treatment including:
• artemether plus lumefantrine,
• artesunate plus amodiaquine,
• artesunate plus mefloquine,
• artesunate plus sulfadoxine-pyrimethamine,
• dihydroartemisinin plus piperaquine.
Second-line treatment:
• an effective alternative ACT (efficacy of ACTs depend on efficacy of the partner medicine,
therefore it is possible to use two different ACTs as 1st and 2nd line options)
• quinine + tetracycline or doxycycline or clindamycin
Note: The ART derivatives (oral, rectal, or parenteral formulations) and partner medicines
of ACTs are not recommended as monotherapy for uncomplicated malaria due to high rates
of recrudescence associated with ART monotherapy.
To treat severe malaria, the primary objective of antimalarial treatment is to prevent death.
Prevention of recrudescence and avoidance of minor adverse effects are secondary. In treat‐
ing cerebral malaria, prevention of neurological deficit is also an important objective. In the
treatment of severe malaria in pregnancy, saving the life of the mother is the primary objec‐
tive. The following WHO policies are recommended for treatment of severe and complicat‐
ed falciparum malaria as first-line treatment (WHO 2010):
Any of the following antimalarial medicines have been recommended by the WHO in 2010
for initial treatment.
• artesunate (i.v. or i.m.)
• artemether (i.m.)
• quinine (i.v. infusion or i.m. injection).
Follow-on treatment: once the patient recovers enough and can tolerate oral treatment, the
following options can be used to complete treatment:
• full course of an ACT or
• quinine + clindamycin or doxycycline
Consistent with WHO recommendations (2006; 2010), malaria endemic countries which are
experiencing resistance to currently used antimalarial drug monotherapies (chloroquine,
sulphadoxine/pyrimethamine or amodiaquine) should change treatment policies to the
highly effective ART-based combination treatments (ACTs).
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2.2.2. ACT is a "policy standard" for first line malaria treatment
Antimalarial combination therapies can improve treatment efficacies of failing individual
components and provide some protection for individual components against the develop‐
ment of higher levels of resistance. ACTs have been advocated as the best available op‐
tion,  and  are  the  most  commonly  adopted  regimen  in  countries  changing  antimalarial
policy  in  the  last  decade.  ACTs  are  most  preferred  for  their  enhancement  of  efficacy
(Price 2000; White and Olliaro, 1998; White 1999a), lower malaria incidence and their po‐
tential  to  lower  the  rate  at  which  resistance  emerges  and  spreads  (Nosten  et  al.,  2000;
White  1999b).  Five  ACTs recommended by a  WHO Expert  Consultative  Group in  2010
include  AM-lumefantrine  (Coartem),  AS-mefloquine  (Artequin),  AS-amodiaquine,  and
AS-sulfadoxine/pyrimethamine. Recently, WHO has endorsed ACTs as the “policy stand‐
ard” for  all  malaria  infections in areas  where P.  falciparum  is  the predominant  infecting
species (WHO 2006; 2007).
ARTs  rapidly  reduce  parasitemia,  but  have  poor  efficacy  as  short  course  monotherapy.
When used in combination with another agent,  the rapid reduction in parasite numbers
results in relatively few parasites being exposed to the second drug (to which significant
resistance may already exist),  theoretically preventing emergence of additional resistance
mutations (White 2004). Furthermore, since ARTs themselves are not required to mediate
final cure, there should also be little opportunity for ART resistance to develop. In addi‐
tion, rapid reduction of the parasite burden in vivo by ACT drug combinations reduces
the frequency of gametocyte generation, increases the rates of cure and may also reduce
transmission of resistant parasites (Price, 2000).  Most currently recommended drug com‐
binations  for  falciparum  malaria  are  variants  of  ACT where  a  rapidly  acting  ART com‐
pound is  combined with a  longer  half-life  drug of  a  different  class.  ARTs used include
DHA, AS, AM and companion drugs include mefloquine, amodiaquine, sulfadoxine/pyri‐
methamine,  lumefantrine,  piperaquine,  pyronaridine,  and  chlorproguanil/dapsone.  The
standard of  care must  be to cure malaria  by killing the last  parasite.  Combination anti‐
malarial treatment is vital not only to the successful treatment of individual patients but
also for public health control of malaria.
ACTs continue to be the mainstay treatment of uncomplicated falciparum malaria. For the
next 8–10 years, no alternative medicines to the ART derivatives able to offer similar high
levels of therapeutic efficacy are expected to enter the market. For this reason, WHO has fo‐
cused its efforts not only to increase access to quality ACTs, but also to contain the risk of
development of falciparum resistance, associated with the large-scale use of oral monothera‐
pies for treatment of uncomplicated malaria (WHO 2006; 2007).
In  January  2006,  WHO  appealed  to  manufacturers  to  stop  marketing  oral  ART  mono‐
therapies  and instead to  promote quality  ACTs in line with WHO policy.  This  position
has been widely disseminated via WHO Offices,  WHO briefings to hospital  staff  and in
regional and inter-country briefings to representatives of national health. Major procure‐
ment  and funding agencies  and international  suppliers  have accepted the WHO recom‐
mendation  and agreed  not  to  fund or  procure  oral  ART monotherapies.  In  April  2006,
the Global Malaria Programme of WHO provided a technical briefing to 25 pharmaceuti‐
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cal companies involved in the production and marketing of ART monotherapies.  Out of
these,  15  declared their  willingness  to  stop marketing ART monotherapies  over  a  short
period of  time,  but  10  companies  did  not  disclose  their  marketing  plans  for  the  future
(meeting report available at: www.who.int/malaria/docs/ Meeting_briefing19April.pdf). In
addition,  some  countries,  like  China  and  Pakistan,  have  been  visited  by  WHO  delega‐
tions  to  address  multiple  domestic  manufacturers  involved in  this  sector.  The  evolving
position of  manufacturers and of  National  Drug Regulatory Authorities  (NDRA) in ma‐
laria  endemic  countries  is  monitored  and  displayed  on  the  WHO  Global  Malaria  Pro‐
gramme website front-page: http://malaria.who.int/.
In May 2007, the 60th World Health Assembly resolved to take strong action against oral
monotherapies and approved the resolution WHA60.18, which:
1. urges Member States to progressively cease the provision, in both the public and pri‐
vate sectors, of oral ART monotherapies, to promote the use of ART-combination thera‐
pies, and to implement policies that prohibit the production, marketing, distribution
and the use of counterfeit antimalarial medicines;
2. requests international organizations and financing bodies to adjust their policies so as
progressively cease to fund the provision and distribution of oral ART monotherapies,
and to join in campaigns to prohibit the production, marketing, distribution and use of
counterfeit antimalarial medicines;
The above-mentioned benefits of ACTs make them an important tool for malaria treatment
and control that has led to their increased use by 2010, most countries (89 countries), adopt‐
ed ACTs as their first-line treatment of uncomplicated falciparum malaria. Only two coun‐
tries adopted ACTs exclusively as second-line treatment (Bosman and Mendis, 2007).
2.3. Anti-cancer activities of ARTs
ART and its bioactive derivatives (AS, DHA, and AM) exhibit potent anti-cancer effects in a
variety of human cancer cell model systems. The pleiotropic response in cancer cells to ART
includes: 1) growth inhibition by cell cycle arrest, 2) apoptosis, 3) inhibition of angiogenesis,
4) disruption of cell migration, and 5) modulation of nuclear receptor responsiveness. These
effects of ARTs result from perturbations of many cellular signaling pathways in vitro and in
animal models. Considerable research has been focused on the most active ART com‐
pounds, namely, DHA and AS.
Molecular, cellular and physiological studies have demonstrated that, depending on the tis‐
sue type and experimental system, ART and its derivatives arrest cell growth, induce an
apoptotic response, alter hormone responsive properties and/or inhibit angiogenesis of hu‐
man cancer cells. The Developmental Therapeutics Program of the National Cancer Institute
(NCI), USA, which analyzed the activity of AS on 55 human cancer cell lines (IC50 values
shown between nano- to micro-molar range, depending on the cancer cell line), showed that
AS displays inhibitory activity against leukemia, colon, melanoma, breast, ovarian, prostate,
central nervous system (CNS), and renal cancer cells (Efferth et al., 2001; 2003; Efferth, 2006).
DHA also has remarkable anti-neoplastic activity against pancreatic, leukemic, osteosarco‐
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ma, and lung cancer cells (Lu et al., 2009). Moreover, artemisone (second generation ART
compound) has shown better activity than ART and considerable synergistic interactions
with other anti-cancer agents (Gravett et al., 2010).
ART has been found to act either directly by inducing DNA damage (genotoxicity) or in‐
directly by interfering with a range of signaling pathways involved in several hallmarks
of malignancy. Direct DNA damage is only described in specific systems, however, while
indirect  effects  are  more  commonly  noted  in  the  literature.  In  pancreatic  cells  (Panc-1),
artesunate was shown to cause DNA fragmentation and membrane damage. Interesting‐
ly,  low doses of  artesunate were associated with oncosis-like cell  death,  whereas higher
concentrations were shown to induce apoptosis (Du et al.,  2010). The extent and type of
cellular  damage  seems  to  depend  on  the  phenotype  and  the  origin  of  cell  line,  and  it
may also vary in a time- and dose-dependent manner (Crespo-Ortiz and Wei, 2012). No‐
tably,  higher  sensitivity  to  AS  was  observed  in  rapidly  growing  cell  lines  when  com‐
pared with slow growing cancer cells (Efferth et al., 2003).
Moreover,  the  highly stable  ARTs and ART-derived trioxane dimers  were shown to  in‐
hibit  growth and selectively kill  several  human cancer  cell  lines  without  inducing cyto‐
toxic  effects  on  normal  neighboring  cells.  One  proposed  mechanism  by  which  ART
targets  cancer  cells  involves  cleavage of  the  endoperoxide bridge by the  relatively  high
concentrations  of  iron  in  cancer  cells,  resulting  in  iron  depletion  in  those  cells  coupled
with generation of free radicals such as reactive oxygen species (ROS) capable of induc‐
ing subsequent  oxidative  damage.  This  mechanism resembles  the  known mechanism of
action  of  ART  in  malarial  parasites.  In  addition  to  possessing  higher  iron  influx  via
transferrin receptors,  cancer cells  are also sensitive to oxygen radicals because of a rela‐
tive deficiency in antioxidant enzymes. A significant positive correlation can be made be‐
tween  AS  sensitivity  and  transferrin  receptor  levels  as  well  as  between  AS  sensitivity
and expression of ATP binding cassette transporters (Efferth, 2006).
Expression  profiling  of  several  classes  of  tumor  cells  has  shown  that  ART  treatment
caused  selective  expression  changes  of  many  oncogenes  and  tumor  suppressor  genes
than genes responsible for  iron metabolism, which suggests  that  the anti-cancer proper‐
ties of ARTs cannot be explained simply by the global toxic effects of oxidative damage.
Alternatively, DHA, AS, and AM may well be to modulating genes and proteins coordi‐
nating growth signals, apoptosis, proliferation capacity, angiogenesis and tissue invasion,
and metastasis.  A complex network of  interactions through different  pathways may en‐
hance  the  anti-cancer  effect  of  these  endoperoxide  drugs  leading  to  cancer  control  and
cell death (Crespo-Ortiz and Wei, 2012).
ARTs have also been observed to attenuate multidrug resistance in cancer patients, an effect
due in part to the inhibition of glutathione S-transferase activity. ART and its bioactive de‐
rivatives elicit their anti-cancer effects by concurrently activating, inhibiting and/or attenuat‐
ing multiple complementary cell signaling pathways, which have been described in a
variety of human cancer cell systems as well as in athymic mouse xenograft models. The
ART compounds exert common as well as distinct cellular effects depending on the pheno‐
type and tissue origin of the human cancer cells tested. (Firestone and Sundar 2009)
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2.4. Anti-cancer mechanism of ART and its derivatives
The anti-cancer potential of ARTs has been demonstrated in various cancer cells including
those of leukemia and other cancer cells of breast, ovary, liver, lung, pancreas and colon
(Tan et al., 2011).The mechanisms of action of ARTs in cancer cells are associated with: 1)
anti-angiogenic effects, 2) induction of apoptosis, 3) oxidative stress response, 4) oncogenes
and tumor suppressor genes, and 5) multidrug resistance (Figure 2) (Efferth 2006; 2007).
Figure 2. Schema of tumor angiogenesis induced by hypoxia and the inhibitions of tumor growth by antiangiogenic
artemisinins (ART) and its derivatives of dihydroartemisinin (DHA), artesunate (AS) and artemether (AM) follows three
directions, including the inhibition of tumor cell synthesis of angiogenic proteins, the neutralization of angiogenic
proteins by antibodies or traps, and the inhibition of endothelial cell binding to angiogenic proteins or direct induc‐
tion of endothelial cell apoptosis.
2.4.1. Anti-cancer mechanism of ARTs based on antimalarial actions
The  endoperoxide  moiety  of  ART  has  been  shown  to  be  pharmacologically  important
and  responsible  for  antimalarial  activity  against  the  malaria  parasites.  The  potent  anti-
cancer action of ARTs can be also attributed to the endoperoxide bond. In most of the in
vitro  cancer cell  lines tested,  preloading of  cancer cells  with iron or iron-saturated holo‐
transferrin  triggers  ART  cytotoxicity  with  an  increase  in  ARTs  activity  up  to  100-fold
against  some cell  lines.  It  has  been hypothesized that  iron-activated ARTs induce dam‐
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age by release of highly alkylating carbon-centered radicals and ROS. Radicals may play
a  role  in  the  cell  alterations  reported  in  ARTs-treated  cancer  cells  such  as  enhanced
apoptosis,  arrest  of  growth,  inhibition  of  angiogenesis,  and  DNA  damage.  Microarray
analyses found that the action of ARTs seems to be modulated by the expression of oxi‐
dative  stress  enzymes  including  catalase,  thioredoxin  reductase,  superoxide  dismutase
and the glutathione S-transferase family. ARTs-sensitive cells demonstrate down-regulat‐
ed oxidation enzymes whereas over-expression of these enzymes renders cancer cells less
sensitive  to  chemotherapeutic  agents.  The antineoplastic  toxicity  of  ARTs appears  to  be
also  modulated by  calcium metabolism,  endoplasmic  reticulum (ER)  stress,  and the  ex‐
pression of the translationally controlled tumor protein, TCTP, a calcium binding protein
which  has  been  also  postulated  as  a  parasite  target.  Although  the  expression  of  the
TCTP gen,  tctp,  was  initially  correlated with  cancer  cell  response  to  ARTs,  a  functional
role  for  TCTP in  the  action of  ARTs has  yet  to  be  found.  As for  malaria  parasites,  the
role  of  sarcoendoplasmic  Ca2+ ATPase (SERCA) as  a  target  of  ARTs in  cancer  cells  has
also been explored (Crespo-Ortiz and Wei, 2012).
Expression profiling of several classes of tumor cells has shown that ART treatment caus‐
es  selective  expression  changes  of  many  more  oncogenes  and  tumor  suppressor  genes
than genes responsible for  iron metabolism, which suggests  that  the anti-cancer proper‐
ties of ART cannot be explained simply by the global toxic effects of oxidative damage.
ART has also been observed to attenuate multidrug resistance in cancer patients,  an ef‐
fect due in part to the inhibition of glutathione S-transferase activity. ART and its bioac‐
tive derivatives elicit their anti-cancer effects by concurrently activating, inhibiting and/or
attenuating multiple complementary cell signaling pathways, which have been described
in a variety of human cancer cell systems as well as in athymic mouse xenograft models.
The ART compounds exert common as well as distinct cellular effects depending on the
phenotype  and  tissue  origin  of  the  human  cancer  cells  tested.  (Firestone  and  Sundar,
2009).
2.4.2. Potential general mechanisms of ART and its derivatives
Studies have identified potential general anti-cancer mechanisms of anti-cancer ARTs such
as normalization of the upregulated Wnt/β-catenin pathway in colorectal cancer. Other
pathways for anti-cancer activity include inhibition of enhanced angiogenesis associated
with tumors. ARTs have been shown to inhibit proliferation, migration and tube formation
of human umbilical vein endothelial cells (HUVEC), inhibit VEGF binding to surface recep‐
tors on HUVEC and reduce expression of VEGF receptors Flt-1 and KDR/flk-1 on HUVECs.
In cancer cells, artemisinins reduce expression of the VEGF receptor KDR/flk-1 in tumor and
endothelial cells and slow the growth of human ovarian cancer HO-8910 xenografts in nude
mice. HUVEC apoptosis by artesunate is associated with downregulation of Bcl-2 (B-cell
leukemia/lymphoma 2) and upregulation of BAX (Bcl-2-associated X protein). In addition,
mRNA expression of 30 out of 90 angiogenesis-related genes correlated significantly with
the cellular response to ARTs, supporting the hypothesis that ARTs exert their anti-tumor
effects by inhibition of tumor angiogenesis (Krishna et al., 2008).
The Use of Artemisinin Compounds as Angiogenesis Inhibitors to Treat Cancer
http://dx.doi.org/10.5772/54109
185
2.4.3. Anti-angiogenesis of ARTs including Anti-proliferation
In the process of angiogenesis, the formation of new blood vessels from pre-existing ones is
essential for the supply of tumors with oxygen and nutrients. If cancers reach a size for
which diffusion alone cannot supply enough oxygen and nutrients angiogenesis is promot‐
ed by numerous pro-angiogenic or anti-angiogenic factors. The anti-angiogenic activities of
ARTs were shown using various models of angiogenesis, namely, proliferation, migration
and tube formation of endothelial cells. As a consequence, inhibitors of angiogenesis were
considered as interesting possibilities for cancer therapy. As shown by several groups
around the world, ART and its derivatives inhibit angiogenesis, and a detailed description
of the ART-induced anti-angiogenic mechanisms will be described in Section 3.
2.4.4. Induction of apoptosis
ARTs induce cell cycle arrest in various cell types (Efferth, 2006). For example, DHA and AS
effectively mediate G1 phase arrest in HepG2 and Hep3B cells (Hou et al., 2008), and DHA
treatment has been shown to reduce cell numbers of HCT116 colon cancer cells in S phase
(Lu et al., 2011). Interestingly, DHA treatment has also been shown to trigger G2 phase ar‐
rest in OVCA-420 ovarian cancer cells (Jiao et al., 2007). Thus, ART-mediated cell cycle arrest
is possibly cell type dependent. ARTs have also been shown to induce apoptotic cell death
in a number of cell types, in which the mitochondrial-mediated apoptotic pathway plays a
decisive role (Lu et al., 2011). For instance, DHA has been shown to enhance Bax and re‐
duces Bcl-2 expression in cancer cells (Hou et al., 2008; Chen et al., 2009). DHA-induced
apoptosis is abrogated by the loss of Bak and is largely reduced in cells with siRNA-mediat‐
ed down-regulation of Bak or NOXA (Handrick et al., 2010). DHA has been shown to acti‐
vate caspase-8, however, which is related to the death receptor-mediated apoptotic pathway
in HL-60 cells (Liu et al., 2008). DHA has also been shown to enhance Fas expression and
activates caspase-8 in ovarian cancer cells (Chen et al., 2009). In addition, DHA enhances
death receptor 5 and activates both mitochondrial- and death receptor-mediated apoptotic
pathways in prostate cancer cells (He et al., 2010). ARTs-induced apoptosis in cancer cells
may involve p38 MAPK, however, rather than p53 (Hou et al., 2008; Lu et al., 2008).
Since most anti-cancer drugs kill tumor cells by the induction of apoptosis, the same may be
true for ART and its derivatives. AS was first shown to promote apoptosis in tumor cells
(Efferth et al., 1996). This has been subsequently confirmed by other groups (Li et al., 2001;
Sadava et al., 2002; Singh and Lai, 2004; Wang et al., 2002; Yamachika et al., 2004). By micro‐
array and hierarchical cluster analyses, several apoptosis-regulating genes were identified,
whose mRNA expression correlated significantly with the IC50 values for AS in the NCI can‐
cer cell lines (Efferth et al., 2003).
2.4.5. Oxidative stress response
ART is first activated in malaria parasites by intra-parasitic heme-iron, which catalyzes the
cleavage of the endoperoxide bond. The Plasmodium trophozoites and schizonts live within
red blood cells, where hemoglobin serves as an amino acid source. It is taken up by the para‐
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sites into food vacuoles, where enzymatic degradation takes place (Semenov et al., 1998;
Shenai et al., 2000). The release of heme-iron during hemoglobin digestion facilitates the
cleavage of the endoperoxide moiety by a Fe (II) Fenton reaction. Breaking the endoperoxide
bridge of ART results in the generation of reactive oxygen species, such as hydroxyl radicals
and superoxide anions, which damage the food vacuole membranes and leads to subse‐
quent auto-digestion (Krishna et al., 2004; O’Neill and Posner, 2004). In addition, the heme
iron (II)-mediated decomposition of ART leads to the generation of carbon-centered radical
species (Butler et al., 1998). The cleavage of the endoperoxide bond of ART and its deriva‐
tives also leads to the alkylation of heme and some Plasmodium-specific proteins, including
the Plasmodium falciparum translationally controlled tumor protein (TCTP) and the sarco/
endoplasmic reticulum Ca2+ ATPase (SERCA) ortholog of Plasmodium falciparum (Eckstein-
Ludwig et al., 2003). Recent observations indicate, however, that heme iron (II) and oxida‐
tive stress are not the only mechanisms of ART’s anti-malarial activity (Parapini et al., 2004).
By comparing the baseline antioxidant mRNA gene expression in the NCI cell line panel
with the IC50 values for AS, oxidative stress was found to play a role in the anti-tumor activi‐
ty of AS (Efferth, 2006). The expression of thioredoxin reductase and catalase correlated sig‐
nificantly with the IC50 values for AS against the tumor cell lines in the NCI panel. As tumor
cells contain much less iron than erythrocytes, but more than other normal tissues (Shter‐
man et al., 1991), the question arises as to whether iron may be critical for ART’s activity
against tumor cells (Payne, 2003). The growth of tumors in rats was significantly retarded by
daily oral administration of ferrous sulfate followed by dihydroartemisinin, while treatment
with each drug applied alone had no effect (Moore et al., 1995). Cellular iron uptake and in‐
ternalization are mediated by binding of transferrin-iron complexes to the transferrin recep‐
tor (CD71) expressed on the cell surface membrane which leads to subsequent iron
endocytosis. CD71 is normally expressed in the basal epidermis, endocrine pancreas, hepa‐
tocytes, Kupfer cells, testis, and pituitary, while most other tissues are CD71-negative. In
contrast, CD71 is highly expressed in proliferating and malignant cells (Sutherland et al.,
1981) and it is widely distributed among clinical tumors (Gatter et al., 1983).
Interestingly, exposure of ART and its derivatives produces no or only marginal cytotoxicity
to non-tumor cells. Human breast cells do not respond to treatment with transferrin plus
DHA, while the growth of breast cancer cells is significantly inhibited (Singh and Lai, 2001).
Similarly, ART tagged to transferrin has been shown to be more cytotoxic to MOLT-4 leuke‐
mia cells than to normal lymphocytes (Lai et al., 2005).
2.4.6. Oncogenes and tumor suppressor genes
Oncogenes and tumor suppressor genes frequently affect downstream processes in tumor
cells. The expression of several oncogenes and tumor suppressor genes has been shown to
correlate with response to artesunate, including the epidermal growth factor receptor
(EGFR), the tumor growth factor ß (TGFB), FBJ murine osteosarcoma viral oncogene homo‐
logue B (FOSB), FOS-like antigen-2 (FOSL2), the multiple endocrine neoplasia 1 gene
(MEN1), v-myb avian myeloblastosis viral oncogene homolog (MYB), v-myc avian myelocy‐
tomatosis viral oncogene homolog
The Use of Artemisinin Compounds as Angiogenesis Inhibitors to Treat Cancer
http://dx.doi.org/10.5772/54109
187
(MYC), c-src tyrosine kinase (CSK), v-raf murine sarcoma viral oncogene homolog B1
(BRAF), the RAS oncogene family members ARHC, ARHE, RAB2 and RAN, the breast cancer
susceptibility gene 2 (BRCA2), and others (Efferth et al., 2003).
The epidermal growth factor receptor (EGFR) represents an exquisite target for therapeu‐
tic  interventions,  and  molecular  approaches  to  study  the  expression  of  the  EGFR  gene
have yielded some very interesting findings.  Glioblastoma cells  transfected with a  dele‐
tion-activated EGFR cDNA were more resistant to AS than the control cells which agrees
well with microarray gene expression data (Efferth et al.,  2003). In addition to playing a
role in drug resistance, the activation of EGFR-coupled signaling routes drives mitogenic
and other  cancer-promoting processes,  e.g.  proliferation,  angiogenesis,  and inhibition  of
apoptosis (Efferth 2006). In addition, combination treatment of the EGFR tyrosine kinase
inhibitor,  OSI-774,  plus  AS was investigated and synergistic  effects  were  found in  glio‐
blastoma  cells  transfected  with  a  deletion-activated  EGFR  cDNA,  and  additive  effects
were shown to  occur  in  cells  transfected with wild-type EGFR  (Efferth et  al.,  2004a).  A
profile  of  chromosomal  gains  and  losses  was  determined  by  comparative  genomic  hy‐
bridization in nine non-transfected glioblastoma cell lines, and this profile correlated well
with the IC50  values determined after treatment of the same glioblastoma cell  lines with
the combination treatment of AS and OSI-774. Genes located at genomic loci correlating
to cellular response to AS and OSI-774 may serve as candidate genes to determine drug
sensitivity and resistance (Efferth 2007).
By screening a panel of isogenic Saccaromyces cerevisiae strains with defined genetic muta‐
tions in DNA repair, DNA checkpoint, and cell proliferation genes, one yeast strain with a
defective mitosis-regulating BUB3 gene showed increased sensitivity to AS treatment. An‐
other strain with a defective proliferation-regulating CLN2 gene showed increased AS resist‐
ance over the wild-type strain. None of the other DNA repair or DNA check-point deficient
isogenic strains were different from wild-type yeast (Efferth et al., 2001). The conditional ex‐
pression of the CDC25A gene by a tetracycline repressor expression vector (tet-off system)
has been shown to increase cellular sensitivity to AS treatment (Efferth et al., 2003). CDC25A
is a key regulator of the cell cycle, which drives cells from the G1 phase into S phase. AS has
been shown to down-regulate the expression of the CDC25A protein which supports the hy‐
pothesis that AS interferes with cell cycle regulation (Efferth et al., 2003).
The IC50 values for artesunate were correlated with the constitutive mRNA expression levels
measured by microarray hybridization. Scientists selected expression data of 559 genes de‐
posited in the NCI’s database (http://dtp.nci.nih.gov). The mRNA expression has been deter‐
mined as reported. These genes belong to different categories of biological functions (63
apoptosis-regulating genes, 113 proliferation associated genes, 140 anti-oxidative stress re‐
sponse genes, 90 angiogenesis-regulating genes, 123 oncogenes and tumor suppressor
genes). For example, p53, the ‘‘guardian of the genome’’, is a transcription factor that can
bind to promoter regions of hundreds of genes where it either activates or suppresses gene
expression. Thereby, p53 serves as a tumor suppressor by inducing cell cycle arrest, apopto‐
sis, senescence and DNA repair. In normal cells, p53 is frequently undetectable due to fast
ubiquitination by mdm-2 and subsequent proteasomal degradation. However, upon DNA
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damage and several other stresses, including drug stress, the amount of p53 is increased due
to disruption of its degradation. Artesunate could inhibit HSCs proliferation in vitro
through increase the expression of p53 (Efferth et al., 2006; Hou et al., 2008; Lu et al., 2008).
2.4.7. Multidrug resistance
A prominent feature of ART and its derivatives in malaria treatment shows early signs of
cross-resistance to other antimalarial drugs. ARTs are therefore very valuable for the treat‐
ment of otherwise unresponsive, multidrug-resistant malaria parasites (Li and Weina 2011).
Therefore, it is reasonable to ask whether ARTs are involved in the multidrug-resistance
phenotypes observed in tumor cells. A comparison of the microarray-based mRNA expres‐
sion of the multidrug resistance-conferring ABCB1 gene (MDR1; P-glycoprotein) was con‐
ducted with the IC50 values determined for tumor cells treated with AS and
dihydroartemisinyl ester stereoisomer 1, but no significant relationships were observed.
Similarly, the flow cytometric measurement of the fluorescent probe rhodamine 123, which
represents a functional assay for P-glycoprotein, did not reveal significant correlations, and
similar results were obtained with other ARTs. As a control, we used the established anti-
tumor drug docetaxel (taxotere), which is a known substrate of MDR1 (Shirakawa et al.,
1999). The IC50 values determined for cells treated with docetaxel correlated both with rhod‐
amine 123 efflux and MDR1 mRNA expression. To validate these results obtained by corre‐
lation analyses, cell lines over-expressing MDR1/P-glycoprotein as well as other drug
resistance-conferring genes were used. AS was shown similarly active towards drug-sensi‐
tive and multidrug resistant cell lines (Efferth et al., 2002; 2003). Likewise, methotrexate-re‐
sistant CEM/MTX1500LV cells with an amplification of the dihydrofolate reductase (DHFR)
gene and hydroxyurea-resistant CEM/HUR90 cells with over-expression of ribonucleotide
reductase (RRPM2) were not cross-resistant to AS. In addition, other research has shown
that ART increased the tissue permeability for standard cytostatic drugs. i.e. doxorubicin in
mouse embryonic stem cell-derived embryoid bodies (Wartenberg et al., 2003).
3. Anti-cancer effect of ARTs via an anti-angiogenic activity
In the process of angiogenesis, the formation of new blood vessels from pre-existing ones is
essential for the supply of tumors with oxygen and nutrients and for the spread of metastat‐
ic cells throughout the body. Normal angiogenesis is strictly controlled by some transient,
typical physiological processes such as reproduction, development, wound healing; contin‐
ued angiogenesis is also a characteristic of pathological alteration such as neoplasia. Neopla‐
sia is an angiogenesis-dependent disease, and the growth of tumors, intravasation and
metastases require angiogenesis. In human and experimental cancers, new vessels are re‐
quired for increased delivery of nutrients and are a target for invading tumor cells, and
there is a large body of evidence to support a key role for angiogenesis in disease progres‐
sion. The growth, invasion and metastasis of tumors have been shown to be dependent on
angiogenesis. A summary of the anti-angiogenic effects of ARTs is shown in Table 1.





1) Induction of apoptosis in KS-IMM cells
2) Reduced F1t-1 and KDR/flk-1 expressions
3) Lowered VEGF and KDR/flk-1 expression
4) inhibited the proliferation of HUVEC
5) Inhibited HUVEC and VEGF expression
6) Suppress angiogenic ability & Decreased VEGF
7) Decreased HIF-1α levels
8) Decreased VEGF and Ang-1 secretion
9) Decreased the secretion of VEGF and IL-8
10) Either increased cytotoxicity or cytostasis
Dell’Eva et al., 2004
Huan-huan et al., 2004
Chen et al., 2004a
Chen et al., 2004b
Chen et al., 2004c
Zhou et al., 2007
Zhou et al., 2007
Chen et al., 2010a
He et al., 2011
Liu et al., 2011
Dihydro-artemisinin
(DHA)
1) DHA was more effective than AS
2) Reduced VEGF binding to its receptors
3) Induced K562 cells apoptosis, inhibited VEGF
4) Reduced VEGF secretion by RPMI8226 cells
5) Attenuated the levels of VEGFR-3/Flt-4.
6) Decreased KDR levels and NF-kB DNA binding
7) Inhibition of PKCalpha/Raf/MAPKs
8) Decreased VEGF receptor KDR/flk-1
9) Inhibited the expression of several MMPs
10) DHA inactivates NF-kappaB and potentiates
11) Down-regulated VEGF
12) Inducted iron-dependent endoplasmic reticulum stress
13) DHA inhibits formation of HUVECs, MMP9
Chen et al., 2003
Chen et al., 2004a
Lee et al., 2006
Wu et al., 2006
Wang et al., 2007
Chen et al., 2010b
Hwang et al., 2010
Zhou et al., 2010
Rasheed et al., 2010
Wang et al., 2010
Aung et al., 2011
Lu et al., 2011
Wang et al., 2011
Artemisinin (ART)
1) Decreased VEGF-A transcription
2) Decreased MMP2, MMP9 and BMP1 levels
3) Decreased VEGF-C, IL-1 β-induced p38
4) Decreased αvβ3 transcription
Anfosso et al., 2006
Anfosso et al., 2006
Wang et al., 2008
Buommino et al., 2009
2nd Artemisinin
artemisone
less anti-angiogenic effect than DHA in all the experimental
models
D’Alessandro et al., 2007
Artemisinin-like
compounds (ART-like)
1) Active against solid tumor-derived cell lines and good
correlation with other ARTs
2) More active in vitro and in vivo than the commonly used
AS
Galal et al., 2009 Soomro et al.,
2011
Thioacetal ARTs inhibitiory activity upon HUVEC Oh et al., 2003
ART-glycolipid hybrids Showed potent in vivo anti-angiogenic activity on CAM Ricci et al., 2010
VEGF = vascular endothelial growth factor; HIF = hypoxia-inducible factor; NF-kB = nuclear factor of kappa light poly‐
peptide gene enhancer in B cells 1; KDR = kinase insert domain protein recepto; MMP = matrix metalloproteinase;
BMP = bone morphogenic protein; αvβ3 = Transmembrane heterodimeric protein expressed on sprouting endothelial
cells; HUVEC = human umbilical vein endothelial cells. CAM = chorioallantoic membrane
Table 1. Anti-angiogenic effects of ART and its derivatives
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3.1. Anti-angiogenic effects of ARTs
3.1.1. In vitro anti-angiogenic effects of ART and its derivatives
While most of the research on the anti-cancer activities of ARTs has been performed with
cell lines in vitro, there are a few reports in the literature showing activity in vivo against xen‐
ograft tumors, e.g., breast tumors, ovarian cancer, Kaposi sarcoma, fibrosarcoma, or liver
cancer. The in vitro data in the literature supports the hypothesis that ART and its deriva‐
tives kill or inhibit the growth of many types of cancer cell lines, including drug-resistant
cell lines, suggesting that ART could become the basis of a new class of anti-cancer drugs. In
addition, the co-administration of holotransferrin and other iron sources with ARTs has
been shown to increase the potency of ARTs in killing cancer cells.
Artemisinin (ART)
ARTs are antimalarial agents, but also reveal profound antitumor activity in vitro and in
vivo. Ina microarray study of cancer cells treated at the 50% inhibition concentration with
eight ARTs, (ART, AS, arteether, artemisetene, arteanuine B, dihydroartemisinylester stereo‐
isomers 1 and 2) the mRNA expression data of 89 known angiogenesis-related genes was
obtained and correlated against the sensitivity of these tumor cells to ARTs treatment. The
constitutive expression of 30 genes correlated significantly with the cellular response to
ARTs. The finding cell sensitivity and resistance of tumor cells could be predicted by the
mRNA expression of angiogenesis related genes supports the hypothesis that ARTs reveal
their antitumor effects at least, in part, by inhibition of tumor angiogenesis. As many chemo-
preventive drugs exert anti-angiogenic features, ARTs might also be chemo-preventive in
addition to their cytotoxic effects (Anfosso et al., 2006).
A recent  study demonstrated that  ART-induced cell  growth arrest  in  A375M malignant
melanoma  tumor  cells  also  affected  the  viability  of  A375P  cutaneous  melanoma  tumor
cells  with  both  cytotoxic  and growth inhibitory  effects,  while  ART was  not  effective  in
inhibiting the growth of other tumor cell lines (MCF7 and MKN). In addition, ART treat‐
ment  affected  the  migratory  ability  of  A375M  cells  by  reducing  metalloproteinase  2
(MMP-2) productions and down-regulating αvβ3 integrin expression. These findings sup‐
port  the  hypothesis  that  ART  may  serve  as  a  chemotherapeutic  agent  for  melanoma
treatment (Buommino et  al.,  2009).  Furthermore,  IL-1beta-induced p38 mitogen-activated
protein kinase (MAPK) activation and upregulation of VEGF-C mRNA, and VEGF-C re‐
ceptor protein levels in LLC cells were also suppressed by ART or by the p38 MAPK in‐
hibitor  SB-203580,  suggesting  that  p38  MAPK  could  serve  as  a  mediator  of  pro-
inflammatory  cytokine-induced  VEGF-C  expression.  These  data  support  the  hypothesis
that ART may be useful for the prevention of lymph node metastasis by downregulating
VEGF-C and reducing tumor lymphangiogenesis (Wang et al., 2008).
Dihydroartemisinin (DHA)
DHA and AS have been shown to be remarkable inhibitors of tumor cell growth and sup‐
pression of angiogenesis in vitro. The anti-cancer activity of ARTs has been demonstrated by
an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) growth inhibition
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assay of four human cancer cell lines, cervical cancer HeLa, uterus chorion cancer JAR, em‐
bryo transversal cancer RD and ovarian cancer HO-8910 treated with DHA and AS. IC50 val‐
ues obtained through this MTT growth inhibition assay demonstrated that DHA was more
effective at inhibiting cancer cell lines than AS. The anti-angiogenic activities of DHA and
AS were tested on in vitro models of angiogenesis by assessing the proliferation, migration
and tube formation of human umbilical vein endothelial (HUVE) cells. The results showed
that DHA and AS significantly inhibited angiogenesis in a dose-dependent manner. These
results also showed that DHA was more effective than ART in inhibiting angiogenesis
(Chen et al., 2003).
The effect of DHA on human multiple myeloma-induced angiogenesis under hypoxia and
elucidated its mechanism of action has been performed. An in vivo chicken chorioallantoic
membrane model was used to examine the effect of DHA on multiple myeloma-induced an‐
giogenesis. Compared with conditioned medium of control, conditioned medium from hu‐
man multiple myeloma RPMI8226 cells pretreated with 3 µM DHA in hypoxia was
observed to reduce microvessel growth on chicken chorioallantoic membranes by approxi‐
mately 28.6% (P < 0.05). The level of VEGF in conditioned medium was determined by en‐
zyme-linked immunosorbent assay. The results confirmed that 3 µM DHA could
significantly decrease VEGF secretion by RPMI8226 cells (P < 0.05), which correlated well
with the reduction of multiple myeloma-induced angiogenesis on chicken chorioallantoic
membranes. Western blot and reverse transcription-PCR results revealed that DHA downre‐
gulated the expression of VEGF in RPMI8226 cells in hypoxia. Therefore, DHA possesses
potential as an antiangiogenic drug in multiple myeloma therapy and thereby may improve
patient outcome (Wu et al., 2006).
The effect of DHA on VEGF expression and apoptosis in chronic myeloid leukemia (CML)
K562 cells was assessed. The results demonstrated that in addition to its anti-proliferation
effect on CML cells, DHA was also found to induce K562 cells apoptosis. The percentage of
apoptotic cells was increased to 6.9 and 15.8% after being treated with 5 and 10 µM DHA for
48 h, respectively (P < 0.001). All these experiments suggested that DHA could inhibit the
VEGF expression and secretion effectively in K562 cells, even at a lower concentration (2
µM, P < 0.05). Moreover, we further assessed the stimulating angiogenic activity of CM from
K562 cells on CAM model. Also, the angiogenic activity was decreased in response to the
CM from K562 cells pretreated with DHA in a dose-dependent manner. Taken together,
these results from our study together with its known low toxicity make it possible that DHA
might present potential anti-leukemia effect as a treatment for CML therapy, or as an ad‐
junct to standard chemotherapeutic regimens (Lee et al., 2006)
DHA  was  found  to  have  a  potent  ability  in  influencing  lymphatic  endothelial  cells
(LECs) behavior. DHA also exerted a significant inhibitory effect on migration and tube-
like  formation  of  LECs  in  a  dose-dependent  manner.  Quantitative  RT-PCR  further
showed  that  DHA  remarkably  downregulated  the  expression  of  antiapoptotic  bcl-2
mRNA,  but  upregulated  that  of  the  proapoptotic  gene  bax  mRNA.  In  addition,  DHA
could  strongly  attenuate  the  mRNA  and  protein  levels  of  VEGFR-3/Flt-4.  In  summary,
these findings indicate that DHA may be useful as a potential lymphangiogenesis inhibi‐
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tor under induction of cell apoptosis, inhibition of the migration, and formation of tube-
like structures in LECs (Wang et al., 2007). In addition, to investigate the effects of DHA
on cell cycle progression and NF-kappaB activity in pancreatic cancer cells, the cell cycle
progression was determined. The translocation and DNA-binding activity of  NF-kappaB
were inhibited in DHA-treated cells in a dose-dependent manner, indicated the inactiva‐
tion effects of DHA in pancreatic cancer cells.  Study shows that DHA induces cell  cycle
arrest and apoptosis in pancreatic cancer cells, and this effect might be due to inhibition
of NF-kappaB signaling (Chen et al., 2010b).
One study showed that DHA is an effective anti-metastatic agent that functions by down-
regulating the MMP-9 gene which is associated with metastasis. 1) DHA was shown to re‐
duce phorbol myristate acetate (PMA)-induced activation of MMP-9 and MMP-2 and
further inhibited cell invasion and migration. 2) DHA was also shown to suppress the PMA-
enhanced expression of the levels of MMP-9 protein and mRNA, and enhanced transcrip‐
tional activity of the MM-9 gene through suppression of NF-kappaB and activation of AP-1
without changing the level of tissue inhibition of metalloproteinase (TIMP)-1. 3) DHA has
been shown to reduce PMA-enhanced MMP-2 expression by suppressing membrane-type 1
MMP (MT1-MMP), but was not shown to t alter TIMP-2 levels. 4) DHA was shown to inhib‐
it PMA-induced NF-kappaB and c-Jun nuclear translocation, which are upstream of PMA-
induced MMP-9 expression which enhances metastasis. 5) DHA strongly repressed the
PMA-induced phosphorylation of Raf/ERK and JNK, which are dependent on the PKC al‐
pha pathway. In summary, this study demonstrated that the anti-invasive effects of DHA
may occur through inhibition of PKC alpha/Raf/ERK and JNK phosphorylation and reduc‐
tion of NF-kappaB and AP-1 activation, leading to down-regulation of MMP-9 expression.
(Hwang et al., 2010)
Wang et al. demonstrated that DHA enhances gemcitabine-induced growth inhibition and
apoptosis in both BxPC-3 and PANC-1 cell lines in vitro. The effect is at least partially due to
the DHA-driven deactivation of gemcitabine-induced NF-kappaB activation, which in turn
leads to a tremendous decrease in the expression of NF-kappaB target gene products, such
as c-myc, cyclin D1, Bcl-2, Bcl-xL (Wang et al., 2010). DHA was also shown to exhibit signifi‐
cant anti-cancer activity against the renal epithelial LLC cell line. In addition, DHA was
shown to induce apoptosis of LLC cells and influenced the expression of the vascular endo‐
thelial growth factor (VEGF) receptor KDR/flk-1. Furthermore, in both tumor xenografts, a
greater degree of growth inhibition was achieved when DHA and chemotherapeutic drugs
were used in combination. The combined effect of DHA administered with chemotherapy
drugs on LLC tumor metastasis was shown to be significant (Zhou et al., 2010).
The effect of DHA was investigated using in vitro/in vivo optical imaging combined with
cell/tumor growth assays of the pancreatic cancer cell line BxPc3-RFP which stably expresses
red fluorescence protein. DHA inhibited the proliferation and viability of pancreatic cancer
cells in a dose-dependent manner and induced apoptosis. The results of this experiment
demonstrated DHA-induced down-regulation of PCNA and Bcl-2, and up-regulation of
Bax. VEGF expression was down-regulated by DHA in cells under normoxic, but not hypox‐
ic, conditions. The anti-angiogenic effect of DHA appears to be a complicated process (Aung
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et al., 2011). DHA was shown to significantly inhibit NF-κB DNA-binding activity, which in
turn results in a tremendous decrease in the expression of NF-κB-targeted pro-angiogenic
gene products such as VEGF, IL-8, COX-2, and MMP-9 in vitro: These findings suggest that
DHA could be developed as a novel agent against pancreatic cancer (Wang et al., 2011). Ad‐
ditional supporting evidence of the potential of DHA to be used as an anti-pancreatic cancer
agent were shown through a DHA driven up-regulation of glucose-regulated protein 78
(GRP78), which is known to be involved in endoplasmic reticulum stress (ER stress),. Fur‐
ther study demonstrated that DHA could enhance expression of GRP78 as well as the
growth arrest and DNA-damage-inducible gene 153 at both the mRNA and protein levels.
These studies suggest that redox imbalance may result in DHA-induced ER stress, which
may contribute, at least in part, to its anti-cancer activity (Lu et al., 2011).
Artesunate (AS)
AS has been shown to inhibit the growth of Kaposi’s sarcoma cells, a highly angiogenic mul‐
tifocal tumor, and the degree of cell growth inhibition correlated with the induction of apop‐
tosis. AS was also shown to inhibit the growth of normal human umbilical endothelial cells
and of KS-IMM cells that were established from a Kaposi's sarcoma lesion obtained from a
renal transplant patient. The inhibition of cell growth correlated with the induction of apop‐
tosis in KS-IMM cells. Apoptosis was not observed in normal endothelial cells, which
showed drastically increased cell doubling times upon AS treatment (Dell’Eva et al., 2004).
AS has been shown to greatly inhibit  cell  proliferation and differentiation of endothelial
cells in a dose-dependent manner in the range of 12.5-100 µM. AS was also shown to re‐
duce Flt-1 and KDR/flk-1 expression of endothelial cells when dosed in vitro in a range of
0.1-0.5 µM. In subsequent studies by the same author, the AS-driven apoptosis of a human
microvascular dermal endothelial cell line was studied. The apoptosis was detected utiliz‐
ing a morphological dual staining assay composed of ethidium bromide and acridine or‐
ange  as  well  as  a  DNA  fragmentation  TUNEL  assay  quantified  by  a  flow  cytometric
propidium iodide (PI) assay. The results suggest that the anti-angiogenic effect induced by
AS treatment might occur by the induction of cellular apoptosis (Huan-huan et al., 2004). In
addition, the inhibitory effect of AS on in vitro  angiogenesis was tested using aortic cells
cultured in a fibrin gel. AS was shown to effectively suppress the stimulating angiogenic
ability of chronic myeloid leukemia cells (line K562) when the K562 cells were pretreated
for 48 h with AS in a time-dependent manner (days 3-14). AS treatment was also found to
decrease the VEGF level in chronic myeloma K562 cells, even at a lower concentration (2
µmol/l, P < 0.01). (Zhou et al., 2007).
The addition of Fe(II)-glycine sulfate and transferrin has been shown to enhance the cytotoxici‐
ty (10.3-fold) of free AS in vitro. AS microencapsulated in maltosyl-ß- cyclodextrin, and ARTs
were tested against CCRF-CEM leukemia and U373 astrocytoma cells in vitro (Efferth et al.,
2004). Treatment with AS at more than 2.5 µM for 48 h inhibited the proliferation of human vein
endothelial cells (HUVEC) in a concentration dependent manner using an MTT (3-(4,5-dime‐
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)  based  growth  proliferation  assay  (p  <
0.05). The IC50 value of this growth inhibition assay was 20.7 µM, and HUVEC cells were also
shown to be growth inhibited by 88.7% after treatment with 80 µM AS (Chen et al., 2004b).
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AS at low concentration was shown to significantly decrease VEGF and Ang-1 secretion by
human multiple myeloma cells (line RPMI8226, P < 0.05), which correlated well with the re‐
duction of angiogenesis induced by the myeloma RPMI8226 cells. This study also showed
that AS down-regulated the expression of VEGF and Ang-1 in RPMI8226 cells and reduced
the activation of extracellular signal regulated kinase 1 (ERK1) as well. Therefore, AS has
been shown to block ERK1/2 activation, downregulate VEGF and Ang-1 expression and in‐
hibit angiogenesis induced by human multiple myeloma RPMI8226 cells. Combined with
previous published data, the results from this study supports the hypothesis that AS pos‐
sesses potential anti-myeloma activity (Chen et al., 2010a).
AS has also been shown to decrease the secretion of VEGF and IL-8 from TNFα- or hy‐
poxia-stimulated rheumatoid arthritis fibroblast-like synoviocyte (line RA FLS) in a dose-
dependent  manner.  In  addition,  AS  treatment  resulted  in  the  inhibition  of  TNFα-  or
hypoxia-induced  nuclear  expression  and  translocation  of  HIF-1α.  AS  treatment  was
shown to prevent Akt phosphorylation, but there was no evidence that phosphorylation
of p38 and ERK was averted. TNFα- or hypoxia-induced secretion of VEGF and IL-8 and
expression  of  HIF-1α  were  hampered  by  treatment  with  the  PI3  kinase  inhibitor
LY294002,  suggesting  that  inhibition  of  PI3  kinase/Akt  activation  might  inhibit  VEGF,
IL-8  secretion,  and HIF-1α expression  induced by  TNFα or  hypoxia.  Therefore,  AS has
been shown to inhibit angiogenic factor expression in the RA FLS cell  line, and this lat‐
est study provides new evidence that, as a low-cost agent, AS may have therapeutic po‐
tential for rheumatoid arthritis (He et al., 2011).
Using a polyploid cell line, research on the role of AS in impacting cell cycle arrest was as‐
sessed. The results of this study show that AS treatment of polyploid cells resulted in a
dose-dependent decreases in cell number, which was associated with either increased cyto‐
toxicity or cytostasis. Of the two possibilities, cytostasis, a simultaneous arrest at all phases
of the cell cycle, appeared to be a more likely possibility. This deduction was supported by
molecular profiling, which showed reductions in cell cycle transit proteins. AS appeared to
maintain cells in this arrested state, however, reculturing these treated cells in drug-free me‐
dium resulted in significant reductions in cell viability. Taken together, these observations
indicate AS and its related compounds may be effective for the treatment of polyploid tu‐
mors, and that activity is related to the cell cycle schedule. Therefore, it is important to care‐
fully select the most appropriate schedule to maximize AS efficacy when using AS as a
primary or adjuvant anti-tumor therapy (Liu et al., 2011)
3.1.2. In vivo anti-angiogenic effects of ART and its derivatives
There are many reports discussing the in vivo anti-cancer activity of ARTs which may pro‐
vide insight into the potential activity of ARTs as anti-cancer agents.
Artemisinin (ART)
The effect of ART on tumor growth, lymphangiogenesis, metastasis and survival in mouse
Lewis lung carcinoma (LLC) models was examined. The results of this study showed that
orally administered artemisinin inhibited lymph node and lung metastasis and prolonged
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survival without retarding tumor growth. ART-treated mice showed significant decreases in
lymph node metastasis, tumor lymphangiogenesis and expression of VEGF-C as compared
to control mice. (Wang et al., 2008).
Dihydroartemisinin (DHA)
The anti-angiogenic activity of DHA in vitro  and in vivo,  and investigated DHA-induced
apoptosis  in  human umbilical  vein  endothelial  cells  (HUVEC).  DHA markedly  reduced
VEGF binding  to  its  receptors  on  the  surface  of  HUVEC.  The  expression  levels  of  two
major VEGF receptors, Flt-1 and KDR/flk-1, on HUVEC were lower following DHA treat‐
ment as shown by an immunocytochemical staining assay. The in vivo anti-angiogenic ac‐
tivity was evaluated in the chicken chorioallantoic membrane (CAM) neovascularization
model.  DHA  significantly  inhibited  CAM  angiogenesis  at  low  concentrations  (5-30
nmol/100  microl  per  egg).  This  group also  investigated both  qualitatively  and quantita‐
tively the induction of  HUVEC apoptosis  by DHA. A dose-related (5-80 µM) and time-
dependent  (6-36  h)  increase  in  DHA-induced  HUVEC apoptosis  was  observed  by  flow
cytometry.  These  results  suggest  that  the  anti-angiogenic  effect  induced by DHA might
occur by induction of cellular apoptosis and inhibition of expression of VEGF receptors.
These findings and the known low toxicity of DHA indicate that it might be a promising
candidate angiogenesis inhibitor (Chen et al., 2004a).
The anti-angiogenic effect of DHA on pancreatic cancer was assessed using BxPC-3 xeno‐
grafts  subcutaneously established in BALB/c nude mice.  DHA demonstrated remarkable
activity against pancreatic cancer studies concuted in vivo. DHA treatment resulted in re‐
duced tumor volume and decreased microvessel density, and there were additional tran‐
scriptional effects demonstrated in these studies as well regarding the expression of NF-
κB-related  pro-angiogenic  gene  products  which  were  down-regulated.  This  finding  of
relating to the inhibition of NF-κB activation is likely one of the mechanisms involved in
DHA anti-angiogenic  activity against  human pancreatic  cancer.  This  suggests  that  DHA
could be developed as a  novel  agent against  pancreatic  cancer (Wang et  al.,  2011).  In a
further  study,  the  co-administration  of  the  chemotherapeutic  agent  gemcitabine  with
DHA was  shown to  result  in  remarkably  enhanced anti-tumor  effects,  as  demonstrated
by significantly increased apoptosis, as well as a decreased Ki-67 index, reduced NF-kap‐
paB activity, reduced downstream angiogenic gene products, and predictably, significant‐
ly  reduced tumor volume.  The authors  conclude that  inhibition  of  gemcitabine-induced
NF-kappaB activation is  one of  the mechanisms by which DHA could promote its  anti-
tumor effect on pancreatic cancer (Wang et al., 2010).
Artesunate (AS)
The anti-angiogenic effect in vivo of artesunate was evaluated in nude mice f implanted with
human ovarian cancer cells (HO-8910). The effects of artesunate on angiogenesis in this in
vivo study were evaluated by immune-histochemical staining for microvessel associated an‐
tigens (CD31), VEGF and the VEGF receptor KDR/flk-1. AS significantly inhibited angiogen‐
esis in a concentration-dependent form in the range of 0.5-50 µM. The IC50 of AS for HUVE
cells was 21 µM. Growth of the xenograft tumor was decreased and microvessel density was
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reduced following drug-treatment with no apparent toxic effects on the nude mice. AS ad‐
ministration was shown to dramatically reduce VEGF expression on tumor cells and KDR/
flk-1 expression on endothelial cells as well as tumor cells. Accordingly, these results sup‐
port the hypothesis that AS is capable of inhibiting angiogenesis in vitro and in vivo. These
findings together with the known low toxicity of AS are clues that AS may be a promising
angiogenesis inhibitor (Chen et al., 2004c).
Further studies on the anti-angiogenic effects of AS have been conducted in vivo and in vitro.
The anti-angiogenic effect of AS in vivo was evaluated utilizing the chicken chorioallantoic
membrane (CAM) neovascularization model. At low concentrations of 10 nM/100 µl/egg, AS
was shown to significantly inhibit CAM angiogenesis, and completely inhibited angiogene‐
sis at concentrations of 80 nM/100 µl/egg. The results of this study suggest that the anti-an‐
giogenic effect induced by AS might occur by the induction of cellular apoptosis. These
findings and the known low toxicity of AS support the hypothesis that AS might be a prom‐
ising candidate as an angiogenesis inhibitor (Huan-huan et al., 2004). Similarly, AS was
shown to significantly impair primary tumor growth and metastasis in the chicken embryo
metastasis (CAM) model where AS was shown to suppress invasion and metastasis of non-
small cell lung cancer (NSCLC) cells. The transcriptional findings of these experiments
showed AS treatment reduced transcription of u-PA, MMP-2 and MMP-7, supporting the
hypothesis that AS has promise as a novel therapeutic for NSCLC (Rasheed et al., 2010).
Also, AS has been studied in a variety of tumor models as a potential antitumor drug. In one
study of vascularization, a critical element of tumor metastasis, AS was shown to strongly
reduce angiogenesis of Kaposi’s sarcoma cells in vivo by inhibiting vascularization in Matri‐
gel plugs injected subcutaneously into syngenic mice. This data suggests that AS represents
a promising candidate drug for the treatment of the highly angiogenic Kaposi's sarcoma. As
a low-cost drug, it might be of particular interest for use in areas of the world where Kapo‐
si's sarcoma is highly prevalent. (Dell’Eva et al., 2004).
The efficacy of AS, as an anti-cancer agent, to reduce tumor growth was studied in rats giv‐
en AS subcutaneously at a dose of 50 mg/kg/day and at a dose of 100 mg/kg/day for 15 days.
The results of this experiment showed animals with AS treated tumors showed a reduction
in tumor growth by 41%, in the 50 mg/kg treatment group and 62% in the 100 mg/kg treat‐
ment group. The density of micro-vessels which was used as a measure of angiogenic activi‐
ty in the tumors of animals treated with 100 mg/kg of AS daily was at least four times lower
than in the control group (Chen et al., 2004b). The anti-angiogenic activity of AS in vivo was
also evaluated in nude mice implanted with a human ovarian cancer cell line (HO-8910).
Evaluation of angiogenesis in the AS treated and control animals with an ovarian cancer
xenograft were determined through immunohistochemical staining for microvessel forma‐
tion (CD31), VEGF and the VEGF receptor KDR/flk-1. Tumor growth was noted to be de‐
creased, and the density of the tumor microvessels was reduced following AS treatment
with no apparent toxicity to the animals (Chen et al., 2004a, 2004b).
The anti-angiogenic effect of AS was further evaluated in vivo in the chicken chorioallantoic
membrane (CAM) neovascularization model. The results showed that stimulating angiogen‐
ic activity was decreased in response to the treatment of myeloblastic K562 cells with ART,
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and tumor growth was inhibited when K562 cells were pretreated with ART in a dose-de‐
pendent manner (3-12 µmol/l). Further analyses of the level of VEGF expression by Western
blot and also assays of VEGF mRNA by RT-PCR in K562 cells showed that ART could inhib‐
it VEGF expression, and the inhibition correlated well with the level of VEGF secreted in the
culture medium. These findings suggest that AS may have potential as a treatment for
chronic myelogenous leukemia (CML) or as an adjunct to standard chemotherapeutic regi‐
mens (Zhou et al., 2007).
3.1.3. Anti-angiogenic effects of novel ARTs and ART-like compounds
Artesunate has been shown to exhibit anti-angiogenic, anti-tumorigenic and anti-viral prop‐
erties in addition to its known antimalarial properties. The array of activities of the ARTs,
and the recent emergence of malaria resistance to AS, prompted one group to synthesize
and evaluate several novel ART-like derivatives. Sixteen distinct derivatives were therefore
synthesized, and the in vitro cytotoxic effects of each were tested with different cell lines.
The in vivo anti-angiogenic properties were evaluated using a zebrafish embryo model. This
groupreported the identification of several novel ART-like compounds that are easily syn‐
thesized, stable at room temperature, may overcome drug-resistance pathways and are
more active in vitro and in vivo than the commonly used AS. These promising findings raise
the hopes of identifying safer and more effective strategies to treat a range of infections and
cancer (Soomro et al., 2011).
Twelve ART acetal dimers were synthesized and tested for antitumor activity against 60 in
vitro tumor cell lines compiled by the National Cancer Institute (NCI), producing a mean
GI50 concentration between 8.7 (least active) and 0.019 µM (most active). The significant ac‐
tivity of the compounds in this preliminary screen led to additional in vitro antitumor and
anti-angiogenesis studies. Several active dimers were also evaluated in the in vivo NCI hol‐
low fiber assay followed by a preliminary xenograft study. The title compounds were found
to be active against solid tumor-derived cell lines and showed good correlation with other
artemisinin-based molecules in the NCI database (Galal et al., 2009).
In addition, various thioacetal ART derivatives can inhibit the angiogenesis and might be
angiogenesis inhibitors. In particular, 10 alpha-phenylthiodihydroartemisinins, 10 beta-ben‐
zenesulfonyl-9-epi-dihydroartemisinin and 10 alpha-mercaptodihydroartemisinin exhibit
strong growth inhibition activity against HUVEC proliferation. Compound 11 have a good
inhibitory activity upon HUVEC tube formation, and 5 and 11 show a strong inhibitory ef‐
fect on angiogenesis using CAM assay at 5 µg/egg by 90% (Oh et al., 2004).
Artemisone is a novel 10-alkylamino derivative which is not metabolized to DHA. It was se‐
lected as a clinical drug candidate on the basis of its potency in vitro against Plasmodium falci‐
parum and its lack of detectable neurotoxicity in both in vitro and in vivo screens. Artemisone
was tested in vitro and in vivo for anti-angiogenic effects which may support its use as an
anti-angiogenic agent as an adjunct to standard tumor chemotherapy. The various studies of
artemisone’s anti-angiogenic activity include proliferation of human endothelial cells and
their migration on a fibronectin matrix, the sprouting of new vessels from rat aorta sections
grown in collagen, and the production of pro-angiogenic cytokines such as vascular endo‐
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thelial growth factor (VEGF) and interleukin-8 (CXCL-8). The data showed that artemisone
is significantly less anti-angiogenic than DHA in all the experimental models tested, sug‐
gesting that artemisone will be safer to use than the current clinical artemisinins during
pregnancy for an antimalarial indication but perhaps less efficacious for an anti-angiogenic
indication as part of a anti-cancer regimen (D’Alessandro et al., 2007).
3.2. Mechanistic perspectives for the anti-angiogenic activities of ARTs
Angiogenesis and vasculogenesis refer to the growth of blood vessels. Angiogenesis is the
growth most often associated with repair of damaged vessels or the growth of smaller blood
vessels, while vasculogenesis is the process by which the primary blood system is being cre‐
ated or changed. Vasculogenesis occurs during the very early developmental stages of an or‐
ganism when the blood vessel pathways are created. Angiogenesis, while a similar process,
does not depend on the same set of genes as vasculogenesis, and this process is activated
instead in the presence of an injury to a blood vessel. In the last three decades, considerable
research has been reported that supports the hypothesis that tumor growth and metastasis
require angiogenesis. Angiogenesis, the proliferation and migration of endothelial cells re‐
sulting in the formation of new blood vessels, is an important process for the progression of
tumors (Figure 3). ARTs have been shown in a number of published reports to have anti-
angiogenic effects.
Figure 3. The modes of vasculogenesis and angiogenesis. Vasculogenesis occurs during the very early developmental
stages of an organism when the blood vessel pathways are created. Angiogenesis, while a similar process, does not
depend on the same set of genes as vasculogenesis, and this process is activated instead in the presence of an injury to
a blood vessel. Angiogenesis finishes the circulatory connections begun by vasculogenesis and builds arteries and
veins from the capillaries (Modified from Hanahan, 1997
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As malignant tissues grow, metastases and solid tumors require extra blood supply for
thriving and survival. Thus, cancer cells induce neovascularization by regulating proteins
and pathways involved in the generation and restructure of new vasculature. Angiogenesis
process leads to enhanced proliferation of endothelial cells through induction of VEGF, fi‐
broblast growth factor (FGF), its receptors, and cytokines. This event occurs via multiple ef‐
fects including hypoxia-driven activation of expression of HIF-1α and the aryl hydrocarbon
receptor nuclear translocator (ARNT). Angiogenesis control is mediated by angiostatin, en‐
dostatin, thrombospondin, TIMPs, PAI-1, and others. Due to their role in tumor survival, the
pro-angiogenic factors and the molecules involved in their regulatory networks are relevant
drug targets (Crespo-Ortiz and Wei, 2012)
Cancers are capable of spreading through the body by two mechanisms: invasion and meta‐
stasis. Invasion is the direct migration and penetration by cancer cells into neighboring tis‐
sues. Metastasis is the ability of cancer cells to penetrate into lymphatic and blood vessels,
circulate through the bloodstream, and then grow in a new focus (metastasize) in normal tis‐
sues elsewhere in the body. Without a connection to a network of blood vessels, a tumor can
only grow to about the size of a pinhead (1-2 mm), that is to say a tumor is in a vascular,
quiescent status. When a subgroup of cells within the tumor switches to an angiogenic phe‐
notype by changing the local equilibrium between positive and negative regulators of angio‐
genesis, tumor starts to grow rapidly and becomes clinically detectable. Anti-angiogenesis
therapy is a novel approach in cancer treatment and prevention of tumor metastasis. It is
therefore expected that angiogenesis inhibitors may be clinically useful for the treatment of
tumors.
3.2.1. Anti-cancer mechanism of ARTs on angiogenesis-related genes
Angiogenesis involves tissue restructuring, and genes that regulate angiogenesis, such as che‐
mokine receptors, can also affect tumor metastasis. A vital requirement of neovasculogenesis
is endothelial mitosis, which occurs in response to activation by pro-angiogenic signaling from
VEGF and its receptors. Three human genes encode for VEGF (VEGFA, VEGFB and VEGFC)
and splice variants add more heterogeneity to the biological actions of the VEGF gene family
(Tischer et al., 1991). Analysis of VEGF transcripts in cultured vascular smooth muscle cells by
PCR and cDNA cloning revealed three different forms of the VEGF coding region, which has
also been previously reported in HL60 cells. The three forms of the human VEGF protein chain
predicted from these coding regions are 189, 165, and 121 amino acids in length. Comparison of
cDNA nucleotide sequences with sequences derived from human VEGF genomic clones indi‐
cates that the VEGF gene is split among eight exons and that the various VEGF coding region
forms arise from this gene by alternative splicing. Analysis of the VEGF gene promoter region
revealed a single major transcription start, which lies near a cluster of potential Sp1 factor bind‐
ing sites. Northern blot analysis demonstrated that the level of VEGF transcripts is elevated in
cultured vascular smooth muscle cells after treatment with the phorbol ester 12-O-tetradeca‐
noyl-phorbol-13-acetate (Tischer et al., 1991).
In a study using an US National Cancer Institute (NCI) panel of 60 tumor cell lines, ART
and related compounds displayed anti-angiogenic activities based on the altered expres‐
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sion of genes implicated in angiogenesis. The mRNA expression data of angiogenesis-relat‐
ed genes  correlated well  with  the  50% growth inhibition  concentration values  for  eight
ARTs (ART, AS, arteether, artemisetene, arteanuine B, dihydroartemisinylester stereoisom‐
ers 1 and 2). The constitutive expression of 30 different genes correlated significantly with
the cellular response to ARTs. The finding that drug sensitivity and resistance of tumor
cells could be predicted by the mRNA expression of angiogenesis related genes supports
the hypothesis that the antitumor activity of ARTs may be due, at least in part, by inhibi‐
tion of  tumor angiogenesis.  As many chemo-preventive drugs exert  anti-angiogenic  fea‐
tures, ARTs might also have a chemo-preventive effect in addition to their cytotoxic effects
(Anfosso et al., 2006).
These findings are consistent with previous published work (Wartenberg et al., 2003) show‐
ing an artemisinin-dependent decrease in expression levels of hypoxia-inducible factor 1a
(HIF-1a; H1F1A), which is known to be a transcriptional activator of VEGFA and is critical
in neovasculogenesis in hypoxic tissues. The inhibition of angiogenesis by ART (at a concen‐
tration of 12 mM) involving VEGF and HIF-1a was also demonstrated in leukemic and glio‐
ma cells (Huang et al., 2008; Zhou et al., 2007). Loss of HIF-1α and VEGF expression by
artemisinin appears to depend on ROS as co-treatment with free-radical scavengers such as
vitamin E and mannitol reversed the effects of artemisinin (Wartenberg et al., 2003). The
sensitivity and resistance of these tumor cells has been shown to correlate with mRNA ex‐
pression of angiogenesis-related genes. This suggests that the anti-tumor effects of ARTs are
potentially due to their role in inhibiting tumor angiogenesis (Anfosso et al., 2006). The find‐
ing that tumor cell drug sensitivity and resistance could be predicted by mRNA expression
of angiogenesis-related genes supports the hypothesis that artemisinins their anti-tumor ef‐
fects at least in part by inhibition of tumor angiogenesis.
In addition, an investigation to determine the sensitivity and resistance of cancer cells to‐
wards AS was conducted. The gene-hunting approach applied by us delivered several novel
candidate genes that may regulate the response of cancer cells to AS. These results merit fur‐
ther investigations to prove the contribution of these genes for AS resistance. Study demon‐
strated that AS was no inhibitor of ABC transporters ABCB1 and ABCG2. Although AS may
exhibit specific inhibitory functions towards particular ABC transporters, but not towards a
wide spectrum of several different ABC transporters. This approach showed that response
of tumor cells towards AS is multi-factorial in nature and is determined by gene expression
associated with AS sensitivity on the one hand and with gene expression associated with AS
resistance on the other hand (Sertel et al., 2010).
3.2.2. Anti-proliferative mechanisms of ARTs
The anti-cancer mechanism of ARTs is likely to be related to the cleavage of the iron- or
heme-mediated peroxide bridge, followed by the generation of ROS (Mercer et al., 2011;
Zhang et al., 2010). The anti-cancer potential of ARTs is possibly connected to the expression
of TfR. The synergism of AS and iron (II)-glycine sulfate co-treatment is unsuitable for all
types of tumor cells. Endoplasmic reticulum stress is partially involved in some cases of
ARTs-mediated anti-proliferation (Lu et al., 2010; Stockwin et al., 2009).
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In normal cells, cyclin-dependent kinases (CDK) are the proteins translating signals in order
to guide cells through the cell-division cycle. Normal growth relies on the ability to translate
signals in order to replicate and divide in an effective manner (McDonald and El-Deiry,
2000). Uncontrolled proliferation in cancer cells is known to result from mutations inducing
amplification of growth signals, deregulation of checkpoints, and loss of sensitivity to
growth inhibitors. Abnormal cell growth is also triggered by deregulation of programmed
cell death or apoptosis (Vogelstein and Kinzler, 2004). ARTs have been shown to effectively
induce cell growth arrest in cancer lines either by disrupting the cell cycle kinetics or by in‐
terfering with proliferation-interacting pathways.
DHA and AS are very potent growth inhibitors, and multiple studies have demonstrated
that DHA is the most potent anti-cancer artemisinin-like compound (DHA > AS > AM) (Ef‐
ferth et al., 2003; Woerdenbag et al., 1993). Recently, artemisone has shown impressive anti‐
tumor efficacy in 7 cells lines including melanoma and breast cancer cells (Gravett et al.,
2010). ART compounds have been shown to exert cytostatic and cytotoxic action on cancer
cells (Efferth et al., 2003; Hou et al., 2008). ART-induced growth arrest has been reported at
all cell cycle phases; however, arrest at the G0/G1 to S transition seems to be more common‐
ly affected (Efferth et al., 2003). Arrest at all cell cycle phases at the same time has been inter‐
preted as a cytostatic effect. Disruption of the cell cycle at G2/M was observed after DHA
treatment in osteosarcoma, pancreas, leukemia (Yao et al., 2008) and ovarian cancer cells
(Jiao et al., 2007). Similarly, AS interferes with G2 in osteosarcoma, ovarian, and other differ‐
ent cancer lines (Ji et al., 2011).
Several ART derivatives displayed higher cytotoxicity to murine bone marrow cells than to
murine Ehrlich ascites tumor cells in a clonogenic assay (Beekman et al., 1998). The IC50 val‐
ues for HeLa cervical cancer cells, uterine chorion cancer JAR cells, embryo transversal can‐
cer RD and ovarian cancer HO-8910 cell lines after 48-h treatment with ART and DHA
ranged from 15 to 50 µM and from 8 to 33 µM, respectively (Chen et al., 2003). ART potenti‐
ated the differentiation of 1α, 25-dihydroxyvitamin-D3-induced HL-60 leukemia cell pre‐
dominantly into monocytes and all-trans RA-induced cell differentiation into granulocytes,
respectively (Kim et al., 2003). Signal transducers involved in the differentiation process,
such as extracellular-signal regulated kinase (ERK) and protein kinase C ß1 (PKCB1) were
affected by ART.
Inhibition of proliferation may also be attributed to down-regulation of interacting proteins
targeting multiple pathways (Firestone and Sundar, 2009). It has been shown that DHA
treatment of pancreatic cells (BxPC3, AsPC-1) inhibited cell viability by decreasing the levels
of proliferating cell nuclear antigen (PCNA) and cyclin D with parallel increase in p21 (Chen
et al., 2009). Another study in the same system showed that DHA counters NF-κB factor ac‐
tivation leading to inhibition of its targets in the proliferation (c-myc, cyclin D) and apoptot‐
ic pathways (Bcl2, Bcl-xl) (Wang et al., 2010). In prostate cancer, DHA has been shown to
induce cell cycle arrest by disrupting the interaction of Sp1 (specificity protein 1) and the
CDK4 promoter (Willoughby et al., 2009). Dissociation of the Sp1-CDK4 complex promotes
caspase activation and cell death. In addition, another study has identified AS as a topoiso‐
merase II inhibitor which inhibits growth by interaction with multiple pathways (Youns et
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al., 2009).Overall, a wide body of research supports the hypothesis that ARTs are capable of
interfering with several pathways known to be involved in neoplasia.
3.2.3. Anti-VEGF mechanisms of ARTs
Angiogenesis is promoted by numerous factors including cytokines such as VEGF, bFGF,
PDGF and others. It is negatively regulated by angiostatin, endostatin, thrombospondin,
TIMPs and other factors. The factors that are produced in tumor cells as well as in surround‐
ing stromal cells act in a balance to promote either pro-angiogenic or anti-angiogenic proc‐
esses. Among the cytokines for regulating angiogenesis, VEGF and angiopoietin-1 (Ang-1)
have specific modulating effects on the growth of vascular endothelial cells, and they play a
key role in the process of angiogenesis (Thurston 2002). VEGF is a homodimeric 34-42 kDa, a
heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-
enhancing activities specific for endothelial cells. Two receptor tyrosine kinases have been
described as putative VEGF receptors, Flt-1 and KDR. Flt-1 (fms-like tyrosine kinase), and
KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF
with high affinity.
ART and DHA have been shown to significantly inhibit angiogenesis in a dose-dependent
manner as demonstrated by measurement of the proliferation, migration and tube formation
of human umbilical vein endothelial (HUVE) cells (Chen et al., 2003). DHA was shown to
markedly reduce VEGF binding to its receptors on the surface of HUVE cells and reduced
the expression levels of two major VEGF receptors, Flt-1 and KDR/flk-1, on HUVE cells.
ART derivatives also inhibited HUVE cell tube formation and exhibited anti-angiogenic ef‐
fects (Oh et al., 2004). By utilizing the chicken chorioallantoic membrane (CAM) culture
technique, it is possible to detect the microangium-like structures formed by in vitro cultivat‐
ed arterial rings associated with angiogenesis. By using this method, AS has been shown to
also have anti-angiogenic effects. Treatment with AS significantly inhibited chicken cho‐
rioallantoic membrane (CAM) angiogenesis, proliferation, and differentiation of human mi‐
crovascular dermal endothelial cells in a dose-dependent manner and reduced Flt-1 and
KDR/flk-1 expression (Huan-Huan et al., 2004).
Tumor hypoxia activates the transcription factor hypoxia inducible factor-1α (HIF-1α). This
adaptation increases tumor angiogenesis to support the survival of poorly nourished cancer
cells. Hypoxic tumors are resistant to radiation and many anti-cancer agents. HIF-1α is acti‐
vated during angiostatic therapy, and HIF-1α has also been shown to up-regulate the ex‐
pression of transferrin receptors. Since ART is selectively toxic to iron-loaded cells, radio
and drug-resistant tumors might be selectively susceptible to attack by a treatment strategy
consisting of iron-loading and ART treatment (Li et al., 2008; Zhou et al., 2007).
These findings are consistent with previous findings (Wartenberg et al., 2003) that noted ART-
dependent decreases in expression levels of HIF-1α. HIF-1α is known to be a transcriptional
activator of VEGF, and it plays a crucial role in neo-vasculogenesis in hypoxic tissues. ART
treatment of leukemic and glioma cells in vitro at a concentration of 12 mM was shown in an‐
other study to inhibit angiogenesis. This ART driven angiogenesis inhibition was shown to in‐
volve suppression of VEGF and HIF-1α expression at the transcriptional level. (Huang et al.,
The Use of Artemisinin Compounds as Angiogenesis Inhibitors to Treat Cancer
http://dx.doi.org/10.5772/54109
203
2008; Zhou et al., 2007). Loss of HIF-1α and VEGF expression after ART treatment appears to
be dependent on production of ROS because co-treatment with free-radical scavengers such as
vitamin E and mannitol reversed the effects of ART (Wartenberg et al., 2003).
In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF has
been shown to activate phospholipase C and induce rapid increases of free cytosolic Ca2+.
VEGF has also been shown to stimulate the release of von Willebrand factor from endothe‐
lial cells and induce expression of tissue factor activity in endothelial cells as well as in mon‐
ocytes, and. VEGF has been shown to be involved in the chemotaxis of monocytes and
osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular perme‐
ability. As a vascular permeability factor, VEGF acts directly on the endothelium and does
not degranulate mast cells. It promotes extravasation of plasma fibrinogen, leading to fibrin
deposition which alters the tumor extracellular matrix. The modified extracellular matrix
subsequently promotes the migration of macrophages, fibroblasts and endothelial cells.
Based on its in vitro and in vivo properties, VEGF is believed to play important roles in in‐
flammation and also in normal and pathological aspects of angiogenesis, a process that is
associated with wound healing, embryonic development, growth, and metastasis of solid tu‐
mors. Elevated levels of VEGF have been reported in synovial fluids of rheumatoid arthritis
patients and in sera from cancer patients.
In the last three decades, there is a growing body of evidence on the role of angiogenesis in
tumor growth and metastases of tumors (Firestone and Sundar, 2009). Angiogenesis can be
divided into a series of temporally regulated responses, including induction of proteases,
migration of endothelial cells, cell proliferation and differentiation. This is a highly complex
process, in which a number of cytokines and growth factors released by endothelial cells,
tumor cells and matrix cells are involved. The expression of VEGF has been suggested to be
related to some fundamental features of solid tumors, such as the growth rate, the density of
tumor microvessels, and the development of tumor metastases.
It is interesting to note that torilin, another sesquiterpene (derived from the fruits of Torilis
japonica), has also been shown to be a potent anti-angiogenic factor which also inhibits blood
vessel formation by disrupting VEGFA expression. A similar finding was also shown by us‐
ing DHA (Kim et al., 2007). Hence, the ability of ART to inhibit angiogenesis may be due to
its chemical nature as a sesquiterpene. Another compelling finding is that other phytoses‐
quiterpene lactones, such as costunolide from Saussurea lappa, can inhibit KDR signaling
(Jeong et al., 2002). Comparisons with other sesquiterpenes may shed more light on the
unique features of the anti-cancer actions of ART, and potentially lead to better angiostatic
drug design. Taken together, ART and its derivatives, and other sesquiterpene lactones,
have been shown to have potent anti-angiogenic effects in tumor cells. These observations
have many implications in terms of cancer therapy as well as cancer prevention since angio‐
genesis is a promotional event.
3.2.4. Other anti-angiogenic mechanisms of ARTs
Anti-cancer activity of ARTs has been reported both in vitro and in vivo. The inhibitory ef‐
fects of ART on the migratory ability of melanoma cell lines (A375P and A375M) were ana‐
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lyzed, and the results demonstrated that ART induces cell growth arrest in the A375M cell
line, and affects the viability of A375P melanoma cells through both cytotoxic and growth
inhibitory effects. In addition, ART was shown to affect the migratory ability of A375M mel‐
anoma cells by reducing metalloproteinase 2 (MMP-2) production and down-regulating al‐
pha v beta 3 integrin expression (Buommino et al., 2009). Other studies, however, showed
ART was not effective in inhibiting proliferation of other tumor cell lines such as MCF7, a
breast adenocarcinoma cell line, and MKN, a gastric carcinoma line.
Similarly, ARTs have been shown to inhibit Matrigel invasion of 6 non-small cell cancer
(NSCLC) cell lines and inhibited urokinase-type plasminogen activator (u-PA) activity, -pro‐
tein and -mRNA expression. Furthermore, in a PCR-metastasis array, ARTs were shown to
inhibit the expression of several matrix metalloproteinases (MMPs), especially MMP-2 and
MMP-7 mRNA/protein. In luciferase reporter assays, ARTs were shown to down-regulate
MMP-2-, MMP-7- and u-PA-promoter/-enhancer activity, in parallel to AP-1- and NF-kB-
transactivation. Si-RNA knockdown of u-PA, MMP-2 and MMP-7 abolished ART's ability to
inhibit invasion, further supporting hypotheses of the anti-cancer activity of ARTs In conclu‐
sion, this study showed that ART treatment suppresses invasion and metastasis in NSCLC,
specifically targeting transcription of u-PA, MMP-2 and MMP-7. These studies all support
the utility of ART compounds as novel therapeutic agents or adjunct therapies for NSCLC
(Rasheed et al., 2010).
DHA displayed significant anti-proliferative activity in human colorectal carcinoma
HCT116 cells, which may be attributed to its induction of G1 phase arrest and apoptosis. To
further elucidate the mechanism of action of DHA, a proteomic study employed two-dimen‐
sional gel electrophoresis (2-DE) and matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) was performed. Glucose-regulated protein 78
(GRP78), which is related with endoplasmic reticulum stress (ER stress), was identified to be
significantly up-regulated after DHA treatment. Further study demonstrated that DHA en‐
hanced expression of GRP78 as well as growth arrest and DNA-damage-inducible gene 153
(GADD153, another ER stress-associated molecule) at both mRNA and protein levels. DHA
treatment also led to accumulation of GADD153 in cell nucleus. Moreover, pretreatment of
HCT116 cells with the iron chelator deferoxamine mesylate salt (DFO) abrogated induction
of GRP78 and GADD153 upon DHA treatment, indicating iron is required for DHA-induced
ER stress. This result is consistent with the fact that the anti-proliferative activity of DHA is
also mediated by iron. Accordingly, it is possible that a redox imbalance may be the mecha‐
nism behind DHA-induced ER stress, which may contribute, at least in part, to its anti-can‐
cer activity (Lu et al., 2011).
DHA has been shown to enhance gemcitabine-induced growth inhibition and apoptosis in
both BxPC-3 and PANC-1 cell lines. The mechanism is at least partially due to DHA’s role in
deactivating gemcitabine-induced NF-kappaB activation, which, in turn, so as to dramatical‐
ly decreases the expression of its target gene products, such as c-myc, cyclin D1, Bcl-2, Bcl-
xL. In vivo studies have shown that, gemcitabine also manifested remarkably enhanced anti-
tumor effects when combined with DHA, as demonstrated by significantly increased
apoptosis, as well as decreased Ki-67 index, NF-kappaB activity and its related gene prod‐
The Use of Artemisinin Compounds as Angiogenesis Inhibitors to Treat Cancer
http://dx.doi.org/10.5772/54109
205
ucts, and predictably, significantly reduced tumor volume. The inhibition of gemcitabine-in‐
duced NF-kappaB activation is one of the mechanisms that is known by which DHA
dramatically promotes its anti-tumor effect on pancreatic cancer (Wang et al., 2010).
Embryotoxicity appears to be connected with defective angiogenesis and vasculogenesis in
certain stages of embryo development. This may prevent the use of ART derivatives in ma‐
laria during pregnancy, when both mother and fetus are at high risk of death. Artemisone is
a novel 10-alkylamino derivative which is not metabolized to DHA. It was selected as a clin‐
ical drug candidate on the basis of its high efficacy against Plasmodium falciparum in vitro and
its lack of detectable neurotoxicity in both in vitro and in vivo screens. A comparative study
of the anti-angiogenic properties of both artemisone and dihydroartemisinin in different
model systems was conducted. In this study, the effects of both artemisone and DHA were
evaluated by measuring the proliferation of human endothelial cells and their migration on
a fibronectin matrix, the sprouting of new vessels from rat aorta sections grown in collagen,
and the production of pro-angiogenic cytokines such as VEGF and interleukin-8 (CXCL-8).
The data show that artemisone is significantly less anti-angiogenic than DHA in all the ex‐
perimental models, suggesting that it will be safer to use than the current clinical ARTs dur‐
ing pregnancy (D’Alessandro et al., 2007).
3.3. Anti-cancer clinical trials and case treatments of ARTs
Antitumor activity of ARTs has also been documented in human trials and individual clini‐
cal cases. ART, AM and AS have been used in cancer therapy, and they have been shown to
be well tolerated without significant side effects (Table 3).
3.3.1. Clinical trials of ARTs as anti-cancer agents
Clinical evidence has accumulated showing that ART-derived drugs have promise for treat‐
ment of laryngeal carcinomas, uveal melanomas and pituitary macroadenomas. AS is also in
phase I-II trials for treatment of breast, colorectal and non-small cell lung cancers. Similarly,
a clinical trial in 120 patients with advanced non-small cell lung cancer has shown that arte‐
sunate in combination with a chemotherapy regimen of vinorelbine and cisplatin elevated 1-
year survival rate by 13% with a significant improvement in disease control and time to
progression. No additional AS-related side effects were reported (Zhang et al., 2008).
1. Phase I study of oral AS to treat colorectal cancer (Completed)
The primary objective of this study was to determine the effects of oral AS in inducing apop‐
tosis in patients awaiting surgical treatment of colorectal adenocarcinoma. The secondary
objective of this study was to establish the tolerability of oral AS for the treatment of colorec‐
tal cancer. Subjects were randomized to receive either 200 mg AS or placebo orally once dai‐
ly for 14 days while awaiting surgery for definitive surgical treatment of colorectal
adenocarcinoma. A significant difference in the proportion of colorectal adenocarcinoma
cells exhibiting apoptosis was noted between the two treatment groups (placebo and AS),
assessed at the time of surgery after two weeks of drug treatment. No result was publicly
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issued (Protocol Number: ISRCTN05203252, 2008. http://www.controlled-trials.com/
ISRCTN05203252/).
2. Phase  II  study  of  AS  treatment  as  an  adjunct  to  treat  non-small  cell  lung  cancer
(Completed)
This study was designed to compare the efficacy and toxicity of AS treatment combined
with NP (a chemotherapy regimen of vinorelbine and cisplatin) and NP alone in the treat‐
ment of advanced non-small cell lung cancer (NSCLC). One hundred and twenty cases of
advanced NSCLC were randomly divided into an NP chemotherapy group and a combined
AS with NP therapy group. Patients in the control group were treated with the NP regimen
of vinorelbine and cisplatin. Patients in the trial group were treated with the NP regimen
supplemented with intravenous AS injections (120 mg, once-a-day intravenous injection,
from the 1st day to 8th day, for 8 days). At least two 21-day-cycles of treatment were per‐
formed. There were no significant differences in the short-term survival rates, mean survival
times and the 1-year survival rates between the trial group and the control group, which
were 44 weeks and 45 weeks, respectively. The disease controlled rate of the trial group
(88.2%) was significantly higher than that of the control group (72.7%) (P < 0.05), and the tri‐
al group's time to disease progression (24 weeks) was significantly longer than that of the
control group (20 weeks). No significant difference was found in toxicity between the two
treatment groups. Therefore. AS combined with NP can increase the disease controlled rate
and prolong the time to progression of patients with advanced NSCLC without significant
side effects (Zhang et al., 2008).
3. Phase I study with metastatic breast cancer (Completed)
The purpose of this study was to evaluate the tolerability of an adjunctive therapy with AS
for a period of 4 weeks in patients over the age of 18 years with advanced metastatic breast
cancer, which was defined as a histologically or cytologically confirmed. Women of child‐
bearing potential were tested to rule out pregnancy prior to their treatment. Relevant neuro‐
logical symptoms, adverse events, and the relation between adverse events and the use of
AS, as an adjunct, saliva cortisol profile, overall response rate, clinical benefit, and assess‐
ment of patients’ expectations will be monitored as study endpoints. No result of this study
has yet been publicly issued (Protocol Number: NCT00764036, 2011, http://www.cancer.gov/
clinicaltrials/search/view/print?cdrid=616937&version=HealthProfessional).
3.3.2. Treatment reports of ARTs used to treat cancers
AS was successfully used in the treatment of laryngeal squamous cell carcinoma where
treated patients showed a substantial reduction in tumor size (by 70%) after two months of
treatment (Singh and Verma, 2002). Furthermore, AS used in combination with standard
chemotherapy increased survival and substantially reduced metastasis in patients with ma‐
lignant skin cancer (Berger et al., 2005). Another report describes a beneficial improvement
in a patient with pituitary macroadenoma who was treated with artemether for 12 months
(Singh and Panwar, 2006). Other cases describing the use of ARTs for treatment of cancer
have been reported in the Cancer Smart Bomb Part I and II study (White, 2002)
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1. Metastatic uveal melanomas treated with AS
Berger et al. reported on the first long-term treatment of two cancer patients with AS in com‐
bination with standard chemotherapy. These patients with metastatic uveal melanoma were
treated on a compassionate-use basis, after standard chemotherapy alone was ineffective in
stopping tumor growth. The therapy regimen was well tolerated with no additional side ef‐
fects other than those caused by standard chemotherapy alone. One patient experienced a
temporary response after the addition of AS to Fotemustine while the disease was progress‐
ing under therapy with Fotemustine alone. The second patient first experienced a stabiliza‐
tion of the disease after the addition of AS to Dacarbazine, followed by objective regressions
of splenic and lung metastases. This patient is still alive 47 months after first diagnosis with
stage IV uveal melanoma, a diagnosis with a median survival of 2-5 months, without addi‐
tional side effects. One patient experienced a temporary response after the addition of AS
while the disease was progressing under standard therapy with Fotemustine alone. This pa‐
tient died after 24 months.
Despite the small number of treated patients, AS may be a promising adjuvant drug for the
treatment of melanoma and possibly other tumors in combination with standard chemothera‐
py. AS is well tolerated, and the lack of serious side effects will facilitate prospective random‐
ized trials in the near future. From in vitro studies already conducted (Efferth et al., 2004b), it is
further conceivable that loading tumor cells with bivalent iron, by simply providing Fe2+ in tab‐
let form, might increase the susceptibility of cancer cells to AS treatment. It is tempting to spec‐
ulate that, in the case of the second patient previously discussed, the addition of Fe2+ had an
actual clinical impact and resulted in an improved response to therapy (Berger et al., 2005).
2. Laryngeal carcinoma treated with AS
AS injections and tablets were used in one study to treat a laryngeal squamous cell carcino‐
ma patient over a period of nine months. The tumor was significantly reduced in size by 70%
after two months of treatment. Overall, AS treatment of the patient was beneficial in prolong‐
ing and improving quality of life. Without treatment, laryngeal cancer patients die within an
average of 12 months. The patient lived for nearly one year and eight months until his death
due to pneumonia.
The observations that the patient regained his voice, appetite, and weight after a short term
treatment with AS, and the fact that the tumor was significantly reduced in size without any
apparent adverse side effects suggests that AS treatment could be an effective and economi‐
cal alternative treatment for cancer, especially in cases of late cancer detection where availa‐
ble  treatments  are  limited.  Since  this  case  report  was  published,  several  patients  with
different types of cancers have begun treatment with ART and its analogs with promising re‐
sults. AS therapy has potential to prevent and treat a wide range of cancers given its efficacy,
low cost, and due to the common mechanisms of action demonstrated against various cancer
cells (Singh and Verma, 2002).
3. Pituitary macroadenoma treated with AM
AM, an ART analogue, was used to treat a 75-year old male patient with pituitary macroa‐
denoma. This patient presented with vision, hearing, and locomotion-related problems as a
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consequence of his disease. AM was administered orally to the patient over a period of 12
months. Although the tumor remained consistent in size, CT scans showed a reduction in
tumor density, and clinically, the related symptoms and signs improved significantly as
therapy progressed. Overall, the AM treatment was beneficial in improving the patient’s
quality of life. AM and other ART analogs appear to have promise for treatment of this type
of cancer (Singh and Panwar, 2006).
3.4. Why are not there more trials or more wide-spread use of ARTs?
ARTs are largely non-toxic, with related compounds having been administered to over 2
million patients; both children and adult, world-wide without reports of significant serious
side effects, and ARTs are very inexpensive when compared to conventional cancer drugs.
The final results of current clinical trials utilizing ARTs as therapy or adjunct against a wide
variety of cancers have not yet been published although initial findings released suggest
positive results. How positive or efficacious these results are remains to be seen until full
and final results are published. One question, however, remains - why are there not more
trials or more wide-spread use of ARTs as an off-label cancer treatment?
3.4.1. PK mismatch of ARTs in cancer therapy
ARTs as angiogenesis inhibitors are unique cancer-fighting agents because they tend to in‐
hibit the growth of blood vessels rather than tumor cells. Therefore, the angiogenesis inhibi‐
tor therapy does not necessarily kill tumors but instead may prevent tumors from growing.
This type of therapy may therefore need to be administered over a long period.
Following oral administration, however, AS and DHA have short mean residence times
(MRT) of 1.95 and 2.71 hr, respectively, and ART has a longer MRT of 7.4 hr. Intramuscular
AM and arteether have longer MRTs ranging from 13.9 - 42.9 hrs in humans s due to pro‐
longed absorption and accumulation at the injection sites. The shortest MRT (0.90 hr) was
found in humans following intravenous injection of AS (Table 2). It is obvious that the dif‐
ferent ARTs administered in different regimens have significant differences in pharmacoki‐
netic (PK) characteristics in humans, and only intramuscular ARTs can provide a long
period of therapy. Therefore, injectable AM has been recommended as a longer acting com‐
pound that may be suitable for cancer treatment (White, 2002).
Pharmacokinetics (PK) studies of ARTs show three phases (absorption, distribution, and
elimination) of ART drugs in blood following oral, intravenous, or intramuscular adminis‐
tration. After multiple daily administrations, four ARTs showed declining daily drug con‐
centrations (ART, DHA, AS, and AM) which has been shown is believed to be due to an
auto-induced metabolism pathway during multiple oral treatments in patients and health
subjects (van Agtmael et al., 1999; Ashton et al., 1996; 1998; Khanh et al., 1999; Park et al.,
1998). The Cmax and AUC values of ARTs are markedly reduced from one-third to one-sev‐
enth on the last dose day compared with the first day. The decrease in drug exposure levels
during treatment is not disease-related, since the PK profile of ART drugs on the last day
shows a similar decrease to that reported in healthy subjects. Similar time-dependent de‐
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clines have been reported in animals dosed with oral AM (Classen et al., 1999). One possible
explanation for the decrease in plasma concentration-time during treatment is an increase in
metabolic capacity due to auto-induction of hepatic drug-metabolizing enzymes.
Similar observations have shown that decreasing absorption of ART derivatives may be a
problem for the longer-term use required for treatment of cancer. In treating malaria, the
ART derivatives are given for a short four or five day course. In these short treatments, no
absorption resistance has been observed to occur. Recent information has come to light that
indicates that the intestine builds up resistance to absorbing oral ART compounds very
quickly, within several days. Resistance is demonstrated by a >30% drop of the original rate
of absorption. Research indicates that this resistance can be overcome very quickly by dis‐
continuing use of the ART compounds for several days to a week; when resumed, their ab‐
sorption will be at the previous higher level. One study author, Dr. Lai, pointed out that this
intestinal resistance and subsequent lowered absorption rate may be the basis of the plateau
PK Parameters AS AS DHA ART AM AE
Route of
administration
Intravenous Oral Oral Oral Intramuscula
r
Intramuscular
First loading dosage 120 mg 100 mg 200 mg 500 mg 3.2 mg/kg 4.8 mg/kg
Maintaining dosage Oral 100 mg at
8 hr
50 mg b.i.d. x 4 100 mg x 4 250 x 2 x 5 1.6mg/kg x 41.6mg/kg
x 5
Total dose 220 mg and
mefloquine**
500 mg 600 mg 3000 mg 9.6 mg/kg 12.8 mg/kg




437.5 588.0 74.9 110.1
Tmax (hr) 0.13 0.75 1.4 2.4 6.0 8.2
Tlag (hr) 0.2 0.45




1329 2601 1230 4702
t1/2 (absorption, hr) 0.36 (DHA) 0.67 1.21 1.88 3.2
t1/2 (elimination, hr) 0.67 (DHA); 0.05 (AS)0.70 (DHA) 0.85 2.3 7.83 22.7
MRT (hr) 0.90 (DHA) 1.95 (DHA) 2.71 7.41 13.94 42.9
*The data was fitted with WinNonlin (V5.0) by author. **Oral 750 mg mefloquine at 24 hr after IV injection. PK = phar‐
macokinetics; PD = pharmacodynamics; MRT = Mean residence time; PC50 = Mean time for parasitemia to fall by half;
AUIC = area under inhibitory curve; QHS = Artemisinin; DHA = Dihydroartemisinin; AM = Artemether; AE = Arteether;
AS = Artesunic acid; MPC = minimum parasiticidal concentration; IM = intramuscular.
Table 2. Pharmacokinetics (PK) parameters of intravenous artesunate (AS), oral AS, oral dihydroartemisinin (DHA), oral
artemisinin (ART), intramuscular artemether (AM) and arteether (AE) in human treatments with uncomplicated and
severe/complicated malaria on day 1*.
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that many patients reach after treatment with these compounds. After an initial quick re‐
sponse, many patients seem to stabilize without a complete remission (White, 2002).
Artemisinins Cancer targets Clinical studies Protocols & References
Artesunate Colorectal cancer Clinical trial, Phase I ISRCTN05203252, 2011 UK
Artesunate




Clinical trial Phase I-II
Case report
Case report
Clinical Trial, Phase I-II
Zhang et al., 2008 CHINA
Berger et al., 2005 GERMANY




Artemether Pituitary macroadenoma Case report Singh& Panwar 2006 INDIA
All clinical trials listed here are completed
Table 3. Anti-cancer effects of artemisinin (ART), artesunate (AS), and artemether (AM) in case reports of treatments
and clinical trials (Ghantous et al., 2010)
3.4.2. Possible optimization of clinical trials with ARTs
ARTs are anti-angiogenic agents with a variety of targets that inhibit tumor angiogenesis in
two ways: 1) blockade of angiogenic pathways and 2) inhibition of endogenous angiogene‐
sis (Efferth, 2006; 2007; Crespo-Ortiz and Wei, 2012). Cancers produce a variety of angiogen‐
ic factors or cytokines to stimulate angiogenesis, which is essential for tumor growth and
metastasis (Cao and Liu, 2007). These cancer-derived angiogenic factors include VEGF, fi‐
broblast growth factor-2 (FGF-2), platelet-derived growth factor (PDGFs), angiopoietins
(Angs), hepatocyte growth factor (HGF), and insulin-like growth factors (IGFs). The angio‐
genic signals triggered by these angiogenic factors are mediated by their specific tyrosine
kinase receptors (TKRs) expressed in endothelial cells (Nissen et al., 2007; Xue et al., 2008).
ARTs responses seem to be mediated by those angiogenic factors with strong multi-tar‐
geted anti-angiogenic  potency.  However,  ART targets  cancer cells  is  cleavage of  the en‐
doperoxide bridge by the relatively high concentrations of iron in cancer cells,  resulting
in generation of free radicals such as reactive oxygen species (ROS) and subsequent oxi‐
dative damage as well as iron depletion in the cells. Studies demonstrated that co-admin‐
istration  of  holotransferrin  and  other  iron  sources  with  ARTs  have  been  shown  to
increase the potency of ARTs in killing cancer cells  (Lai et  al.,  2009;  Mercer et  al.,  2011;
Zhang et  al.,  2010).  Also,  DHA in  combination  with  butyric  acid  acts  synergistically  at
low dose (Singh and Lai, 2005).
Current combinations with chemotherapy for the treatment of patients with cancer have
produced only modest beneficial effects (Cao et al., 2009). Optimization of anti-angiogenic
therapy is urgently needed in order to maximize therapeutic efficacy of these drugs. Obvi‐
ously, defining novel therapeutic targets other than VEGF would be an important approach
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to increase clinical responses as a majority of cancer patients have been shown to demon‐
strate intrinsic resistance to anti-VEGF therapy. Given the fact that most tumors produce a
broad spectrum of angiogenic factors to stimulate angiogenesis and to sustain the establish‐
ed vasculature, it is not surprising that blockade of a single angiogenic pathway would be
insufficient to suppress tumor growth and multitargeted “dirty drugs” would be more effec‐
tive. In support of this view, anti-angiogenic monotherapy with tyrosine kinase inhibitors
such as sunitinib and sorafenib targeting multiple signaling pathways has been shown to re‐
sult in increased survival in patients treated for metastatic renal cell carcinoma (Escudier et
al., 2007; Motzer et al., 2006)
ARTs are delivered to cancer patients by systemic administration, which may lead to a uni‐
versal impact on healthy vasculatures distributed in multiple tissues and organs (Cao, 2010).
In the conventional view of anti-cancer drugs, off-tumor targets would be associated with
unwanted adverse effects of drugs. Interestingly, clinical benefits of ARTs have been posi‐
tively associated with neurotoxicity and embryotoxicity, which have been shown to result
from the systemic effects of these drugs (Li et al., 2009). In preclinical tumor models, it has
been demonstrated that anti-angiogenic agents administered at a low dose normalize vascu‐
latures in healthy tissues including those fenestrated vasculatures in endocrine organs such
as bone marrow, liver and adrenal gland without affecting the tumor vasculature (Xue et al.,
2008). Normalization of tumor VEGF-induced vascular tortuosity in non-tumor tissues has
been shown to significantly prolong the survival of tumor-bearing mice by improving the
cancer associated systemic syndrome. These findings suggest that the off-tumor targets of
anti-angiogenic agents such as ARTs may provide clinical benefits to cancer patients. Un‐
fortunately, clinical trials based on improvement of paraneoplastic syndrome and cancer ca‐
chexia by ARTs have neither been designed nor reported (Cao, 2011).
3.4.3. Animal model results differ from human cancer patients
Preclinical models for assessment of anti-angiogenic and antitumor activities are xenograft
tumor models in mice that carry implanted mouse or human tumors. Although this is a
commonly used animal tumor model for studying anti-angiogenic and antitumor effects of
different molecules, the relevance of this xenograft model to the clinical setting is far from
reality. The subcutaneous implantation site does not usually represent physiologically or‐
thotropic sites where human tumors arise. The tissue site is probably one of the most impor‐
tant issues related to response of tumors to drugs because angiogenic vessels in various
tissues may express different receptors that are activated by specific ligands. Selective ex‐
pression of different subsets of the same ligand receptors exists in different tissues. Differen‐
tial expression of angiogenic factor receptors in various tissues and organs may lead to
distinctive ARTs specific responses.
It is known that angiogenesis occurs at different rates in various aged populations (Rivard et
al., 1999). Thus, a difference between human cancers and mouse tumor models is the speed
of cancer development. In human patients, spontaneous development of a clinical detectable
cancer may take years whereas development of a similar sized mouse tumor may only take
weeks (O’Reilly et al., 1994). The differential growth rates between human and mouse tu‐
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mors may create completely different environments, leading to dissimilar angiogenic pro‐
files and drug responses. Young human or animal subjects are susceptible to angiogenic
stimuli by triggering relatively robust angiogenic responses under physiological and patho‐
logical settings. In contrast, older human or animal subjects often show delayed or impaired
angiogenic responses under the same conditions.
In animal tumor models, the endpoint of any drug study is the effect of the drug on tu‐
mor size, whereas in human patients, survival improvements by ARTs are often the clin‐
ical  endpoints  measure.  Therapeutic  efficacy  of  anti-angiogenic  agents  is  often  assessed
as monotherapy in animals whereas the same agents are delivered to cancer patients as
combinatorial  therapy with chemotoxic drugs.  In animal tumor models,  delivery of che‐
motherapeutic drugs alone at the conventional dose levels often produces overwhelming
anti-tumor effects  and addition of  anti-angiogenic  agents  as  an extra  component  would
be difficult to enhance the chemotherapeutic effect. Thus, the anti-angiogenic monothera‐
py  with  most  available  drugs  has  not  demonstrated  clinical  benefits  in  cancer  patients
(Cao, 2009; 2011; Hurwitz et al., 2004).
Unlike humans, inbred experimental homogenous mice represent the same genetic back‐
ground and tumors are artificially manipulated to grow at the same or at least a similar
pace. Unsurprisingly, these genetically identical animals would produce a similar response
to the same drug. Indeed, anti-angiogenic monotherapy in mice regardless of whether the
tumor implanted is a xenograft or derived from a genetically prone mouse tumor model
shows the predicted power of drug tumor suppression. Thus, this type of animal model
would not be appropriate for assessment of the therapeutic efficacy of ARTs in human can‐
cer patients. Therefore, the difference in anti-angiogenic profiles between human and mouse
cancers in relation to the therapeutic efficacy of drug treatment may well explain the varia‐
tion in human cancer patient responses to ARTs therapy.
3.4.4. Potential toxicities of ARTs in the cancer therapy
There have been a variety of reasons to believe that anti-angiogenic drugs for clinical use as
a cancer treatment may have a number of side effects. First, the generation of new blood ves‐
sels is a very complicated, multi-step biological process, and VEGF plays an important role
in a variety of biological processes such as hematopoiesis, myelopoiesis and endothelial cell
survival. Therefore, anti-angiogenic therapy could cause several toxicities due to these pleio‐
tropic biologic effects. Furthermore, many of the angiogenic inhibitors tested target multiple
tyrosine kinases in several different pathways, and thus toxicities may not only arise from
the inhibition of one pathway but also possibly from the concomitant inhibition of several
pathways. Moreover, many of these biological agents are used or will be used in combina‐
tion with other cytotoxic agents as a treatment strategy. It is not surprising that there is more
toxicity in some studies using combination therapies involving angiogenesis inhibitors than
those using single agents. The toxicities associated with administration of angiogenesis in‐
hibitors have been shown to include bleeding, disturbed wound healing, thrombosis, hyper‐
tension, hypothyroidism and fatigue, proteinuria and edema, skin toxicity, leukopenia,
lymphopenia, and immunomodulation (Wu et al., 2008).
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In addition, there are published studies showing potential toxicities associated with the use
of ARTs as anti-angiogenic agents. Various animal studies have documented neurotoxicity
and embryotoxicity associated with ARTs administration, which has raised the question of
whether those toxicities might occur in humans, particularly, in anti-cancer therapy and pre‐
vention of metastasis.
Neurotoxicity of ARTs
Studies  with  laboratory  animals  have  demonstrated  neurotoxicity  associated  with  a
number of  adverse  effects  including movement  disturbances,  spasticity,  balance deficits,
brainstem  tissue  damage,  and  even  death  following  administration  of  some  intramus‐
cular  doses  of  oil-soluble  AM  and  arteether,  or  intragastric  water-soluble  artelinate.
There  are  significant  differences  in  neurotoxicity  observed  between  rats,  dogs  and  rhe‐
sus  monkeys  after  treatment  with  different  ARTs suggesting that  the  exposure  time re‐
quired  to  induce  neurotoxicity  after  dosing  with  ARTs  is  likely  to  be  longer  in
humans.  Since  toxicity  is  dependent  on  chemical/drug  exposure  levels  and  time  (Ran‐
gan  et  al.,  1997;  Rozman and Doull  2000),  the  neurotoxicity  of  ARTs  has  been  demon‐
strated  to  occur  through  continued  drug  exposure  over  a  longer  period  of  time  rather
than through an elevated drug exposure  level  over  a  shorter  period of  time (Jorgensen
1980;  Li  et  al.,  2002  and  2006;  Rozman  1998).  Accordingly,  the  3-5  days  dosing  dura‐
tion  currently  used  in  ART  antimalarial  therapy  should  be  quite  safe.  Neurotoxicity
may  be  caused  in  humans,  however,  with  inappropriate  dose  regimens,  and  therefore,
sustained  drug  exposure  times  appear  to  be  the  critical  factor  to  assess  and  prevent
neurotoxicity  (Li  and Hickman,  2011).
The current clinical dose regimens of three-day ART combined therapies (ACTs) for un‐
complicated cases  of  malaria,  and the  dose  regimens  recommended for  intravenous  AS
treatments  for  severe malaria  which include a  few days of  a  loading doses may be too
short  of  a  drug exposure time to  induce neurotoxicity  in  humans.  Also,  with regard to
acute toxicity, humans appear to be less sensitive than animals (Geyer et al.,  1990; Kim‐
brough 1990),  and humans appear  to  have much better  repair  capabilities  than animals
to respond to such toxicity (Culotta and Koshland 1994). TK/TD analysis of neurotoxicity
after ART treatment has provided a wealth of data to provide a means of predicting the
neurotoxic exposure time of ARTs in humans (Li and Hickman, 2011). Based on this da‐
ta,  we predict the safe dosing duration of ARTs in the neurotoxic exposure time should
be longer than 7 days (168 hr). Advances in our knowledge of ART-induced neurotoxici‐
ty can help refine the treatment regimens used to treat malaria with ACTs as well as in‐
jectable  AS  products  to  avoid  the  risk  of  neurotoxicity.  If  the  drug  exposure  time  of
ARTs administered for anti-cancer therapy occurs over 14 days or even longer anti-can‐
cer, ARTs-induced neurotoxicity may well occur (Li and Hickman, 2011).
Embryotoxicity of ARTs
In  animal  work,  there  is  clear  evidence  of  ARTs-induced  embryo  death  and  some evi‐
dence  of  morphological  abnormalities  in  mice,  rats,  hamsters,  guinea  pig,  rabbits  and
monkeys in early pregnancy especially after administration of injectable AS (Li and Wei‐
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na,  2010b).  The  mechanisms  and  the  pharmacokinetic  profiles  that  affect  reproductive
toxicity  in  animal  species  are  currently  understood.  These  animal  studies  have  shown
that only injectable AS (intramuscular, intravenous, or subcutaneous) induces reprotoxici‐
ty at a lower dose (0.6-1.0 mg/kg) than the therapeutic dose (2-4 mg/kg) in humans. Oth‐
er doses in different regimens (oral artemisinins or intramuscular AM) are safe at higher
levels (6.1-51.0 mg/kg) than the therapeutic doses used. Orally dosing, the most common‐
ly used route of administration in pregnant women with Artemisinin-based combination
therapies (ACTs), has been shown to result in lower peak drug concentrations and short‐
er exposure times, which is less likely to induce embryotoxicity.
Toxicokinetic  and tissue  distribution data  has  shown that  the  severe  embryotoxicity  in‐
duced by  injectable  AS  is  associated  with  six  risk  factors:  1)  Injectable  AS  can  provide
much higher peak concentrations (3–25 fold) than oral ARTs or intramuscular AM when
administered  to  animals.  In  vitro  results  have  shown that  the  drug  exposure  level  and
time are important factors required for induction of embryotoxicity (Longo et al.,  2006a;
2006b; 2008). In vivo  studies have shown that the drug exposure level, however, is more
important than the drug exposure time as AS and DHA both have been shown to have
very short half–lives (< 1 h) when administered to various animal species. 2) AS is com‐
pletely  converted  to  DHA,  and  therefore,  AS  serves  as  a  prodrug  of  DHA.  DHA  has
been shown to be more effective than AS in inhibition of angiogenesis and vasculogene‐
sis  in  vitro  (Chen  et  al.,  2004a;  White  et  al.,  2006).  3)  Among  the  ARTs,  AS  has  been
shown to have the highest conversion rate to DHA. The conversion rate of  AS to DHA
was  shown  to  range  from  38.2–72.7%  while  of  the  conversion  rate  of  AM  and  AE  to
DHA ranges from 12.4–14.2%. 4) The conversion rate of AS to DHA was significantly in‐
creased in  pregnant  animals  than in  non–pregnant  rats  following multiple  injections.  5)
The buildup of high peak concentrations of AS and DHA in the plasma of pregnant rats
was significantly higher than those of non–pregnant animals after repeated dosing. 6) In‐
jectable AS administration results in a higher distribution of AS and DHA in the tissues
of feto–placental units in pregnant animals after multiple administrations (Li et al., 2008).
It is not clear how these findings from animals translate to human patients treated for ma‐
laria in with a 3-5 day treatment regimen (WHO, 2006b; Wang, 1989). Data from limited
clinical trials in pregnant women (1837 cases) exposed to ART compounds and ACTs, in‐
cluding a small number (176 cases) in the first trimester, have not shown an increase in the
rates of abortion or stillbirth; they have also not shown evidence of abnormalities.  Since
more than 99% of pregnant patients have been treated with oral ARTs or intramuscular AM
in the previously referenced trials, the lack of sensitivity and enhanced repair capabilities of
humans to respond to ARTs induced embryotoxicity may explain the lack of embryotoxici‐
ty observed.
The possible embryotoxicity associated with ARTs therapy should be avoided by limiting ex‐
posure of pregnant women in the first trimester which is the critical period for induction of em‐
bryo damage and resorption. In addition, to protect pregnant women from embryotoxicity
associated with ARTs treatment, injectable AS should be used very cautiously. There is agree‐
ment that ART derivatives should not be withheld at any stage of pregnancy, in cases of severe
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and complicated malaria, if the life of the mother is at risk. It is believed that oral ARTs regi‐
mens are much safer than parenteral administrations in pregnant patients. When relating the
animal and human toxicity associated with ARTs administration, there are differences in sensi‐
tivity, the timing of the most vulnerable period of the embryo to ARTs administration, and the
different pharmacokinetic profiles between animals and humans which may possibly provide
a greater margin of safety for the use of ARTs by pregnant women.
In  accordance  with  WHO recommendations  and the  new research described above,  the
two major issues for considering ART drug use in a program for prevention or manage‐
ment of malaria in pregnant women are safety and efficacy (WHO, 2006a). First,  the ex‐
posure to injectable AS should be very limited, during the early sensitive period (GD 15
to week 6 in humans), which is the likely critical phase for induction of embryo damage.
This  is  essentially  the  same recommendation  that  the  WHO has  provided where  ARTs
should not be used in the first trimester of pregnancy in women. Secondly, in uncompli‐
cated  malaria  WHO  recommends  that  the  oral  ARTs,  including  ACTs,  should  only  be
used in the second and third trimester when other treatments are considered unsuitable?
We feel that oral regimens could be used to treat pregnant women in all trimesters, how‐
ever, when other treatments are considered unavailable, because the common oral ARTs
regimens utilized provide a lower peak concentration and short exposure time, and that
can make these ARTs combination drugs safer for use in pregnant women than intrave‐
nous or intramuscular injection of AS. Therefore, this policy should also suitable in anti-
cancer therapy and prevention (Li and Weina, 2011).
4. Therapeutic implications of new and alternative mechanisms of anti-
angiogenesis
Until recently, normal and abnormal processes of angiogenesis were considered to be based
on a limited number of known mechanisms. Recent advances have been made in identifying
a number of novel alternate processes involved in angiogenesis. If these new findings of al‐
ternate mechanisms are confirmed, cancer therapy strategies may also be affected
4.1. New signaling molecules and pathways that influence the angiogenic response
The first generation of clinically useful anti-angiogenic agents including ARTs focused on
VEGF and targets in the VEGF pathway. VEGF and its receptors represent one of the best-
validated signaling pathways in angiogenesis (Ferrara et al., 2003), and the current FDA ap‐
proved anti-angiogenic agents inhibit the VEGF pathway (Ferrara, 2010). The strengths and
limitations of this therapeutics are now clear. Some tumors do not respond to VEGF-direct‐
ed therapies de novo, and others become non-responsive or resistant over time by switching
to other angiogenic pathways. The next generation of angiogenesis-directed therapeutics
will expand the field beyond the VEGF pathway and become more disease selective. New
signaling molecules and pathways, including new VEGF-independent cancer angiogenesis
pathways, have been recently reported (Teicher, 2011):
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1. Over-expression of VEGF results in increased angiogenesis in normal and pathological
conditions. The existence of an alternative splicing site at the 3’untranslated region of
VEGF mRNA results in the expression of isoforms with a C-terminal region which are
down-regulated in tumors and may have differential inhibitory effects. This suggests
that control of splicing can be an important regulatory mechanism of angiogenesis in
cancer cells (Biselli-Chicote et al., 2012).
2. The VEGF family includes VEGF-A, -B, -C, -D, -E factors and the placenta growth factor
(PIGF). The most studied and best characterized member of the VEGF family is VEGF-
A or VEGF, which is secreted by tumors- and plays an important role in both normal
and tumor-associated angiogenesis. The biologic effect of VEGF-A is exerted through
interaction with cell surface receptors that include VEGF receptor-1 (VEGFR-1, flt-1)
and VEGF receptor-2 (VEGFR-2, KDR/flk-1), which are selectively located on vascular
endothelium and are up-regulated during angiogenesis, and VEGFR-3, a lymphatic
growth factor. The role of VEGFR-1 seems to be complex, and studies indicate that
VEGFR-1 may negatively regulate angiogenesis, although it has also been shown that it
contributes to vascular sprouting and metastasis. The VEGF-A–VEGFR-2 interaction al‐
so plays a crucial role in angiogenesis, through the coordinated signaling of endothelial
cell proliferation, migration and recruitment of endothelial cell progenitor cells. VEGF-
B has recently been found to be largely necessary for vascular survival rather than an‐
giogenesis (Ferrara, 2009; 2010; Zhang et al., 2009).
3. Placental growth factor (PlGF), a member of the VEGF family of growth factors, is in‐
duced as tumors lose responsiveness to VEGF-directed therapies (Van de Veire et al.,
2010). PlGF was first described, crystallized and identified as a ligand for VEGFR1 in
the early 1990s (Ribatti, 2008). The functional biology of PlGF is still being explored.
PlGF appears to have direct effects on some malignant cells and has been shown to in‐
crease cell proliferation and migration (Chen et al., 2009d).
4. Angiopoietins  (Angs)  are  another  family  of  endothelial  cell-specific  molecules  that
bind Tie  receptors,  and they play an important  role  in  vessel  maintenance,  growth
and stabilization. There are four types of angiopoietins known: Ang-1, -2, -3 and -4.
Tie1 mRNA is highly expressed in embryonic vascular endothelium, angioblasts, en‐
docardium, and lung capillaries while it  is weekly expressed in the endocardium of
adults The Tie2 receptor takes part in vessel maturation by transducing survival sig‐
nals for endothelial cells. Ang-1 acts as an agonist promoting vessel stabilization in a
paracrinal manner, whileAng-2 is an autocrine antagonist inducing vascular destabi‐
lization  at  high  concentrations.  Ang-2  has  been  found to  be  dramatically  increased
during  vascular  remodeling,  and it  has  been  implicated  in  tumor-associated  angio‐
genesis and tumor progression. It  has been found that VEGF also activates the Tie2
receptor (Makrilia et al., 2009).
5. The Notch signaling pathway is critical for many developmental processes including
physiologic angiogenesis. The Notch pathway has also been shown to have a key role in
tumor angiogenesis. Preclinical and clinical studies of various anti-angiogenic combina‐
tions suggests that the mechanism associated with poor efficacy may involve tumor re‐
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sistance and recurrence, which has led to the search for alternative angiogenic treatment
strategies. Significant progress has been made in shedding light on the complex mecha‐
nisms by which Notch signaling can influence tumor growth by disrupting vasculature
in an array of tumor models (Ridgway et al., 2006). The Notch pathway is being investi‐
gated as a target for anti-angiogenesis treatment. The VEGF and Notch pathways inter‐
act and intersect such that the VEGF pathway stimulates angiogenesis while the Notch
pathway helps to guide cell fate decisions that appropriately shape activation (Li and
Harris, 2009; Garcia and Kandel, 2012).
Delta-like ligand 4 (Dll4) is a key endothelial Notch ligand. The Notch pathway and
the  VEFG  pathway  interrelate  via  the  interaction  between  Dll4  and  VEGF.  This
cross-talk occurs through VEGF-induced upregulation of Dll4 and Dll4 downregula‐
tion  of  the  VEGFR signaling.  Both  pathways  are  essential  for  normal  angiogenesis,
and blockade  of  one  may produce  compensatory  changes  in  the  other.  Dll4–Notch
signaling has sparked high interest in exploring molecular targets in these intercon‐
nected pathways for cancer therapy (Oon and Harris, 2011)
6. Fibroblast growth factors (FGFs) in signaling pathways are a family of heparin-binding
proteins required for the development and differentiation of various organs from the
early stages of embryogenesis. Acidic and basic fibroblast growth factors (aFGF or FGF1
and bFGF or FGF2 respectively) are described as inducers of angiogenesis. FGFs stimu‐
late endothelial cell proliferation and migration, as well as production of collagenase
and plasminogen activator. FGFs induce sprouting of blood vessels in vivo in the chick
chorioallantoic membrane and cornea, thus supporting their role in angiogenesis (Mak‐
rilia et al., 2009). In addition, the HGF/c-Met pathway is upregulated in some tumors as
an alternate angiogenic pathway. The HGF/c-Met tyrosine kinase signaling pathway is
upregulated in many cancers resulting in invasive growth consisting of physiological
processes including proliferation, invasion and angiogenesis (Eder et al., 2009).
7. The CXCL12 (SDF-1)/CXCR4 pathway represents a stromal chemokine axis involved in
tumor angiogenesis. CXCR2 is a G-protein coupled receptor with several ligands in‐
cluding interleukin-8 and other angiogenic cytokines and may represent a useful target
for anti-angiogenic agents. The CXCL12/CXCR4 axis is involved in tumor progression,
angiogenesis, metastasis and survival (Teicher and Fricker, 2010).
8. Sphingosine-1-phosphate (S-1-P) is a bioactive lipid that regulates many cellular and
physiological processes including cell proliferation, survival, motility, angiogenesis,
vascular maturation, immunity and lymphocyte trafficking. Sphingosine-1-phosphate
can be neutralized with a monoclonal antibody. Anti-S-1-P antibodies are under investi‐
gation as an anti-angiogenic agent. (Hait et al., 2009).
9. Several small molecules and antibodies targeting additional pro-angiogenic cell surface
molecules are under investigation as anti-angiogenic agents. Tumor necrosis factor-a
(TNF-α), transforming growth factor-α (TGF-α), epidermal growth factor (EGF), colo‐
ny-stimulating factors (CSFs) and others have been implicated in the process of angio‐
genesis. Several multi-targeted kinase inhibitors each with a unique pattern of
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inhibitory potency are in clinical trials with a focus on anti-angiogenic activity. Matrix
metalloproteinases (MMPs) are a family of enzymes that cleave the extracellular matrix,
a process which is considered important for the formation of new blood vessels. Inhibi‐
tion of MMPs activity seems to be a crucial step in the process of vessel stabilization
during the resolution phase of angiogenesis, since uncontrolled proteolysis results in re‐
gression of newly formed vessels (Makrilia et al., 2009).
4.2. Potential targets in angiogenesis and angioprevention
Angiogenesis is an essential process in tumor growth, and new basic science research find‐
ings in angiogenesis have had considerable impact on cancer therapy research, as the sur‐
vival and proliferation of cancer is fundamentally dependent on angiogenesis,. In past years,
numerous anti-angiogenic agents were developed, and some of them have been applied
clinically. Angiogenesis is a complex and multistep process, however, and the intertwining
of interrelated angiogenesis pathways is still not completely understood. Discoveries of new
and alternative angiogenesis signaling molecules and pathways, combined with studies on
the major signaling proteins and pathways related to tumor angiogenesis, have led to new
drug development research to target tumor angiogenesis.
Similarly, angiopreventive strategies may involve various targets including angiogenic mol‐
ecules from tumors cells, inflammatory system and their respective receptors on endothelial
cells such as VEGF, PDGF, FGF and their receptors, angiopoietin (Ang) family, endothelial
cells, matrix metalloproteinases (MMPs), cyclooxygenases (COXs), lipoxygenases (LOXs)
etc. Inflammation, for example, has been shown to be one of the most important processes in
mediating angiogenesis, and may be a valid target for mediating anti-angiogenic therapies.
Accordingly, long-term angiostasis treatments will likely be an important element in pre‐
venting metastasis of tumors that have been treated and are in remission. Emphasis should
be placed on screening and identification of non-toxic anti-angiogenic molecules or com‐
pounds and their further evaluation in clinical trials to discover the most efficacious anti-
angiogenic treatments for cancer therapy.
VEGF-A (VEGF)
VEGF has a number of different gene family members including VEGF-A, -B, -C, -D, and -E
and placental growth factor (PlGF). Among them, VEGF-A (or VEGF) has been the most
well-characterized and is considered a key angiogenic factor with various splicing variants
such as VEGF-A125, -A145, -A165, -A183, -A189, and -A206. VEGF-A is indispensable during em‐
bryonic vascular development, and even the loss of a single VEGF-A allele in mice has been
shown to result in embryonic lethality due to defective vasculature. Hypoxia, often seen in
the center of tumors, strongly up-regulates VEGF-A expression via increased production of
hypoxia inducible factor (HIF). Under normal conditions, HIF is ubiquitinated and degener‐
ated by binding to von Hippel-Lindau (VHL) proteins, but, in under hypoxic conditions,
HIF cannot bind to VHL, resulting in increased active HIF. HIF acts as a transcriptional acti‐
vator by mediating transcription at the HIF-1 binding site, the hypoxia response element
(HRE), and by enhancing transcription of many pro-angiogenic genes including VEGF-A
gene (Ichihara et al., 2011).




VEGF family members bind to VEGFR (VEGFR-1, VEGFR-2, and VEGFR-3), and VEGF-A
binds to VEGFR-1 and VEGFR-2. Although the affinity of VEGF-A to VEGFR-1 is 10-fold
higher than it’s binding to VEGFR-2, VEGF-A signaling is mainly mediated by VEGFR-2 be‐
cause of its intense kinase activity (Olsson et al., 2006). VEGFR-2 signaling in endothelial
cells is mediated through downstream cascades such as PI3K/AKT, p38/MAPK, and PLCγ/
MAPK, triggering proliferation and migration of endothelial cells, production of proteases,
and hyperpermeability of vessels. Currently, researchers agree that VEGF-A/VEGFR-2 sig‐
naling is the key pathway for tumor angiogenesis.
VEGF-B and PlGF bind only  to  VEGFR-1,  in  contrast  to  VEGF-A,  which  binds  to  both
VEGFR-1 and -2.  VEGFR-1 signaling has more complex roles  in  angiogenesis  compared
with that of VEGFR-2. VEGFR-1 exists as a decoy receptor with high affinity for VEGF-
A, and its  low kinase activity prevents VEGF-A from binding to VEGFR-2,  so VEGFR-1
actually functions as a negative regulator of angiogenesis. In fact, VEGFR-1 tyrosine kin‐
ase-deficient  mice,  with normal  ligand binding ability  and deficient  signal  transduction,
have been shown to develop normally, which means VEGFR-1 tyrosine kinase activity is
not indispensable, at least during development. On the other hand, there is growing evi‐
dence that  VEGFR-1 can mediate signaling to downstream cascades.  VEGFR-1 signaling
in bone marrow cells such as macrophage lineage cells has been shown in a subcutane‐
ous injected tumor model to mobilize them to tumor tissues,  contributing to angiogene‐
sis  and  tumor  progression  (Muramatsu  et  al.,  2010).  It  has  also  been  reported  that
VEGFR-1 signaling might be associated with metastasis. Lymphangiogenesis plays an im‐
portant role in the tumor microenvironment and the formation of  new lymphatic  blood
vessels is considered the first step of tumor metastasis.  VEGFR-3 has been shown to in‐
duce lymphangiogenesis after binding VEGF-C or –D (Ichihara et al., 2011).
Angiopoietin/Tie2
Ang/Tie2  signaling  is  an  endothelial  cell-specific  pathway,  like  VEGF/VEGFR signaling,
but it  is  difficult  to target for cancer therapy because of  the complex nature of  this sig‐
naling pathway which will be reviewed in depth later in this chapter. Angiopoietins play
an  important  role  in  vessel  stabilization  and  maturation,  although  they  cannot  directly
induce tumor angiogenesis. There are four types of angiopoietins that are known: Ang-1,
-2, -3 and -4. Tie1 mRNA is highly expressed in embryonic vascular endothelium, angio‐
blasts and in the endocardium; however, in adult tissues it is expressed strongly in lung
capillaries but weakly in the endocardium. The Tie2 receptor takes part in vessel matura‐
tion by mediating survival signals for endothelial cells. Ang-1 acts as an agonist promot‐
ing vessel stabilization in a paracrinal manner, whereas Ang-2 is an autocrine antagonist
inducing vascular destabilization at high concentrations. Ang-2 has been found to be dra‐
matically increased during vascular remodeling and is implicated in tumor-associated an‐
giogenesis and tumor progression. As a further demonstration of the interrelated nature
of  angiogenic  pathways,  it  has  been  shown  that  VEGF  also  activates  the  Tie2  receptor
(Singh and Milner, 2009; Thomas and Augustin, 2009).
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PDGF
The role of platelet-derived growth factor (PDGF) in angiogenesis is not yet fully under‐
stood. More recently, PDGF has been found to stimulate angiogenesis in vivo, and experi‐
ments with knockout mice have suggested a role for PDGF in the recruitment of pericytes
that are needed for the development of capillaries in tumors. PDGF has also been implicat‐
ed in the vascular aging process. It has been shown that some tumors overcome inhibition
of VEGF-mediated angiogenesis by upregulating members of the PDGF family. Epithelial
cancers are characterized by paracrine PDGF signaling, whereas autocrine PDGF signaling
is implicated in neoplasms such as leukemias, gliomas and sarcomas (Yang et al.,  2009).
Thus far, four PDGF family members have been identified, PDGF-A, -B, -C, and -D. They
form 5 different forms of homodimers and heterodimers, PDGF-AA, -AB, -BB, -CC, and -
DD. PDGFs generally act in a paracrine manner in epithelial cancers, while they have been
shown to act in an autocrine manner in gliomas, sarcomas, and leukemia. PDGFs are secret‐
ed from various cells, and PDGF-A and -C are mainly secreted from epithelial cells, muscle,
and neuronal progenitors while PDGF-B is secreted from vascular endothelial cells. PDGF-
D secretion is, unfortunately, not well understood (Andrae et al., 2008).
PDGF Receptors (PDGFR)
PDGFs transmit their signal via PDGFRs. When PDGFRs bind PDGFs, PDGFRs dimerize,
are autophosphorylated at tyrosine residues in the PDGFR intracellular domain, and the
phosphoyrlated PDFGR dimer has been shown to activate downstream pathways, includ‐
ing PI3K, Ras-MAPK, and PLCγ. There are 2 types of PDGFRs, PDGFR-α and PDGFR-β.
PDGFRs can form 3 kinds of homodimers and heterodimers, PDGFR-αα, -ββ, and αβ. Con‐
sidering  the  five  PDGF  dimers  described  above,  there  could  be  multiple  and  complex
PDGF/PDGFR pairings. To date, however, there are only three PDGF/PDGFR pairs proven
to  be  functional  in  vivo,  PDGF-AA/PDGFR-αα,  PDGF-CC/PDGFR-αα,  and  PDGF-BB/
PDGFR-ββ.  PDGFR-α has been shown to be involved in embryonic development,  while
PDGFR-β has been shown to be involved in angiogenesis (Cao et al., 2008).
The PDGFR-α-induced pathway is involved in organogenesis such as in alveogenesis, villus
morphogenesis, hair morphogenesis, and oligodendrogenesis. In addition, PDGFR-α may
indirectly  promote angiogenesis  by recruiting stromal  fibroblast-producing VEGF-A and
other pro-angiogenic factors. PDGFR-β is expressed in pericytes but not in endothelial cells,
and PCGFR-β signaling is believed to play a role in angiogenesis. Due to PDGFR-β’s expres‐
sion in pericytes as opposed to endothelial cells, the PDGFR-β signaling pathway does not
increase the number of tumor vessels but acts to form mature tumor vessels by recruiting
PDGFR-β-expressing pericytes, and, in turn, acting to accelerate tumor growth. Blocking the
PDGFR-β pathway inhibits the maturation of blood vessels, eliciting detachment of peri‐
cytes and disruption of tumor vessels, while blocking the VEGFR pathway impairs forma‐
tion of early-stage immature vessels lacking pericyte coverage but does not affect existing
mature, large blood vessels well-covered with pericytes (Ichihara et al., 2011).
Delta-like ligand 4 (DLL4)
Delta-like ligand 4 (DLL4) belongs to the Delta/Jagged family of transmembrane ligands
that binds to Notch receptors. Delta–Notch signaling has been shown to mediate cell–cell
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communication and regulates  cell  fate  determination.  Delta/Notch signaling is  also criti‐
cally  important  for  proper  vascular  development.  One  particular  endothelial  cell  Notch
ligand, DLL4, has been shown to be required for regulation of tip cell  formation during
angiogenesis.  Activation  of  the  Delta/Notch  signaling  pathway  has  been  shown  to  de‐
crease  endothelial  tip  cell  numbers.  Conversely,  decreased DLL4 signaling  increases  tip
cell formation. Upregulation of DLL4 was also found in tumor vessels. Two groups have
demonstrated independently that inhibiting DLL4 leads to tumor growth suppression by
deregulating angiogenesis, resulting in increased, but non-functional vessels. Importantly,
this strategy is also effective in slowing the growth of tumors that are relatively resistant
to  anti-VEGF  therapy,  and  DLL4  inhibition  also  exhibits  an  additive  effect  when  com‐
bined  with  anti-VEGF  therapy  to  slow  the  growth  of  anti-VEGF  resistant  tumors  (Du‐
fraine et al., 2008, Ferrara, 2010).
In  fact,  not  all  of  the  endothelial  cells  are  stimulated,  due  to  a  mechanism  deciding
which endothelial  cells  should react  to  angiogenic  stimulus  and which should not.  The
DLL4/Notch pathway plays a  key role  in this  mechanism. DLL1,  DLL3,  DLL4,  Jagged1,
and Jagged2 bind to  the  Notch receptor  as  ligands.  Among these ligands related to  tu‐
mor  angiogenesis,  DLL4  has  been  the  most  intensely  investigated,  because  DLL4  is
strongly expressed in tumor vascular endothelial cells but more weakly in normal vascu‐
lar  endothelial  cells.  DLL4 is  a  transmembrane ligand,  and its  expression in tumor ves‐
sels  is  regulated  by  VEGF-A.  VEGF-A up-regulates  DLL4 in  sprouting  endothelial  cells
(tip cells),  and up-regulated DLL4 interacts  with Notch in the adjacent  endothelial  cells
(stalk cells). In reverse, the DLL4/Notch pathway down-regulates VEGFR-2 expression in
Notch-expressing endothelial cells, resulting in the reduction of VEGF-A-induced sprout‐
ing and branching (Lobov et al., 2007). Thus the DLL4/Notch pathway can be considered
a negative feedback VEGFR pathway (Ichihara et al., 2011).
Notch
Notch receptors are single-pass transmembrane proteins in a family consisting of Notch1,
Notch2, Notch3, and Notch4. The Notch receptor signaling pathway has a characteristic
mechanism for signal transduction. After ligand binding, the Notch receptor is cleaved at an
extracellular domain by proteases such as ADAM10 or TACE, followed by cleavage at a
transmembrane domain by γ-secretase. As a consequence, the Notch intracellular domain
translocates to the nucleus and activates the transcription of target genes. Blocking the
DLL4/Notch signaling pathway leads to increased angiogenesis, such as the enhancement of
tip-cell formation, branching, and vessel density. Paradoxically, blockade of the DLL4/Notch
signaling also leads to the inhibition of tumor growth in a variety of tumor models. This is
possibly due to an increase in the number of non-functional tumor vessels induced by the
DLL4/Notch blockade which in turn results in tumor hypoxia (Scehnet et al., 2007).
FGF1 and FGF2
The fibroblast growth factor (FGF) family has been implicated in neurogenesis, organ de‐
velopment,  branching morphogenesis,  angiogenesis  and various pathologic processes in‐
cluding cancer.  Acidic  and basic  fibroblast  growth factors  (aFGF or  FGF1 and bFGF or
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FGF2 respectively)  have been shown to be inducers of  angiogenesis.  FGFs stimulate en‐
dothelial cell  proliferation and migration, as well as production of collagenase and plas‐
minogen activator.  FGFs have also  been shown to  induce sprouting of  blood vessels  in
vivo  in the chick chorioallantoic membrane and cornea, thus supporting their role in an‐
giogenesis (Makrilia et al., 2009).
The FGF signaling pathway plays an important role in embryonic organogenesis, and dis‐
turbance of this pathway leads to various kinds of developmental defects. In the adult or‐
ganism, FGF/FGFR signaling is involved in important physiological processes such as the
regulation of wound healing and angiogenesis. FGFs are heparin-binding growth factors
that are part of a family that includes 23 members, FGF1-23 (Turner and Grose, 2010). Only
18 FGF members work as FGF ligands, because FGF11, 12, 13, and 14 are not functional li‐
gands for FGFR, and the FGF15 gene does not exist in humans. Among these family mem‐
bers, FGF1 and FGF2 have been shown to possess a potent pro-angiogenic effect and they
play a role in inducing proliferation and migration of endothelial cells (Daniele et al., 2012).
FGF Receptors (FGFR)
FGFRs  belong  to  a  receptor  family  consisting  of  FGFR-1,  -2,  -3,  and  -4  (Turner  and
Grose,  2010).  FGFRs  are  expressed  in  most  cells  and  have  various  functions,  including
normal cell growth, differentiation, and angiogenesis., FGFR over expression or mutation
has been shown to be associated with a  variety of  different  neoplasms FGFR activation
has been shown to induce angiogenesis in both cell cultures and in animal models (Cao
et al., 2008; Korc and Friesel, 2009).
TGF-β
The transforming growth factor-β (TGF-β) is thought to have both pro- and anti-angiogenic
properties. Low TGF-β levels contribute to a switch in angiogenesis, by up-regulating angio‐
genic factors and proteinases. On the other hand, high TGF-β levels have been shown to in‐
hibit endothelial cell growth, stimulate smooth muscle cells differentiation and recruitment
and promote basement membrane reformation. In cancer cells, multiple mutations in the
TGF-β signaling pathway have been described. Elevated TGF-β levels have been shown to
induce proliferation of cancer cells, the surrounding stromal cells, immune cells, endothelial
cells and smooth muscle cells. High levels of endoglin, which is part of the TGF-β receptor
complex, have been detected in cancer patients and are directly correlated with tumor meta‐
stasis. More specifically, during the initial stages of tumorigenesis, TGF-β inhibits tumor
growth and development by inhibiting cell proliferation and by inducing apoptosis. In later
stages, tumor stages become resistant to the tumor suppressioni activity of TGF-β, TGF-β
takes on a pro-oncogenic role (Pardali and Dijke, 2009).
Other important tumor angiogenesis targets include:
1. The role of integrin ανβ3 in mediating angiogenesis has been shown through its bind‐
ing of extracellular matrix components and matrix metalloproteinase-2, thus helping to
connect new vessels with pre-existing ones, to produce the intra-tumoral vascular net‐
work. Ephrin ligands and ephrin receptors play a critical role in blood vessel assembly.
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2. The role of VE-cadherin in neovascularization has been shown in a number of studies.
3. Cadherins have been shown to establish endothelial cell junctional stability in the vessel
wall and enhance endothelial cell survival by promoting the transmission of the anti-
apoptotic signal of VEGFs.
4. Cyclooxygenase-2, an enzyme known to regulate cellular processes such as apoptosis,
also has been shown to have an angiogenic effect via thromboxane-A2.
5. The fibrinolytic system is another angiogenesis target, and the activation of this system
depends on the conversion of plasminogen to plasmin by the tissue-type plasminogen
activator (tPA) and the urokinase-type plasminogen activator (uPA).
6. Matrix metalloproteinases (MMPs) are a family of enzymes that cleave the extracellular
matrix, a process which is considered important for the formation of new blood vessels.
Inhibition of the activity of MMPs seems to be a crucial step in the process of vessel sta‐
bilization during the resolution phase of angiogenesis, as uncontrolled proteolysis re‐
sults in regression of newly formed vessels.
7. The hypoxia-inducible factors (HIFs) mediate transcriptional responses to localized hy‐
poxia in normal tissues and in cancers, and HIFs have been shown to promote tumor
progression by altering cellular metabolism and stimulating angiogenesis. Under condi‐
tions of abundant oxygen (N8–10%), HIF-α proteins are translated, but the proteins are
rapidly degraded. Stabilization of HIF proteins in hypoxic cancer cells is thought to pro‐
mote tumor progression, largely by inducing the localized expression of specific target
genes encoding VEGF, glycolytic enzymes (PGK, ALDA), glucose transporters (GLUT1)
and proteins regulating motility (lysl oxidase) and metastasis (CXCR4, E-cadherin).
(Makrilia et al., 2009)
4.3. Vascular normalization in anti-angiogenic cancer therapy
Normal vasculature comprises organized layers of endothelial cells (ECs) and pericytes.
There is evidence for paracrine signaling between ECs and specialized organ-specific cells;
hence, there is some variation in the structure and function of blood vessels depending on
their anatomic location. Pericyte-EC crosstalk facilitates vascular growth and homeostasis,
and once vessels mature, these cells become dormant. Blood vessel proliferation is an essen‐
tial physiological process, and vessel sprouting is one of the major mechanisms of expansion
in the network of vessels in growing tumors through filopodia and endothelial stalk cells.
Unlike blood vessels  in normal tissue,  the tumor-associated vasculature is  irregular  and
unstable, probably due to the over-production of pro-angiogenic proteins such as VEGF.
Tumor vessels  are distinct  in several  respects relative to normal vasculature as they are
disorganized  and  tortuous  and  their  spatial  distribution  is  significantly  heterogeneous,
resulting in uneven drug distribution in tumors. Tumor vessels do not follow the hierar‐
chy of arterioles, capillaries and venules, and tumor vessels are leakier than normal ves‐
sels  since  tumor-associated endothelial  cells  are  widened and loosely  connected.  Recent
studies  suggest  that  tumor  ECs  have  cytogenetic  abnormalities  including  aneuploidy,
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multiple chromosomes, and multiple centrosomes, raising the possibility that such insta‐
bility  may contribute  to  resistance  to  anti-angiogenic  therapies.  Tumor-associated  blood
vessels  are  excessively  branched  and  hemorrhagic,  and  blood  flow  through  these  mal‐
formed vessels is often chaotic and may impede delivery of chemotherapy to the tumor
itself (Ferrara, 2010; Gordon et al., 2010).
A new therapeutic strategy targeting tumor vasculature has gained increased attention in
the scientific community. This method involves targeting abnormal tumor vessel function
by inducing vessel  normalization.  It  is  well  known that  tumor blood vessels  are  highly
abnormal  in  structure  and  function,  characterized  by  a  tortuous,  chaotic,  and  irregular
branching network. In the tumor vasculature, ECs are highly activated, lose their polari‐
ty and alignment,  and detach from the basement membrane, all  resulting in a leaky, fe‐
nestrated network that facilitates bleeding and increases interstitial  fluid pressure. Apart
from the ECs, the entire vessel wall, including the basement membrane and the covering
pericytes, becomes abnormal in most tumors. Tumor ECs are typically covered with few‐
er and more abnormal pericytes, and their associated basement membrane is only loose‐
ly  associated  and  inhomogeneous  in  structure.  It  is  suspected  that  this  abnormal
vasculature  impedes  the  distribution  of  chemotherapy  and  oxygen.  Traditional  anti-an‐
giogenic  therapy  aims  to  maximally  inhibit  angiogenesis  and  to  prune  existing  tumor
vessels, however, this strategy can also increase the risk of aggravating hypoxia and en‐
hancing tumor cell invasiveness (Carmeliet and Jain, 2011).
Recent genetic and pharmacological studies have revealed that targeting abnormal tumor
vessel function by the induction of vessel normalization can offer alternative options for an‐
ti-angiogenic therapy. Vessel normalization can be achieved by several different approaches,
including blockade of VEGF, genetic modulation of the oxygen sensors prolyl hydroxylase
domain containing protein 2 (PHD2), targeting of mechanisms that affect pericyte coverage
and vessel maturation, and targeting myeloid cells via blockade or genetic loss of PlGF. Ves‐
sel normalization could provide a means to increase the responsiveness to chemotherapy,
immunotherapy, or radiation, and may contribute to restricting tumor dissemination (Rolny
et al., 2011; Schmidt and Carmeliet, 2011).
One recent study demonstrated that boron targeting of the largest possible proportion of tu‐
mor cells contributes to the success of boron neutron capture therapy (BNCT), and tumor
blood vessel normalization improves the delivery of boron to the tumor. In this study, blood
vessel normalization was induced by administering two doses of thalidomide (Th) in tumor-
bearing hamsters on two consecutive days. The effect of blood vessel normalization to en‐
hance the efficacy of boronophenylalanine (BPA) administration was assessed through in
vivo BNCT studies at the RA-3 Nuclear Reactor utilizing tumor-bearing hamsters. Overall
tumor control at 28 days post-treatment was significantly higher for Th+ BPA-BNCT than
for Th- BPA-BNCT with a tumor volume reduction of 84 ± 3% in the Th+ BPA-BNCT group
compared to 67 ± 5% in the Th- BPA-BNCT group. Pretreatment with thalidomide enhanced
the therapeutic efficacy of BNCT and reduced precancerous tissue toxicity (Molinari et al.,
2012). Some studies confirmed, however, that antibodies to VEGF in combination with che‐
motherapeutic agents produce synergistic cytotoxicity in a range of cancers. Research data
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shows that the process of normalization of tumor blood vessel structure is not always bene‐
ficial. In the case of cerebral tumors, for example, the process of tumor vessel normalization
may induce a re-establishment of the low permeability characteristics of normal brain micro‐
vasculature, preventing the delivery of chemotherapeutics (Ribatti, 2011).
Despite having an abundant number of vessels, tumors are usually hypoxic and nutrient-
deprived because their vessels malfunction. Such abnormal milieu can fuel disease progres‐
sion and resistance to treatment. Traditional anti-angiogenesis strategies attempt to reduce
the tumor vascular supply, but their success is restricted by insufficient efficacy or develop‐
ment of resistance. Preclinical and initial clinical evidence have shown that normalization of
tumor vascular abnormalities is emerging as a complementary therapeutic paradigm for
cancer therapy and other vascular disorders, which affect more than half a billion people
worldwide. Clearly, additional randomized prospective multi-centered trials should be con‐
ducted in larger patient populations to confirm these initial clinical data. In addition, critical
questions regarding whether vessel normalizing agents can improve tumor oxygenation and
drug delivery in human cancers remain to be answered (Carmeliet and Jain, 2011).
4.4. New vascularization/angiogenesis mechanisms in cancer therapy
Before discussing the different ways a tumor is vascularized, we should emphasize that
these mechanisms are not mutually exclusive. In fact, in most cases, angiogenesis and neo‐
vascularization mechanisms are interlinked, being involved concurrently in physiological as
well as in pathological angiogenesis. Although the molecular regulation of endothelial
sprouting has been extensively studied and reviewed in the literature, the morphogenic and
molecular events associated with alternative cancer vascularization mechanisms are not
nearly as well understood. Cancer cells are not generally controlled by normal regulatory
mechanisms, but tumor growth is highly dependent on the supply of oxygen, nutrients, and
host-derived regulators. It is now established that tumor vasculature is not necessarily de‐
rived from endothelial cell sprouting. Cancer tissue can acquire vasculature by a variety of
mechanisms to include co-opting pre-existing vessels, intussusceptive microvascular
growth, postnatal vasculogenesis, glomeruloid angiogenesis, or vasculogenic mimicry. The
best-known molecular pathway driving tumor vascularization is the hypoxia-adaptation
mechanism. Other pathways involving a broad and diverse spectrum of genetic aberrations,
however, are associated with the development of the “angiogenic phenotype.” Based on this
knowledge, novel forms of antivascular modalities have been developed in the past decade.
When applying these targeted therapies, the stage of tumor progression, the type of vascula‐
rization of the given cancer tissue, and the molecular machinery behind the vascularization
process all need to be considered. A further challenge is finding the most appropriate com‐
binations of antivascular therapies and standard radio- and chemotherapies. The most
promising therapeutic plan of action will involve the integration of recent discoveries in this
field into a rational strategy to for developing effective clinical modalities using antivascular
therapy for cancer (Döme et al., 2007).
Neovascularization  is  essential  for  tumor  growth  and  metastasis.  An  adequate  vascula‐
ture  feeds  tumor growth and enhances  the  potential  of  metastasis.  For  many years,  tu‐
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mor vessels were thought to be lined exclusively by endothelial  cells (ECs).  Therapeutic
benefits  from promising anti-angiogenic strategies targeting genetically stable ECs,  how‐
ever, are frequently limited by the development of resistance, implying an oversimplified
view of tumor vasculature. Recently, great advances in our understanding of cancer vas‐
cularization  have  emerged  with  several  novel  mechanisms  proposed.  In  fact,  the  latest
studies of the most lethal ovarian cancers characterized by widespread metastases within
the  peritoneal  cavity  have  revealed  that  in  addition  to  ECs,  other  cells,  including  bone
marrow-derived  and  plastic  tumor  cells,  contribute  to  tumor  vascularization  There  are
two proposed mechanisms by which tumor-infiltrating bone marrow-derived cells might
participate in tumor angiogenesis:  (1)  direct  incorporation in the tumor vasculature and
(2) as a source of angiogenic factors such as VEGF-A and MMP-9, which may in turn in‐
crease the bioavailability of angiogenic factors.
Current anti-angiogenic therapies have been designed on the assumption that endothelial
cells forming the tumor vasculature exhibit genetic stability. Recent studies demonstrate
that this is not the case. Tumor endothelial cells possess a distinct phenotype, differing from
normal endothelial cells at both the molecular and functional levels. This finding challenges
the concept that tumor angiogenesis exclusively depends on normal endothelial cell recruit‐
ment from the surrounding vascular network. Indeed, recent data suggest alternative strat‐
egies for tumor vascularization, and it has been reported that tumor vessels may be derived
from an intratumor embryonic-like vasculogenesis. This condition might be due to differen‐
tiation of normal stem and progenitor cells of either hematopoietic origin or cells resident in
tissues. Cancer stem cells may also participate in tumor vasculogenesis by virtue of their
stem and progenitor cell properties (Bussolati et al., 2011).
During cancer progression, tumors require a blood supply for growth and use the blood
supply for metastatic dissemination. It is logical that a stronger ability to form de novo net‐
works and channels providing a stable blood supply may confer a survival advantage for
tumors. Ovarian cancers, as discussed previously, can generate tumor vasculature from di‐
verse origins, including EC, EPC, and tumor cells, reflecting a vast capacity for neovasculari‐
zation, which may help to explain its high malignancy. Thus, anti-angiogenic and vascular
targeting strategies against alternative tumor vascularization mechanisms are clearly prom‐
ising as improved, more efficacious cancer therapies.
The existence of multiple signal pathways and complex regulatory systems in vascular for‐
mation means that inhibition of just a single pathway will presumably trigger alternative
vascularization mechanisms and additional signal pathways. Therefore, exploring other
novel signals in neovascularization is essential for further studies to efficiently target blood
vessels in cancer therapy. On the other hand, with the emergence of the concept of normali‐
zation of tumor vasculature as a novel form of anti-angiogenic therapy, new vascular signals
involved in vascular remodeling are becoming appealing therapeutic strategies to research‐
ers, as a better understanding of these normalization mechanisms may ultimately lead to
more effective therapies. Indeed, several novel ligand/receptor pathways are emerging to in‐
clude: Slit/Robo, semaphoring/plexins, Netrin-1/UNC5B, Delta-like 4/Notch, and others. In‐
terestingly, the first three ligand/receptor pairs are all formerly known to be involved with
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neuronal axon guidance, implying a possibility that other neural guidance cues may also
function as vascular signals. Agents developed from these pathways that control the mor‐
phology of the vascular system can induce tumor vascular normalization and, thus, alleviate
hypoxia and increase the efficacy of conventional therapies if both are carefully scheduled.
Alternatively, blockade of these pathways may result in increased amounts of immature,
nonfunctioning vessels, which results in reduced tumor growth, as is the case with blockade
of Delta-like 4 (Tang et al., 2009)
In  addition,  newly  published findings  suggest  that  vessels  in  many non-malignant  dis‐
eases are also abnormal. Pharmacological approaches used to normalize vessels in cancer
can also induce vessel normalization in other angiogenic disorders in animal models and
in  patients.  Moreover,  vascular  normalization  with  bevacizumab  has  provided  the  first
medical treatment to improve hearing in patients with type II neurofibromatosis. Despite
treatment advances for coronary and peripheral  arterial  disease,  the burden of  these ill‐
nesses remains high.  To this  end,  normalization of  abnormal vessels  has been proposed
as a novel strategy to stabilize vulnerable atherosclerotic plaques.  One of the challenges
for this therapeutic approach is that these strategies stimulate the formation of immature,
leaky and disorganized vessels that are poorly perfused, exhibit signs of vessel disorgani‐
zation and are prone to regression once therapy is  halted.  Therapeutic  normalization of
such  neovessels  would  offer  the  advantage  of  creating  more  mature  vessels  that  could
deliver  oxygen  and  nutrients  more  rapidly  and  efficiently  to  the  ischemic  tissue  and
thereby restore tissue performance (Carmeliet and Jain, 2011).
In contrast with the anti-angiogenic therapy, vascular targeting therapy aims at destroy‐
ing the existing vasculature of a tumor. Three different classes of vascular targeting ther‐
apeutics  have  been  proposed,  cytoskeletal  disruption,  targeted  gene  delivery,  and  drug
targeting  of  tumor  endothelial  cells.  The  first  class,  cytoskeletal  disruptors,  utilizes  a
combination  of  combretastatin  derivatives  which  stops  blood  flow  and  inhibits  tumor
growth through the disruption of  the tubulin cytoskeleton of endothelial  cells  which,  in
turn, leads to vasculature thrombosis.  The second class of vascular targeted therapeutics
is targeted gene delivery to the neovasculature. This is achieved by using cationic nano‐
particles bound to an integrin ανβ3 directed ligand that delivers a mutant gene to tumor
vessels.  The third class of vascular targeting therapeutics is cationic liposome-based vas‐
cular targeting therapy,  which relies on a selective propensity for drug delivery to acti‐
vated  tumor  endothelial  cells.  The  mechanism  on  which  this  targeted  drug  delivery  is
based relies on the negative charge associated with angiogenic endothelial cells which in
turn  attracts  cationic  liposomes  which  can  actively  bind  negatively  charged  angiogenic
endothelial cells and deliver cytotoxic drugs (Makrilia et al., 2009).
4.5. Anti-angiogenic gene therapy for cancer
Tumor growth and progression depends on angiogenesis, a process of new blood vessel for‐
mation from preexisting vascular endothelial cells. Tumors promote angiogenesis by secret‐
ing or activating angiogenic factors that stimulate endothelial proliferation and migration
and capillary morphogenesis. The newly formed blood vessels provide nutrients and oxy‐
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gen to the tumor, increasing its growth. Thus, angiogenesis plays a key role in cancer pro‐
gression and development of metastases. Anti-angiogenic therapies have demonstrated
significant efficacy in some patients, however, several side effects of anti-angiogenic therapy
have been noted in the literature. In addition, the cost of several of these therapies is very
high and may not affordable for many patients worldwide
VEGF is an important growth factor that promotes angiogenesis and participates in a variety
of physiological and pathological processes. Over-expression of VEGF results in increased
angiogenesis in normal and pathological conditions. There is significant evidence that alter‐
native splicing of VEGF gene and other genes involved in angiogenesis can regulate the an‐
giogenic process in tumors. Alternative therapies might replace or improve existing ones. In
particular, there is a place for pharmaceutical modulation of angiogenic factors affecting
pre-mRNA splicing. This can be brought about not only by alteration in the splicing of hepa‐
rin-binding isoforms of VEGF but also by the relative balance of pro- and anti-angiogenic
isoforms. The concept of an angiogenic splicing phenotype, which controls a number of dif‐
ferent proteins that can be activated or deactivated by over-expression or activation of key
splicing control factors, is an opportunity for intervention that should be explored in greater
detail in the near future (Biselli-Chicote et al., 2012).
In eukaryotes genes consist of coding sequences (exons) interspersed with non-coding se‐
quences (introns). The regulation of alternative inclusion/exclusion of exons, or parts of
exons, during RNA processing of pre-mRNA into mRNA (alternative splicing) allows a dra‐
matic increase of the protein repertoire versus the gene repertoire. In a number of cases, al‐
ternative splicing of mRNA has been shown to generate proteins with distinct, sometimes
opposite, functions from a given gene. Angiogenesis is the process of vascularization in
physiological conditions, and there are a number of pathologies, including cancer, where an‐
giogenesis favors tumor progression and dissemination of metastasis. In this chapter, we
discuss some key examples showing how alternative splicing may induce a switch from an‐
ti-angiogenic to pro-angiogenic functions reciprocally. For some of these splicing events, the
molecular mechanisms that trigger alternative splicing toward one or the other direction are
now becoming known. The emergence of strategies enabling the regulation of alternative
splicing opens new routes for anti-angiogenic therapies (Munaut et al., 2010).
In tumors of the nervous system, tumor derived endothelial cells (TECs) may present the
same genetic amplification or chromosomal aberrations of the tumor of origin. In human
xenografts of renal carcinoma, melanoma, and liposarcoma, murine TECs are aneuploid,
bearing alterations similar to those observed in human TECs. This observation remains un‐
explained. It cannot be ascribed to cell fusion among tumor and endothelial cells, as no hu‐
man DNA was present in murine TECs. The researchers who conducted this research
speculated that the tumor microenvironment may produce factors capable of inducing ge‐
netic instability, or loss of tumor suppressors and/or check point activity, resulting in aneu‐
ploidy. Altogether, these data suggest two different explanations for the origin of TECs. The
first is that they originate from a common progenitor of tumor and endothelial cells targeted
by neoplastic transformation; the second is that the effect of the tumor microenvironment
leads to genetic instability (Gardlik et al., 2011a).
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In addition, the differentiation of cancer stem cells into endothelial cells and the consequent
involvement of these cells in tumor vascularization have been recently described in different
tumors. The definitive proof that tumor stem cells are bipotent relies on the ability of clones
of tumor stem cells to differentiate in vitro and in vivo into both tumor epithelial and endo‐
thelial cells (Bussolati et al., 2008; 2009). More recently, the ability of tumor cells to differen‐
tiate into endothelial cells has also been reported for cancer stem cells present in
neuroblastomas (Alvero et al., 2009). In particular, only a fraction of stem cells, characterized
by CD133 and CD144 co-expression (Wang et al., 2010), or in a recent report, by co-expres‐
sion of Oct4 and tenascin C, shows vasculogenic potential and is selectively localized in the
proximity of tumor vessels (Pezzolo et al., 2011). An alternative mechanism of tumor blood
perfusion implies the possibility that tumor cells form channels connected to the tumor vas‐
culature, a process defined as “vasculogenic mimicry”. Alternatively, the process of tumor
vasculogenic mimicry could be interpreted as being dependent on tumor stem cells (El Hal‐
lanti et al., 2010; Yao et al., 2011), as a transitional step in stem cell differentiation toward
endothelial cells (Bussolati et al., 2011).
In cancer therapy, recent investigations have focused on using genetically modified bacteria
to actually block tumor angiogenesis. Despite recent progress, only a few studies on bacteri‐
al tumor therapy have focused on anti-angiogenesis. Bacteria-mediated anti-angiogenic ther‐
apy for cancer, however, is an attractive approach given that solid tumors are often
characterized by increased vascularization.
The  first  modern  attempts  at  using  bacteria  for  therapeutic  purposes  were  made  more
than  40  years  ago  by  showing  that  bacteria  could  predominantly  replicate  in  solid  tu‐
mors. The first indications of this phenomenon, however, date back to the 19th century.
These findings remained largely unexplored until the turn of the 20th century, when on‐
colytic bacteria capable of lysing host cells were first studied by various research groups.
The  utilization  of  bacterial  systems  for  therapeutic  anti-cancer  purposes  is  further  en‐
hanced  by  genetic  modifications,  which  make  them  a  very  promising  tool  for  targeted
delivery of  genes and their  products.  Specific  advantages of  using bacteria  for  anti-can‐
cer  gene  therapy  include  the  natural  oncolytic  potential  of  some  strains/species,  direct
targeting of tumor tissues and the ease of positive regulation/eradication. The anti-cancer
effect  of  tumor-targeting  bacteria  can  also  be  achieved  after  oral  administration,  which
may circumvent the use of intravenous routes of delivery and associated adverse events
of intravenous therapy (Chen et al., 2009; Gardlik et al., 2011b).
5. Further development of ARTs as anti-angiogenic cancer agents
Cancer angiogenesis has been confirmed by measurement of high proliferation indices for
endothelial cells, not only in rapidly growing animal tumors, but also in human tumors. The
rationale for developing anti-angiogenic strategies for cancer therapy was based on the fact
that physiological angiogenesis only occurs in a limited number of situations, such as in
wound healing and during menstrual cycle. This suggests there is an opportunity for devel‐
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oping highly tumor-specific anti-angiogenic applications which utilize drugs such as the
ARTs which have demonstrated anti-angiogenic efficacy with little toxicity.
5.1. Further targeting anti-angiogenesis of ART and its derivatives
Our  current  knowledge  of  the  anti-cancer  mechanism  of  ARTs  is  derived  from  our
knowledge of  the antimalarial  activity of  ARTs.  The potent  anti-cancer activity of  ARTs
can  be  attributed  to  the  endoperoxide  bond  of  the  ARTs  compounds  which  is  shared
with the antiparasitic activity of ARTs. In most of the cancers studied, preloading of can‐
cer cells with iron or iron-saturated holotransferrin triggers ART cytotoxicity with an in‐
crease in the activity of ARTs. It has been hypothesized that iron-activated ARTs induce
damage by release of highly alkylating carbon-centered radicals and radical oxygen spe‐
cies (ROS). Generation of free radicals may play a role in the cell alterations reported in
ARTs-treated cancer cells such as enhanced apoptosis, arrest of growth, inhibition of an‐
giogenesis,  and DNA damage. In addition, ARTs-sensitive cancer cells have been shown
to have down-regulated expression of oxidation enzymes while cancer cells with over-ex‐
pression of these molecules are more resistant to ARTs therapy. The antineoplastic toxici‐
ty of ARTs appears to be also modulated by calcium metabolism, endoplasmic reticulum
(ER)  stress,  and the  expression of  the  translationally  controlled  tumor  protein,  TCTP,  a
binding  calcium protein  which  has  been  also  postulated  as  a  parasite  target.  Although
the expression of  the TCTP gen,  tctp,  was initially  correlated with cancer  cell  responses
to  ARTs,  a  functional  role  for  TCTP  in  the  anti-cancer  activity  of  ARTs  has  yet  to  be
found. As for malaria parasites, the role of sarcoendoplasmic Ca2+ ATPase (SERCA) as a
target of ARTs in cancer cells has also been explored (Crespo-Ortiz and Wei, 2012).
ART and its bioactive derivatives elicit their anti-cancer effects by concurrently activating,
inhibiting and/or attenuating multiple complementary cell signaling pathways, especially
those associated with the VEGF family, based on published data. The precise mechanism of
new and alternative actions and other primary targets of ARTs, however, will require fur‐
ther study. In anti-cancer therapy, it has been postulated that ARTs may target organelles
such as pathways involving PlGF growth factors (a VEGF subfamily),, angiopoietins, such
as the Angs proteins, the Notch signaling pathway, signaling pathways involving fibroblast
growth factors (FGFs), and the matrix metalloproteinase (MMPs) family of enzymes (Cres‐
po-Ortiz and Wei, 2012). In a recent study, investigators discovered a panel of genes con‐
taining many fundamental regulators of angiogenic regulators, such as VEGF, was found
that correlate with the cellular response to AS. These genes govern the stimulation, prolifer‐
ation and migration of endothelial cells, a fundamental step in vessel formation. The investi‐
gators decided to further limit their cluster analysis by including in the cluster analysis only
those genes whose mRNA expression correlated with GI50 values of at least four ARTs (An‐
fosso et al., 2006). Three human genes coding for VEGF (VEGFA, VEGFB, and VEGFC) were
discovered in this cluster of ARTs-affected angiogenic regulating genes.. Despite the contin‐
uous investigations on new targets, the ART compounds exert common as well as distinct
cellular effects depending on the phenotype and tissue origin of the human cancer cells ex‐
amined. (Firestone and Sundar, 2009).
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In addition, most of these studies were based on the consideration that an ideal ARTs as
an anti-angiogenic drugs may target different types of tumor, assuming endothelial cells
to be similar  in different  tumor types and genetically stable.  The therapeutic  efficacy of
ARTs, however, was not as successful as expected and endothelial cells acquired drug re‐
sistance.  This  setback  is  possibly  due  to  the  fact  that  most  anti-angiogenic  drugs  were
tested on normal endothelial cells. In light of the involvement of angiogenesis and vascu‐
logenesis  in  tumor  vascularization,  it  can  be  speculated  that  tumor  cytotoxic  therapies,
radiotherapy,  and  anti-angiogenic  drugs,  may  stimulate  vasculogenesis  by  inducing  tu‐
mor  hypoxia  and/or  an  epithelial  mesenchymal  transition.  Therefore,  targeting both  an‐
giogenesis  and  vasculogenesis  in  tumors  may  be  required  to  inhibit  tumor
vascularization, growth, and invasion. In particular, an improved knowledge of the rela‐
tive contribution of vasculogenesis to tumor vascularization is likely to be critical for de‐
velopment of specific therapeutic strategies (Li et al., 2011).
5.2. Prevention and therapy strategies of ARTs for cancer treatments
Angiogenesis inhibition therapy does not necessarily kill tumors but instead may prevent
tumors from growing. Therefore, this type of therapy may need to be administered over
a long period of time. Some common components of human diets also act as mild angio‐
genesis inhibitors and have therefore been proposed for angioprevention, the prevention
of  metastasis  through the inhibition of  angiogenesis.  Phytochemicals  and ART-mediated
anti-angiogenic intervention is a growing area of research that may provide an effective
cancer  prevention  strategy.  Suppression  of  pathological  angiogenesis  by  phytochemicals
and ARTs could have potential applications in cancer prevention and therapy as well as
in  other  diseases  with  similar  etiology.  Chemopreventive  phytochemicals  are  generally
non-toxic and hence will produce minimal side effects. In addition, endothelial cells lack
induced drug resistance and, therefore, angioprevention could be a preferred strategy for
cancer control in comparison to other therapies such as radiotherapy and chemotherapy.
Several anti-angiogenic strategies have been developed to inhibit tumor growth by targeting
different components of tumor angiogenesis. Non-toxic natural chemopreventive agents
that could be part of the daily human diet have been shown to safely target and inhibit dif‐
ferent aspects and components of the process of angiogenesis. ART and its derivatives, and
other sesquiterpene lactones, have been shown to have potent anti-angiogenic effects in tu‐
mor cells as well as in healthy rat embryos in culture. These observations have many impli‐
cations in terms of cancer therapy as well as cancer prevention since angiogenesis is a
promotional event (Firestone and Sundar, 2009).
Studies have shown that, the upper limit of a tumor mass in the absence of angiogenesis is
1-2 mm, and this size limit is related to the maximum size possible for simple diffusion of
nutrients and gases like CO2 and O2. This 1-2 mm tumor size can be maintained by the bal‐
ance of cell proliferation and apoptosis leading to dormancy of small tumors for many
years. Therefore, for tumor growth and the development of vasculature is critical to proceed
towards tumor progression and metastasis., Endothelial cells are a preferential target for
therapy because they are common to all solid tumors, and endothelial cell proliferation nor‐
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mally occurs only in pathological conditions such as injury or endometrial development.
Large number of angiogenic factors, such as VEGF and bFGF. etc., is secreted by tumor cells
are required to cause endothelial cell recruitment and proliferation (Ferrara et al., 2003).
These stimuli are constantly present so the differentiation of the tumor endothelium into
a mature vessel  network is  rarely complete,  and tumor vessels  show an abnormal mor‐
phology.  The  immature  vessel  network  of  tumors  is  a  promising  anti-angiogenic  target
for ARTs compounds. The body of knowledge of endothelial  cell  physiology and tumor
angiogenesis  obtained  through  recent  research  has  been  crucial  to  actually  understand
some  of  the  mechanisms  of  how  ARTs  actually  exert  their  anti-angiogenic  effects  (Ef‐
ferth,  2005;  2007).Endothelial  cells  are  non-transformed  cells,  and  they  should  be  quite
accessible to treat  with physiologically achievable concentrations of  ARTs (Efferth,  2006;
Crespo-Ortiz  and  Wei,  2012).  This  therapeutic  strategy  may  involve  various  targets  in‐
cluding angiogenic molecules from tumors cells  and inflammatory system (such as neu‐
trophils  and  macrophages)  such  as  VEGF,  bFGF,  TNFa,  IL-8,  etc.  and  their  respective
receptors  on endothelial  cells,  endothelial  cells  itself,  matrix  metalloproteinases  (MMPs),
cyclooxygenases  (COXs),  lipoxygenases  (LOXs)  etc  (see  Section  3).  Therefore,  long-term
angiostasis  treatment  will  likely  be  necessary  for  cancer  prevention  and  control.  This
multitargeted anti-angiogenic strategy suggests  drug discovery and development should
be  focused  on  finding  small,  non-toxic  anti-angiogenic  molecules  or  compounds  to  be
used in a multifaceted cancer control regimen (Firestone and Sundar, 2009).
Large numbers of chemopreventive agents, such as ARTs, have been shown to possess anti-
cancer activities in many studies. These agents achieve anti-cancer activities through various
mechanisms by targeting different aspects of cancer progression and development. Since an‐
giogenesis is a pre-requisite for the growth of solid tumors, vascular targeting has been ex‐
plored as a potential strategy to suppress tumor growth and metastasis. In this regard, many
phytochemicals or ARTs have been shown to target tumor angiogenesis using in vitro and in
vivo model systems (Chen and Cleck, 2009a; Cao et al., 2009; 2011).
Since,  angiogenesis  is  critically important for physiological  process such as wound-heal‐
ing, acute injury healing, and healing of chronic ulceration of the gastrointestinal muco‐
sa,  administration  of  ARTs  compounds  that  inhibit  tumor  angiogenesis  might  also
suppress physiological angiogenesis and produce critical side effects when dosed over a
long period of  time.  Therefore,  anti-angiogenic chemopreventive ARTs and phytochemi‐
cals  should  be  studied  and analyzed first  for  their  selective  targeting  of  tumor  specific
angiogenesis  to  find  the  most  effective  anti-tumor  combinations  (Bhat  and  Singh,  2008;
Crespo-Ortiz and Wei, 2012).
5.3. Combination strategies to enhance efficacy and to prevent resistance of ARTs
Anti-angiogenesis is a cytostatic therapy that is likely to have greatest effect when combined
with cytotoxic therapy. It has recently been suggested that anti-angiogenic drugs represent the
universal chemosensitizing agents for cancer treatment. There are a number of mechanisms for
the observed synergism between anti-angiogenic agents and anti-cancer chemotherapeutic
agents that have been proposed 1) the normalization of tumor microvessels by anti-angiogen‐
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ic therapy which enhances chemotherapeutic drug delivery, 2) prevention of tumor cell repo‐
pulation by anti-angiogenic drugs during the break periods after maximum tolerated dose
chemotherapy and 3) augmentation of the antivascular effects of chemotherapeutics by anti-
angiogenic drugs (Makrilia et al., 2009). There is growing evidence supporting the use of ART
and its derivatives in cancer therapy given their potent antiproliferative, antimetastatic and
anti-angiogenic activity, which makes them potential anti-cancer drugs. In a combination ther‐
apy for cancer, the antineoplastic action of ART may contribute to an independent antitumor
activity with no additional side effects. The benefits of combining ARTs with other anti-cancer
agents have been investigated showing that the multifactorial activity of ARTs in different
pathways may provide synergism and improve overall activity (Liu et al., 2011).
Drug combinations that involve ARTs have been reported in vitro, which show value in this
approach, both as a sensitizing agent to chemotherapy in solid tumors (Sieber et al., 2009),
and as a synergistic partner with doxorubicin in leukemia (Efferth et al., 2007). Incubation of
cancer cells with DHA alone was found to be less effective than in combination with holo‐
transferrin, indicating that intracellular iron plays a role in the cytotoxic effects of DHA (Lai
and Singh, 1995). In addition to conventional chemotherapies, ART was also shown to be ef‐
fective when combined with the immune modulatory drug LEN (Galustian and Dalgleish,
2009). These in vitro studies demonstrated the effects of ARTs on the cell cycle, and these
studiesalso demonstrated restoration of cytotoxicity in an ART-resistant cell by adopting a
pulsed-schedule of combination treatment.
Many anti-angiogenic and antivascular agents are now in clinical trials for the treatment of
cancer. It is conceivable that loading tumor cells with bivalent iron by simply providing Fe2+
in tablet form might increase the susceptibility of cancer cells to the action of AS. In a clinical
study of humans with uveal melanoma, one of the patients enrolled was treated with biva‐
lent iron and artesunate, and it is tempting to speculate the addition of Fe2+ had an actual
clinical impact and resulted in an improved response to therapy (Berger et al., 2005). Contin‐
ued research in this area is encouraged by the recent success of a Phase II clinical trial of AS
combined with NP chemotherapy in treatment of advanced non-small cell lung cancer. The
disease controlled rate of the trial group of AS plus NP chemotherapy (88.2%) was signifi‐
cantly higher than that of the NP chemotherapy alone group (72.7%), and the trial group's
time to progression (24 weeks) was significantly longer than that of the NP chemotherapy
alone group (20 weeks). AS combined with NP chemotherapy can increase the short-term
survival rate of patients with advanced non-small cell lung cancer and prolong the time to
progression without extra side effects (Zhang et al., 2008). The diversity in the targets of ART
supports the possibility that it could be used in combination with other agents.
In addition, it has been reported that resistant cancer cell lines become sensitive by adding
ART to the conventional treatment (chemosensitization). Interestingly, DHA and AS have ex‐
hibited the strongest chemosensitizing/synergistic effects, while other ARTs shows only ad‐
ditive and antagonistic interactions (Singh and Lai, 2005). DHA was shown to synergistically
enhance tumor growth inhibition by 45% when administered in combination with gemcita‐
bine, while other ARTs showed only additive effects (Wang et al., 2010). Consistent with this
observation, a greater antitumor activity was observed when DHA was used in a combina‐
tion with cyclosphosphamide in murine Lewis lung carcinoma cell line or in combination
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with cisplatin in non-small cell lung cancer A549 in mice (Zhou et al., 2010). In rat C6 glioma
cells, addition of 1 μM DHA increased the cytotoxic effect of temozolomide, a DNA alkylat‐
ing agent used in the treatment of brain cancer, by 177%,. Further investigation showed that
DHA promotes apoptotic and necrotic activity of temozolomide through ROS generation
(Huang et al., 2008).
Recently, an enhancement of the anti-cancer activity of AS was shown in different combi‐
nation regimens. A striking synergy was achieved in combinations of AS and the immu‐
nomodulator  drug,  lenalidomide  (Liu  et  al.,  2011).  Overall,  this  evidence  suggests  that
DHA and AS have remarkable ability to potentiate antitumor agents and to counter tu‐
mor resistance.  ARTs also have been shown to improve ionizing-based therapies.  In the
glioma cell  line  U373MG,  DHA treatment  was  shown to  inhibit  the  radiation-  induced
expression  of  GST  with  concomitant  ROS  generation.  A  combination  treatment  with
DHA  has  been  shown  to  be  more  effective  than  radiation  or  DHA  alone  (Kim  et  al.,
2006).  The adjuvant effect of ARTs in other cancer treatments including hyperbaric oxy‐
gen has also been reported (Ohgami et al., 2010).
Current available ARTs in combination with chemotherapy for the treatment of cancer pa‐
tients have produced only modest beneficial effects (Cao et al., 2009). Optimization of anti-
angiogenic therapy is urgently needed in order to maximize therapeutic efficacy of these
drugs. Thus, development of a new generation of drugs targeting diverse angiogenic path‐
ways is expected to improve the anticancer benefits of ARTs therapy. In preclinical tumor
models, it has been shown that a combination of anti-angiogenic agents with different mech‐
anistic principles yielded a synergistic effect on tumor suppression. Translation of this pre‐
clinical finding to patient therapy would suggest acombination of different of anti-
angiogenic agents combined with a chemotherapeutic agent will enhance cancer therapy,
and such a combination should be considered in future clinical trials (Cao, 2011).
The mechanism(s) underlying the interaction of combinations of anti-angiogenic agents such
as the ARTs plus chemotherapeutic treatment, and, indeed, the mechanism of ART action
against cancer is still not fully understood, however, many studies in this field of research
are ongoing and will guide the basis of further studies and clinical trials (Liu et al., 2011).
Scientists investigating the cancer-fighting properties of ARTs have found early evidence
that combining it with an existing cancer drug has the potential to make each drug more ef‐
fective in combination versus when these drugs are used alone. There is currently limited
published data exploring the value of ARTs as a combination partner in treatment regimens.
These studies have used simple approaches to studying drug–drug interactions, and as a
consequence, their conclusions are still open to debate (Liu, 2008).
5.4. Strategies to avoid potential drug toxicities of ARTs
At high concentrations, ARTs appear to be active against cancer in vivo. The use of ARTs at
high concentrations or for long drug exposure times, however, has substantial risk of severe
toxicities, including embryotoxicity and neurotoxicity. Animal studies have shown that high
peak concentrations of AS and DHA can induce embryotoxicity, and the longer exposure
times associated with therapy using oil-soluble ARTs, such as AM, will produce fatal neuro‐
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toxicity (Li et al., 2007a). To prevent embryotoxicity in pregnant women with malaria, cur‐
rent WHO policy recommendations on the use of ARTs in uncomplicated malaria state that
ARTs should be used only in the second and third trimester, limiting the use of ARTS in the
first trimester to cases where it is the only effective treatment available (WHO 2006b).
Studies  with  laboratory  animals  have  demonstrated  fatal  neurotoxicity  associated  with
intramuscular  administration  of  AM  and  AE  or  oral  administration  of  artelinic  acid.
These effects suggest that the exposure time of ARTs was extended in these studies due
to the accumulation of drug in the bloodstream, and this accumulation, in turn, resulted
in neurotoxicity.  In one study, the drug exposure time with a neurotoxic outcome (neu‐
rotoxic exposure time) was evaluated as a predictor of neurotoxicity in vivo (Li and Hick‐
man, 2011). The neurotoxic exposure time represents a total time spent above the lowest
observed neurotoxic effect levels (LONEL) in plasma. The dose of AE required to induce
minimal neurotoxicity required a 2-3 fold longer exposure time in rhesus monkeys (179.5
hr) than in rats (67.1 hr) and dogs (113.2 hr) when using a daily dose of 6-12.5 mg/kg for
7-28 days,  indicating that  the safe dosing duration in monkeys should be longer than 7
days  under  this  exposure.  Oral  artelinic  acid  treatment  required  much  longer  LONEL
levels (8-fold longer) than intramuscular AE to induce neurotoxicity, suggesting that wa‐
ter-soluble ARTs appear to be much safer than oil-soluble ARTs. Due to the lower doses
(2-4  mg/kg)  used with  current  ARTs and the  more  rare  use  of  AE in  treating humans,
the exposure time is much shorter in humans. Therefore, the current regimen of 3-5 days
dosing duration should be quite safe.  Advances in our knowledge of ART-induced neu‐
rotoxicity can help refine the treatment regimens used to treat malaria with oral ARTs as
well  as  injectable  AS  products  to  avoid  the  risk  of  neurotoxicity.  Although  the  water-
soluble  ARTs,  like  AS,  appear  to  be  much safer,  further  study is  needed in  when em‐
ploying ARTs as anti-cancer agents (Li and Hickman, 2011).
Thus,  rapid  elimination  of  ARTs  in  oral  formulations  is  safer  than  slow-release  or  oil-
based intramuscular formulations (Efferth and Kaina, 2010). Remarkably, although ARTs
derivatives  have been widely  used as  antimalarials,  their  toxicity  in  humans have been
shown to be negligible. In cancer therapy, ARTs may have multiple benefits as it can be
used in combination with no additional side effects, but also it enhances potency and re‐
duces doses of more toxic anti-cancer partners.  Clinical doses used in malaria treatment
after  ART administration  of  2  mg/kg  in  patients  raise  plasma  concentrations  to  2640  ±
1800  μg/L  (approximately  6.88  ±  4.69  mM)  which  can  be  considered  up  to  3  orders  of
magnitude higher  than those ART concentrations with antitumor activity  (Efferth et  al.,
2003).  It  becomes relevant  to  closely monitor  the safety of  long-term ARTs-based thera‐
pies  as  severe  side  effects  may  be  highly  unusual  but  significant.  So  far,  ARTs  treat‐
ments for as long as 12 months have been reported with no relevant side effects (Berger
et al., 2005; Singh and Verma, 2002; Singh and Panwar 2006).
5.5. Strategies to utiliize current and novel ARTs as anti-cancer agents
A number of first generation derivatives of ART have been created (DHA, AS, AM and AE),
and other novel compounds have been synthesized as second generation derivatives de‐
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signed to improve the anti-cancer activities of ART. This second generation ART derivatives
have shown remarkable anti-angiogenic effects and cytotoxicity towards tumor cells
(D’Alessandro et al., 2007; Krishna et al., 2008). Ether-linked dimers of DHA, for example,
have been shown to cause accumulation of tumor cells in the G1 phase of the cell cycle
(Morrissey et al., 2010). New growth-inhibitory ART derivatives containing cyan and aryl
groups have been shown to cause accumulation of P388 and A549 cells in the G1 phase (Li et
al., 2001). Finally, deoxoartemisinyl cyanoarylmethyl ART derivatives with cytotoxic activi‐
ty have been shown to induce a significant accumulation of L1210 and P388 cells in the G1
phase (Wu et al., 2001)., ART-like endoperoxides have also been synthesized chemically
which show greater cytotoxicity towards tumor cells than native ART, which aids in pre‐
serving the natural resources of the A. annua plants (Soomro et al., 2011).
As mentioned above, AS is completely converted to DHA and is best described as a prodrug
of DHA. DHA has been shown to be more effective than AS in inhibition of angiogenesis
and vasculogenesis in vitro (Longo et al., 2006a; 2006b; Chen et al., 2004b; White et al., 2006).
In addition, the embryotoxicity and neurotoxicity of ARTs can be reduced by using artemi‐
sone, which is a novel derivative of ART that is not metabolized to DHA (D’Alessandro et
al., 2007; Schmuck et al., 2009).
Artemisone is a novel amino alkyl ART that has recently entered Phase II clinical trials
(D’Alessandro et al., 2007). The compound was rationally designed to have reduced lipophi‐
licity in order to impede transport to the brain and embryo. In addition, the inclusion of a
thiomorpholine 1,1-dioxide group at the C10 position blocks the conversion of artemisone to
the more lipophilic DHA. This structural modification does not affect anti-parasitic activity
but reduces neurotoxicity and embryotoxicity, as assessed in vitro against primary neuronal
brain stem cell cultures from fetal rats and in vivo in female rats (Schmuck et al., 2009). The
retention of artemisone antimalarial activity infers that chemical activation of the peroxide
bridge to a toxic parasiticidal chemical species remains unchanged, but recent literature also
suggests that artemisone has a direct cytotoxic activity without activation of the endoperox‐
ide bridge. In fact, two subsequent studies have provided conflicting results concerning the
dependence of the pharmacological activity of artemisone on iron-activation of the endoper‐
oxide group.
Interestingly, an in vitro study by D’Alessandro et al, showed that the anti-angiogenic effects
of artemisone were reduced compared with DHA, and it was suggested that this reduction
may limit the potential of artemisone to cause embryotoxicity mediated by defective angio‐
genesis and vasculogenesis during embryo development (D’Alessandro et al., 2007). Togeth‐
er these studies suggest that, while artemisone was designed to optimize safety by
physicochemical means, the structural changes induced to create artemisone may also affect
the intracellular chemical and molecular pathways which underlie toxicity, perhaps via re‐
duced or alternative mechanisms of bio-activation and/or reduced cellular accumulation,
when compared with the traditional ARTs. Therefore, artemisone represents an exciting
novel compound in which increased anti-parasitic activity is combined with a reduced po‐
tential to cause both embryotoxicity and neurotoxicity.
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Increased knowledge of the molecular mechanisms of ART-derived drugs and recent synthe‐
sis of novel ART derivatives demonstrates that further pharmacokinetic and pharmacody‐
namic analyses of novel ART derivatives are needed to understand why these compounds
differ in efficacy and toxicity. This information will prove useful for the rationale design of
more-effective ART-based molecules for use as anti-cancer agents. New derivatives of ARTs
may act not only as treatment drugs, but also may have potential as potent cancer preventa‐
tive agents due to their inhibition of tumor promotion and progression.
Recently, a series of DHA derivatives were synthesized via an aza-Michael addition reaction,
and these novel compounds showed a high selectivity index and an IC50 in the nanomolar
range against HeLa cells (0.37 μM) (Feng et al., 2000). In another study, a series of deoxoarte‐
misinins and carboxypropyldeoxoartemisinin compounds were synthesized, and the antitu‐
mor effects of these compounds were not associated with lipophilicity, as has commonly
been assumed, but instead was associated with distinctive boat/chair molecular conforma‐
tions which facilitated the interaction of these novel compounds with receptors (Lee et al.,
2000). In many studies, there has been an emphasis on the nature and stereochemistry of the
dimer linker which may influence anti-cancer activity. It has also been shown, however, that
the linker by its own is inactive. Morrisey et al. have described that an ARTs dimer exhibits
up to 30-fold more activity than ARTs against prostate cancer lines (Morrissey et al., 2010).
This dimer selectively exerted both higher cytostatic activity and apoptosis in C4-2 (a cell line
derived from LNCaP) and LNCaP cells compared to ARTs (Morrissey et al., 2010). The ster‐
eoisomery of the linker may be associated with enhanced anti-cancer activity (Alagbala et al.,
2006). In another study, C12 non-acetal dimers and one trimer of deoxoartemisinin showed
similar potency to that of the conventional anti-cancer drugs against many cell lines. The
linker with one amide or one sulfur-centered 2 ethylene group was essential for potent anti-
cancer activity (Jung et al., 2003). The mechanism underlying the antiproliferative action of
the ARTs-derived dimers is not clear and requires further study.
Recently, a series of easily synthesized, potent ARTs-like derivatives with anti-cancer activi‐
ty were created. These endoperoxides exhibit high chemical stability and greater cytotoxicity
than AS against cancer cell  lines. These compounds also exhibit relevant anti-angiogenic
properties as judged by studies in a zebrafish model (Soomro et al., 2011). To overcome the
short half-lives of ARTs, novel, longer lasting derivatives will be required. One such example
is synthetic trioxolanes, endoperoxide drugs which were created to provide long lasting effi‐
cacy against Schistosoma species. ARTs compounds share the endoperoxide bridge structural
feature of the trioxolanes, and they have been shown to have prophylactic activity towards
the younger developmental stages of Schistosoma but are ineffective as curative agents. The
synthetic trioxalane compounds incorporate the endoperoxide “warhead” with enhanced
pharmacokinetic properties and exhibit greater efficacy as curative agents against establish‐
ed Schistosoma infections (Xiao et al., 2007). Given that ARTs may be potentially used as an‐
ti-cancer drugs and possibly in other parasitic and viral infections, the development of novel
endoperoxide compounds with enhanced pharmacokinetic properties and targeted anti-can‐
cer activity is essential. These promising research findings suggest it is possible to identify
safer and more effective strategies to treat a range of infections and cancer (Crespo-Ortiz and
Wei, 2012).
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6. Perspectives and conclusion
ART and its bioactive derivatives are potent anti-cancer phytochemicals that pose minimal
risks to human patients. ART has been shown to arrest cancer cell growth, induce apoptosis,
disrupt angiogenic pathways and has other anti-cancer properties through pleiotropic effects
as shown against a variety of human cancer cell lines. In addition, ART-related compounds
have been shown to inhibit tumor promotion and progression, suggesting these molecules is
not  only effective as  treatment  therapeutics,  but  also  as  potential  anti-cancer  preventive
agents. ARTs have been recommended and widely used as antimalarials for six years, and
they have saved the lives of many patients infected with malaria (WHO, 2006a). Supporting
evidence indicates that ART-like compounds may be a therapeutic alternative or adjunct for
use in treating highly metastatic and aggressive cancers that have no other long term effec‐
tive therapy (Morrissey et al.,  2010) particularly against cancer cells that have developed
drug resistance (Wang et al., 2010). Furthermore, antimalarial endoperoxides may act syn‐
ergistically with other anti-cancer drugs with no additional side effects. The many antitumor
activities, both direct and indirect, of ARTs compounds, however are not entirely explained.
So far, the precise molecular events involved in how, when, and where radical oxygen spe‐
cies (ROS) production is initially triggered in cancer cells remain to be defined. In addition,
the relevance of any ROS-independent mechanism should be also addressed; these might not
be obvious but possibly important for ART-mediated cytotoxicity in some cancer cells. Some
other aspects such as the direct DNA damage induced by ART-like compounds and the role
of p53 status in genotoxicity need to be further analyzed.
Characterizing the anti-cancer effects of existing and novel ARTs derivatives remains an im‐
portant research goal, and research also needs to be focused on unveiling the mechanisms of
cancer cell cytotoxicity by identifying their relation to particular cancer biomarkers and mol‐
ecules. ARTs seem to regulate key players participating in multiple pathways such as VEGF,
NF-κB, survivin, NOXA, HIF-1α, and BMI-1. These molecules and others are to be revealed,
which in turn may be involved in drug response, drug interactions, mechanisms of resist‐
ance, and collateral effects in normal cells. A better understanding of common mechanisms
under similar conditions in different cell systems will greatly aid the development of target‐
ed ART derivatives. This will improve ARTs cytotoxicity by lowering IC50, emerging of re‐
sistance,  drug associated toxicity,  and potentiating drug interactions.  Furthermore,  novel
endoperoxide compounds and combinational therapies can be addressed to target or co-tar‐
get markers of carcinoma progression and prevent invasiveness and metastatic properties in
highly recurrent and aggressive tumors or advanced stage cancers.
Even though the utility of ARTs in the clinical setting have already been assessed, specific in‐
teractions with established chemotherapy regimens need to be further dissected in different
cancer cell lines and their associated phenotypes. This will be crucial to implement clinical
trials and treatment of individual cases. Due to the toxicity of ARTs, long-term therapy also
requires close monitoring. It is important to note that the prototype drug, ART, seems to
modulate responses leading to antagonistic interactions with other anti-cancer drugs. While
it may be useful to have the prototype drug as a control in vitro, however, its pharmacokinet‐
ic properties may differ from the semisynthetic ARTs. Therefore, ART antagonistic reactions
and resistance must be cautiously validated using different semisynthetic derivatives. DHA,
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AS, and AM are the only endoperoxides currently licensed for therapeutic use. So far, AM
has been shown to share similar anti-cancer properties as DHA and AS (Wu et al., 2009).
Cancer research is a permanent discovery of new genes and pleiotropic interactions. The study
of the antitumor activity of ARTs compounds may become even more complex as immunologi‐
cal hallmarks are also involved in the generation of tumors. Immunological hallmarks in can‐
cer  cells  include  the  ability  to  induce  chronic  inflammatory  response,  evasion of  tumor
recognition, and ability to induce tolerance (Cavallo et al., 2011). Whether ART may participate
in the mechanisms involved in these events has yet to be determined. Overall, the real potential
and benefits of the ART drug class remain yet to be uncovered. The imminent possibility of
ARTs being included in the arsenal of anti-cancer drugs has opened the door for challenging re‐
search in this area, one that seems to fulfill many expectations (Crespo-Ortiz and Wei, 2012).
In conclusion, the inhibition of angiogenesis induced by ART-derived drugs has been shown
to be a mechanism of anti-cancer activity in vitro and in vivo. In particular, cancer angiogene‐
sis plays a key role in the growth, invasion, and metastasis of tumors. ARTs-induced inhibi‐
tion of angiogenesis could be a promising therapeutic strategy for treatment and prevention
of cancer. Other anti-cancer mechanisms induced by ARTs have been recognized recently
that have guided various clinical trials in anti-cancer therapy. Since new and alternative an‐
giogenesis mechanisms have been found, further research on the mechanism of efficacy and
toxicity could lead us to understand more deeply the possibilities inherent in therapeutic de‐
velopment of ARTs for malaria, cancer, and other indications. The new therapeutic strategies
for use of ARTs as anti-angiogenic agents should be considered to avoid problems associated
with reproductive toxicity and neurotoxicity. Taken together, ART and its derivatives have
been shown to have potent anti-angiogenic and antivasculogenic effects in tumor cells. These
observations have many implications in terms of cancer therapy and prevention as well as
avoidance of drug toxicity associated with inhibition of angiogenesis.
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